Health technology assessment in maternal and perinatal medicine : delphi survey of practice, systematic reviews of evidence and meta analyses by Velayutham Thangaratinam, Shakila Selvambigai
HEALTH TECHNOLOGY ASSESSMENT IN MATERNAL AND 
PERINATAL MEDICINE 
Delphi survey of practice, Systematic reviews of evidence and Meta analyses 
  
                                           
SHAKILA SELVAMBIGAI VELAYUTHAM THANGARATINAM 
 
A thesis submitted to the Faculty of Medicine and Dentistry of the University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
Academic Department of Obstetrics and Gynaecology 
School of Clinical and Experimental Medicine 
College of Medical and Dental Sciences 
The University of Birmingham 
May 2010 
  
2 
 
SYNOPSIS 
This thesis systematically reviewed published literature on tests and treatments and surveyed 
practice patterns in high-risk conditions in maternal and perinatal medicine. 
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EXECUTIVE ABSTRACT 
Aim 
This thesis performed Health Technology Assessments for a range of tests and interventions in the 
field of maternal and perinatal medicine. The main objectives were  
A. To perform Delphi survey of experts to prioritise the tests in pre eclampsia where there was 
a perceived need for evidence to inform practice and to plan further research  
B. To review the methodological quality of existing reviews in maternal and fetal medicine  
C. To undertake systematic reviews and meta analyses of therapy studies in areas like epilepsy 
and pre term labour,  conditions that have significant influence on maternal and perinatal 
mortality and morbidity  
D. To conduct diagnostic reviews and meta analyses of test accuracy studies in pre eclampsia 
and congenital heart disease, conditions that have significant influence on maternal and 
perinatal mortality and morbidity  
 
Methods 
The work undertaken in this thesis was based on prospective study protocols using the following 
research methodologies: 
 Delphi survey of tests in pre eclampsia 
 Review of quality of reviews in maternal and fetal medicine 
 Systematic reviews and meta-analyses of tests and treatment in maternal (pre eclampsia, 
epilepsy, pre term labour) and perinatal (congenital heart disease in newborn) medicine 
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To achieve the aims of this thesis the work undertaken has been divided in four sections: 
 Section A - Delphi survey:  
Delphi survey to prioritise the accuracy of tests in predicting complications in women with 
pre eclampsia (Chapters 2, 3).  
 Section B - Review of Reviews 
Systematic review of quality of existing reviews in the field of maternal and fetal medicine 
(Chapters 4, 5). 
 Section C - Systematic review of therapy studies 
Systematic quantitative overviews of relevant therapy studies to obtain summary estimates 
of effectiveness of interventions a) anti epileptic drug lamotrigine management in pregnant 
women with epilepsy (Chapter 6) and b) progesterone in women at risk of pre term labour 
(Chapter 7). 
 Section D - Systematic review of test accuracy studies 
In maternal medicine, systematic quantitative overviews of relevant test accuracy studies to 
obtain summary estimates of accuracy of the tests for predicting maternal and fetal 
complications in pre-eclampsia (Chapters  8, 9, 10, 11, 12, 13). In perinatal medicine, 
systematic review of accuracy of pulse oximetry in screening for congenital heart disease in 
newborns (Chapter 14). 
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Results 
Section A: Delphi Survey 
 
 The Delphi survey of experts in the field of high risk obstetrics in UK and Australia 
considered  blood pressure to be the best predictor of complications with mean score (SD) 
of (4.7 ± 0.47), followed by proteinuria (4.6 ± 0.5) and liver function tests (4.5 ± 0.52) 
(scale x to y anchored between 0 -5).  
 
Section B: Review of reviews in maternal and fetal medicine 
 
 A total of 3523 relevant citations were identified from the detailed search in major 
databases. Of these, 336 articles were evaluated in detail and 152 review articles were 
included in the final reviews.  
 Majority of the reviews in maternal medicine (62/68, 91%) specified the question and 54/68 
(79%) had a focussed question with clearly defined population and outcome measures. 
Cochrane reviews specified the questions more often than non-Cochrane reviews (p<0.04) 
and also framed more narrowly focussed questions (p<0.001). Cochrane reviews attempted 
more often to include unpublished data in the literature search (p<0.002). The meta analysis 
technique (p<0.02) and assessment for heterogeneity (p<0.01) was found to be employed 
significantly more often by Cochrane reviews.  
 The majority of reviews in fetal medicine (58/84, 69%) specified the question to be 
answered and only 52% (44/84) had a narrow focus. Fetal growth reviews performed 
significantly better than reviews in other areas in question specification (p<0.03), search 
  
8 
 
without language restriction (p<0.004), assessment of risk of missing studies (p<0.006) and 
study quality assessment (p<0.002). There was no difference in other quality items. 
 
Section C: Systematic review and meta analyses of therapy studies 
 
 A comprehensive search of major databases identified 1819 relevant citations. Full 
manuscripts of 103 papers were retrieved for detailed evaluation and 14 studies with 1149 
patients were included in the reviews evaluating the effectiveness of progesterone and 
lamotrigine in women at risk of pre term labour and pregnant women with epilepsy 
respectively. 
 A significant benefit of progestational agents was observed in reducing preterm delivery 
before 37 weeks (Odds ratio OR 0.42, 95% confidence interval CI 0.31 to 0.57) and before 
34 weeks (OR 0.51, 95% CI 0.34 to 0.77). No heterogeneity was identified for either results.   
 The combined rate of seizure deterioration was 0.40 (95% CI 0.26 to 0.55) in pregnant 
women with epilepsy on lamotrigine treatment managed by serum drug levels compared to 
0.73 (95% CI 0.56 to 0.86) in those managed by clinical monitoring alone. 
 
Section D: Systematic review and meta analyses of test accuracy studies 
 
 The abstracts of 20,058 citations were reviewed to identify the studies to be included in the 
review of accuracy of tests in pre eclampsia including proteinuria, uric acid, liver function 
tests, symptoms and blood pressure and pulse oximetry to detect congenital heart disease in 
the newborns. 
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 Sixteen primary articles with a total of 6749 women met the selection criteria with levels of 
proteinuria estimated by urine dipstick, 24-hour urine proteinuria or urine protein : 
creatinine ratio as a predictor of complications of pre-eclampsia. The area under the curve 
(AUC) for adverse maternal and fetal outcomes are 0.63 (95% CI 0.22, 0.91) and 0.59 (95% 
CI 0.36, 0.79) respectively. 
 There were 18 primary articles that met the selection criteria, including a total of 3675 
women evaluating the accuracy of uric acid in predicting adverse maternal and fetal 
outcomes. The AUC for adverse maternal and fetal outcomes were 0.75 (95% CI 0.46, 0.92) 
and 0.69 (95% CI 0.39, 0.86) respectively. 
 Thirteen primary articles were selected including a total of 2813 women to assess the 
accuracy of liver function tests in predicting complications in pre eclampsia. For predicting 
adverse maternal outcome, the AUC was 0.79 (95% CI 0.51, 0.93). For predicting adverse 
fetal outcomes the AUC was 0.65 (95% CI 0.26, 0.9). The sensitivity of the test was poor 
for both maternal and fetal outcomes. 
 Six primary articles with 2573 women were included in the review of symptoms in pre 
eclampsia.  The AUC for predicting maternal complications with symptoms of headache, 
epigastric pain and visual disturbances were 0.58 (95% CI 0.24, 0.86), 0.70 (95% CI 0.3, 
0.93) and 0.74 (95% CI 0.33, 0.94) respectively.   
 Eight articles with 2304 women evaluated the accuracy of blood pressure in predicting 
adverse outcomes. For the prediction of eclampsia, abruption, renal, neurological and liver 
impairment, mean arterial pressure (MAP) ≥ 140 mmHg or BP ≥ 170/110 had high 
specificity (more than 80%) and low sensitivity (<50%). The area under the curve (AUC) 
for any adverse maternal outcome was 0.68 (95% CI 0.29, 0.92). The specificity for adverse 
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fetal outcomes was more than 70% in 11/15 (73.3%) studies and sensitivity was more than 
70% in 6/15 (40%) studies. 
 Eight studies with 35,960 newborns were included in the review of accuracy of pulse 
oximetry in detecting congenital heart disease. The summary estimates of sensitivity and 
specificity were 0.63 (95% CI 0.39, 0.83) and 0.998% (95% CI, 0.99, 1.00) respectively, 
yielding a false positive rate of 0.2% (95% CI, 0% to 1%). 
 
Conclusion 
This thesis has identified and prioritised the tests that are considered to be useful in the 
management of women with pre eclampsia by a Delphi survey of experts in this field. The 
systematic reviews of the diagnostic value of these prioritised tests have quantified the accuracy in 
predicting adverse maternal and fetal outcomes and been referenced by international guidelines. 
The review on the effectiveness of progesterone in preterm labour has demonstrated its beneficial 
effect in reducing preterm births with significance for clinical practice. The review on the accuracy 
of pulse oximetry has reinforced the role of abnormal pulse oximetry in accurately identifying 
babies with congenital heart disease. The magnitude of proteinuria in women with pre-eclampsia is 
a poor predictor of the major maternal and fetal complications.  Although uric acid as a marker may 
be of value in detecting pre-eclampsia, it has been identified as a poor predictor of any 
complications of pre-eclampsia. In women with preeclampsia, liver function tests had at best 
moderate prediction of maternal and fetal complications.  The test specificity, however, was better 
than sensitivity. Among women with pre-eclampsia, symptoms of visual disturbance and epigastric 
pain were moderately good predictors of maternal complications with better accuracy than 
headache.  The presence of symptoms is clinically more useful for ruling in complications in 
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comparison to their absence for ruling out complications.  Blood pressure was a better predictor of 
adverse fetal than maternal outcomes.  
 
The implications for future research are that maternal and fetal medicine specialties need further 
good quality research.  The systematic review of tests in pre eclampsia has provided the evidence to 
justify a large prospective study in this area. This has led the successful NIHR (National Institute 
for Health Research) grant to conduct a large multicentre prospective study, Prediction of Risks in 
Early onset Pre eclampsia (PREP). The pulse oximetry review generated results that needed to 
confirm the value of pulse oximetry as a screening test, in isolation or in combination with 
antenatal ultrasound to obtain precise estimates of its sensitivity. This led to the successful NIHR 
grant for the multicentre Pulse Ox study. The review of optimal monitoring regimen of anti 
epileptic drugs (AED) in pregnant women with epilepsy established the poor quality small studies 
in this area. Based on these findings, funding for a pilot randomised controlled trial, SOAP (Study 
of Optimal Anti epileptic Drugs in Pregnancy) has been provided by the Research and 
Development (R & D) department of the Birmingham Women‟s Hospital. Recently, the findings 
have been instrumental in the successful NIHR funding for a multicentre randomised controlled 
trial in this area, EMPIRE - Anti Epileptic drug (AED) Management in PREgnancy: An evaluation 
of effectiveness, cost effectiveness and acceptability of dose adjustment strategies.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Health technology assessment 
The term „health technology‟ encompasses a range of methods used to improve health, 
prevent and treat disease and improve rehabilitation and long term care.
1
 Health technology 
assessment (HTA) is the systematic appraisal of properties, effects or other impacts of health 
technology. The main role of HTA is to inform health care decisions at the individual or patient 
level, the level of the health care provider or institution, or at the regional, national and 
international levels. HTA evaluates the direct and intended results of technologies as well as their 
indirect and unintended results. It improves existing knowledge base for improving the quality of 
health care, especially to support development and updating of a wide spectrum of standards, 
guidelines, and other health care policies. 
 
1.1.1 HTA for therapeutic effectiveness 
Effective therapeutic interventions that reduce maternal and fetal mortality and morbidity are 
needed in addition to accurate diagnostic tests or strategies to improve clinical care and prognosis. 
The purpose of treatment is to improve or maintain health status, avoid further deterioration, or 
provide palliation. Evaluation of therapy includes assessment of efficacy and effectiveness of 
intervention, investigation of the technology and its safety, economic attributes, social, legal or 
ethical impact of the intervention studied. Efficacy and effectiveness both refer to how well an 
intervention or technology improves patient outcome. Efficacy refers to the added value of using a 
technology for a particular clinical problem in an ideal situation like a randomised trial conducted 
as per protocol in a tertiary unit.  Effectiveness refers to the added value of using a technology for a 
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particular problem under general or routine conditions like primary or secondary hospitals 
involving a wide range of patients.  
 
1.1.2 HTA for diagnostic technologies 
One of the important medical interventions in the quest for preventing or reducing maternal and 
fetal mortality and morbidity is the prediction or diagnosis of the high risk maternal, fetal or 
neonatal status.  This will help to offer appropriate and timely management aimed at reducing 
maternal and fetal complications.  Clinical prediction of disease complications using a combination 
of patients‟ characteristics, symptoms, physical signs and investigations all of which we consider 
tests, forms the basis of clinical care in these situations.  Therefore, there is a need for guidance 
about the best testing strategies with which to predict development of complications. As well as 
allowing clinicians to avoid unnecessary interventions in low risk groups, this will allow high-risk 
groups to benefit from monitoring of disease severity and use of appropriate treatment.  Diagnostic 
accuracy studies provide information on the discriminatory power of the tests in identifying the 
disease.  The impact of the individual diagnostic tests and diagnostic strategies studied by 
randomised controlled trials depend on the accuracy of the tests as well as the treatment protocol 
based on the test results.  
 
1.2 Conduct of Health Technology Assessment 
There is wide variation in the methods, scope and conduct of HTA. Widely they involve the 
following steps (Fig 1.1). 
1. Specify the problem and its importance to patient and health services: Surveys of clinicians and 
patients  
2. Search and retrieve appropriate evidence, appraise the retrieved evidence, collate or synthesise 
evidence: Systematic reviews of primary studies  
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3. Collect new primary data if insufficient or poor quality evidence: primary research 
4. Generate the results and recommendations: Appropriate interpretation of findings 
5. Disseminate the findings and integrate into clinical practice 
 
Fig 1.1 Health Technology Assessment of tests and treatment 
 
Surveys, Review of reviews 
None or poor quality reviews
Conduct systematic review 
Good quality reviews 
with precise results
Recommendations  for practice
Systematic reviews of 
test accuracy
Systematic reviews of 
therapy
Recommendations  for research
Prioritisation 
of research 
topic
Research
Conclusions
Guidelines, Primary study
 
 
Systematic review provides a key methodology for HTA. It synthesises the best available evidence 
to provide an overall assessment.  Furthermore, it identifies variation in effect or performance 
between various studies. Recently there has been a proliferation of systematic reviews as one of the 
key tools for evidence-based medicine.
2
 In the field of fetal medicine, although the number of 
primary studies has exponentially increased over the last 30 years, their systematic reviews are 
relatively sparse in comparison (Appendix 2). By collating all the available evidence, reviews often 
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highlight the paucity in quality and number of existing studies and provide justification for new 
well defined prospective studies.  
 
1.3 Maternal and perinatal medicine topics reviewed in this thesis 
Maternal medicine is defined as specialised services provided to women with pre-existing or 
pregnancy related disease.  Perinatal medicine deals with the care of the fetus and premature or ill 
newborns.  It is difficult to separately define the various components of maternal and perinatal 
medicine as the care of women in high risk pregnancies considerably overlaps and closely links 
with the care and outcome of the fetus and neonate.  When assessing health technologies aimed at 
improving reducing maternal and neonatal mortality and morbidity, these links need serious 
attention. The following areas that have a significant impact on maternal and perinatal morbidity 
and mortality have been included in this thesis. 
 
a. Pre eclampsia 
Pre eclampsia is a multisystem disorder in pregnancy associated with hypertension and 
proteinuria.
3-5
 Hypertension is defined as systolic blood pressure of 140 mm Hg or more and 
diastolic blood pressure of 90 mm Hg or more on two occasions 4-6 hours apart.
3-5
 Proteinuria is 
defined as 300 mg or more in 24 hour urine collection or urine dipstick of 1+ or more in 2 samples 
6 hours apart or a spot urine protein/creatinine ratio of at least 30 mg/mmol.
4-6
  Hypertensive 
diseases in pregnancy remain one of the leading causes of direct maternal deaths in the UK and 
account for 20% of all stillbirths.
7
  In 1% of pregnant women pre eclampsia occurs before 34 
weeks, so called early onset pre eclampsia.
8;9
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Early onset pre eclampsia is considered to be a pathophysiologically different disease than late 
onset pre eclampsia with considerably increased risk of maternal complications with 20-fold higher 
maternal mortality.
10-12
 The only known cure in this condition is delivery of the baby and placenta. 
In women with early onset pre eclampsia, the decision about when is the best time to deliver can be 
difficult, as fetal and neonatal benefits from prolongation of pregnancy needs to be balanced against 
the risk of multisystem dysfunction in the mother. Preterm delivery accounts for 65% of neonatal 
deaths and 50% of neurological disability in childhood.
13
 Current practice guidelines do not 
consider gestational age at presentation as a criterion for diagnosis, severity, or sub classification to 
stratify risk in women with pre eclampsia.
4;14
 Pre eclampsia is considered to manifest as two 
syndromes: Maternal, associated with hypertension and proteinuria, and fetal, manifested by 
intrauterine growth restriction (IUGR). The maternal syndrome the disease, may persist, often 
worsening briefly, following delivery of the imperfectly implanted placenta.
15
  
 
Although the proportion of women with early onset pre eclampsia is only 1% of all pregnancies, the 
complexity of the treatment gives rise to large health care costs.
8;9
 Patients are often admitted in a 
tertiary care facility and 30% experience complications, which may necessitate an intensive care 
facility.
16
 Infants usually need prolonged intensive care treatment for management of complications 
including lifelong handicaps arising as a result of pre maturity.  
 
One of the key recommendations in the last CEMACH (Confidential Enquiries into Maternal and 
Child Health) report for policy makers, service commissioners and providers, and healthcare 
professionals is the need to adopt an early warning system to help in the timely recognition, 
treatment and referral of treatment of women who have or are developing critical conditions.
7
 This 
applies to women with severe pre eclampsia where early recognition of women at risk of adverse 
outcomes can be transferred early from secondary to tertiary unit to enable care in a high 
dependency unit or neonatal intensive care unit if needed. Timely prediction of complications in 
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women with pre-eclampsia involves the use of a combination of patients‟ characteristics, 
symptoms, physical signs and investigations
17
 these „tests‟ are performed routinely in all units, but, 
in the absence of a structured approach, somewhat haphazardly. 
 
b. Epilepsy In Pregnancy 
Epilepsy affects 0.5-1% of general population.
18
 Approximately one third of people receiving 
anti epileptic drugs (AED) are of reproductive age.
19;20
 There is a 10-fold increase in mortality 
among pregnant women with epilepsy which greatly exceeds the two to three-fold mortality rate 
observed in all people with epilepsy.
21
 In 2000-2002, 13 maternal deaths in the UK were 
attributed to epilepsy.
22
 These were invariably a direct consequence of seizures. There is one in 
250 pregnancies exposed to AEDs .
23;24
 AED exposure in-utero is associated with congenital 
malformations.
25
  Fetal risk is related to the number of AEDs, AED type and probably AED 
dose.  Furthermore, there are concerns about the long-term neurological development of children 
exposed to AEDs in-utero. There is a general consensus that the risks of uncontrolled convulsive 
seizures in the mother outweigh the potential teratogenic risk of the medication, and most 
women with active epilepsy are advised to continue with medication during pregnancy.
18
 The 
effect of seizures extend into daily living resulting in loss of driving license, a negative impact 
on employment and relationships, and reduced Quality of Life (QoL).
26
 The triennial 
Confidential Enquiries into Maternal Deaths in the UK reported concerns about epilepsy 
management during pregnancy.
22
 
 
Seizure control is important during pregnancy. Uncontrolled epilepsy with generalised tonic-
clonic convulsions, carry risk of harm including miscarriage, fetal hypoxia and acidosis and fetal 
loss.
27-29
 The reasons for fetal loss are not entirely understood but are more likely to be related to 
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maternal seizures than to fetal exposure to AEDs.
29;30
 This is supported by the finding of fetal 
heart rate decelerations during maternal seizures.
31
  
 
Data from pregnancy registers and from Study of Standard Versus New Antiepileptic Drugs 
(SANAD), have increasingly influenced clinicians to favour the newer AEDs, with lamotrigine 
(LTG) being the first choice for women of child-bearing age.
32
 Prescription of newer AEDs has 
been increasing in NHS with associated drug costs (£99m of £142m).
33
 There are additional 
costs of monitoring in antenatal clinics and admission in hospitals if significant seizure 
deterioration occurs. Congenital malformations and the adverse effects on the neurodevelopment 
of children exposed to AEDs in utero have added morbidity and long-term costs.  
 
c. Pre-term labour 
Pre-term birth, i.e. delivery at less than 37 completed weeks‟ of gestation, is a heterogeneous 
condition. Spontaneous pre-term birth prior to 37 weeks' gestation occurs in 7-11% of pregnancies 
and occurs in 3-7% of pregnancies before 34 weeks‟ gestation.34 Pre-term delivery particularly that 
before 34 weeks‟ gestation, accounts for three-quarters of neonatal mortality and one-half of long 
term neurological impairment in children. Many of the surviving infants suffer serious morbidity 
such as respiratory distress syndrome, broncho-pulmonary dysplasia, intraventricular haemorrhage, 
retrolental fibroplasia and developmental problems.
34
 The additional NHS costs to care for a 
preterm baby born before 33 weeks and 28 weeks are £61,509 and £94,190 respectively.
35
 £939 
million in extra costs for care of preterm babies per year in the NHS are linked to neo-natal care 
such as incubation, and hospital readmissions.
35
  Delaying premature births by a week could 
potentially save  £ 260 million a year.
35
 Advances in perinatal healthcare have not reduced the rate 
of pre-term birth,
 
but there are some effective interventions to reduce the risk of short and long term 
sequelae to the premature neonates. 
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d. Congenital Heart Disease In Newborns 
Congenital heart disease (CHD)  is the commonest group of congenital malformations and affects 
7-8/1000 newborns.
36;37
  It contributes to 3% of all infant mortality and 46% of deaths from 
congenital malformations, with most deaths occurring in the first year of life. 
36
 A significant 
proportion of these children require surgery in the first year.  One of the major contributors to 
increased infant mortality and morbidity is clinical deterioration and collapse prior to diagnosis and 
treatment.
38-40
  Early detection of congenital heart disease in the asymptomatic period immediately 
after birth will reduce clinical deterioration by instigation of appropriate, timely management.  
Survival rates for infants with CHD have increased dramatically in recent years and over 80% of 
children born with CHD will survive to the age of 16 years; this is due largely to improvements in 
surgical techniques. Although the commonest types of CHD do not usually develop serious 
problems in the neonatal period, there are a number of important cardiac defects which, if 
undiagnosed, can present with potentially life-threatening cardiovascular collapse in the first few 
days of life. Although individually less common, when taken together, these lesions contribute 
significantly to death in infancy. As death or poorer outcome following surgery is much more likely 
if cardiovascular collapse occurs prior to diagnosis, timely recognition of these cardiac defects prior 
to collapse is vital in order to improve outcome. 
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1.4 Aims of thesis 
My thesis aims to conduct the Health Technology Assessment in maternal and perinatal medicine 
through the following four objectives: 
A. To perform Delphi survey of experts where there is no robust evidence to inform practice 
and to plan further research  
B. To review the methodological quality of existing reviews in maternal and fetal medicine 
C. To perform systematic reviews and meta analyses of the effectiveness of various 
interventions that reduce maternal and perinatal mortality and morbidity 
D. To conduct diagnostic reviews and meta analyses in maternal and perinatal medicine to 
assess the accuracy of tests in predicting maternal and fetal complications 
 
The specific reaseach questions that I have attempted to answer in this thesis are given below, and 
summarised in a structured format in Table 1.1 
 What tests in pre eclampsia are considered to be important by clinicians in predicting 
maternal and fetal complications in women with pre-eclampsia? 
 What is the quality of systematic reviews in maternal medicine and is there a difference in 
quality between Cochrane reviews and non Cochrane reviews? 
 What is the quality of systematic reviews in fetal medicine and is there a difference in 
quality between various areas in fetal medicine? 
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 Does the use of progesterones in women at risk of preterm labour reduce the risk of preterm 
births and neonatal mortality and morbidity? 
 Does regular therapeutic monitoring of serum lamotrigine levels in pregnant women with 
epilepsy reduce the risk of seizures compared to management based on clinical features 
alone? 
 How accurate are tests like proteinuria, uric acid, liver function tests, symptoms and blood 
pressure in women with pre eclampsia in predicting maternal and fetal complications? 
 What is the accuracy of pulse oximetry as a screening tool in identifying congenital heart 
disease in newborns? 
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Table 1.1 Structured questions for each chapter of this thesis 
Chapter 
Number 
Population Intervention or Test Outcome(s) Research 
Design 
Objective A: Delphi Survey of practice where there is no robust evidence 
2, 3 Women with pre 
eclampsia 
Tests including clinical history, 
examination and investigation 
Maternal and 
fetal mortality 
and morbidity 
Delphi survey 
 
Objective B: To review the quality of systematic reviews in maternal and fetal medicine 
 
4 Maternal 
medicine reviews 
Cochrane Vs Non Cochrane Adherence to pre 
specified good 
quality items 
Systematic 
review 
5 Fetal medicine 
reviews 
Quality across 4 areas: fetal 
aneuploidy, fetal therapy, fetal 
pathology and fetal growth 
Adherence to pre 
specified good 
quality items 
Systematic 
review 
 
Objective C: To undertake systematic reviews and meta analyses of therapy studies 
 
6 Pregnant women 
at risk of pre term 
labour 
Progeterone Vs Placebo Delivery before 
34 weeks, 36 
weeks, perinatal 
mortality and 
other clinically 
relevant 
outcomes 
Systematic 
review and 
meta analysis 
7 Pregnant women 
with epilepsy on 
lamotrigine 
Routine therapeutic monitoring Vs 
Management based on clinical 
features only 
Seizures, any 
other relevant 
maternal and 
fetal outcome 
Systematic 
review and 
meta analysis 
 
Objective D: To undertake systematic reviews and meta analyses of test accuracy 
 
8-14 Women with pre 
eclampsia 
-Proteinuria 
-Uric acid 
-Liver function tests 
-Symptoms 
-Blood pressure 
 
Adverse 
maternal and 
fetal outcomes 
Systematic 
review and 
meta analysis 
15 Newborns  Pulse oximetry Congenital heart 
disease 
Systematic 
review and 
meta analysis 
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1.5 Health Technology Assessment methods in the thesis 
1.5.1 Delphi survey 
A valid Delphi process would consist of at least a three-iteration questionnaire survey, although 
decision about the number of rounds is largely pragmatic. The purpose of the initial iteration is to 
identify broad issues related to the various components of the issue at hand. A questionnaire 
consisting of open-ended questions is circulated to a panel of experts and opinion leaders. The 
responses to the open-ended questions are analysed qualitatively by sorting, categorising and 
searching for common themes. These responses are edited and then used to construct the second 
questionnaire.  
 
The second and subsequent rounds are more specific with the questionnaire seeking the rating or 
ranking of various items in terms of their significance and analysed quantitatively. As the 
researcher feeds back results from the previous rounds there tends to be convergence to a consensus 
of opinion
41
. 
 
1.5.2 Systematic review of reviews 
A good systematic review should: develop a focussed question, undertake a detailed search to 
identify all the relevant published and unpublished literature, independently selected the studies 
from specific inclusion and exclusion criteria as per the protocol, critically appraise the quality of 
included studies, extract relevant data and conduct appropriate meta analysis to formulate 
recommendations.  
 
The checklist for the review of reviews in maternal and fetal medicine consisted of items divided 
into three domains concerning the review question, the literature search and the review methods. 
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These items evaluated the likelihood of errors and bias in the review process. A 'good' quality item 
was one where there was a clear description in the report of compliance with the items, whereas a 
'bad' quality item either did not comply with or did not report sufficient details to assess the item.
42
 
Some of the items related to explicitness of reporting that results in scientific transparency in a 
review. There are various instruments reported in literature to evaluate the quality of systematic 
reviews. Although some may have face and content validity, they have not demonstrated 
satisfactory reproducibility or construct validity to be applied in practrice.
43
 
 
1.5.3 Systematic review of effectiveness 
Systematic reviews of effectiveness were carried out using review methodology based on a 
prospective protocol in line with the recommendations of the NHS Centre for Reviews and 
Dissemination and the Cochrane Collaboration.
44-49
 The output from the reviews are based on 
existing guidelines and comply with QUOROM  (QUality Of Reporting Of Meta-analyses) 
statement.
50
 The PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 
statement was published recently after completion of the reviews included in the thesis.
51
 The 
reviews are compliant with most of the PRISMA checklist components. 
 
Study identification and selection: The structured questions were focussed and well defined in this 
thesis detailing population, interventions and comparison and study designs. A database of 
published and unpublished literature were assembled from searches in major electronic databases 
including Medline and Cochrane using a comprehensive search strategy, as well as hand searching. 
Language restrictions were not applied. The citation were scrutinised by two reviewers. Copies of 
full manuscripts of all citations that were likely to meet the selection criteria were obtained. Two 
reviewers then independently selected the studies, which met the predefined criteria. These criteria 
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were pilot tested using a sample of papers. Disagreements were resolved by consensus and/or 
arbitration involving a third reviewer.  
 
Study quality assessment and data extraction: The quality of the selected primary randomised 
controlled trials (RCT's) and observational studies were assessed based on accepted contemporary 
standard.
52-54
 To assess the quality, we considered first of all risk of bias (internal validity), i.e. the 
extent to which design, methods, execution and analysis did not control for bias in assessment of 
effectiveness.
46
 Furthermore, we explored the (in-) consistency of results (heterogeneity), (in-) 
directness of the evidence (to the question under consideration, including surrogate parameters), 
(im-) precision of the results and publication bias. Individual studies were described by study type, 
intervention, numbers taking part, population denominator (eg pregnant women or fetuses) and 
study quality. In addition to using study quality as possible explanations for differences in results 
(heterogeneity), the extent to which primary research met methodological standards is important 
per se for assessing the strength of any conclusions that were reached.  Study findings and data 
were extracted in duplicate using pre-designed and piloted data extraction forms. 
 
Data synthesis: Separate analyses were performed on randomised and non-randomised data using 
Stata software.  Any heterogeneity of results between studies was statistically and graphically 
assessed. The causes of the heterogeneity were explored and meta-analysis was performed if 
appropriate. To explore causes of heterogeneity subgroup analyses were planned a priori to see 
whether variations in clinical factors e.g. populations, interventions, outcomes or study quality 
affected the estimation of effects. Conclusions regarding the typical estimate of an effect size of the 
intervention were interpreted cautiously if there was significant heterogeneity. 
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1.5.4  Systematic review of test accuracy 
Systematic reviews of test accuracy were conducted using established systematic review 
methodology
 
 in line with the recommendations of the NHS Centre for Reviews and Dissemination 
and the Cochrane Collaboration including those of Cochrane Methods Working Group on 
Screening and Diagnostic tests.
55;56
 
 
Study identification and selection: This was performed as outlined in Section 1.3.3.  
 
Study quality assessment and data extraction: Methodological quality of the selected primary 
studies were assessed based on elements of study design, conduct and analysis included in the 
validated assessment tool, QUADAS (Quality of Diagnostic Accuracy Studies), adapted to the topic 
area as necessary.57 Data extraction was performed by two reviewers using pre-designed, piloted 
data extraction forms. 
 
Data synthesis: Sensitivity, specificity and likelihood ratios for individual studies were derived. 
Presence of a threshold effect were examined by plotting sensitivity against 1- specificity in a 
receiver operating-characteristic analysis (ROC analysis) and by calculating Spearman correlation 
coefficients.
58
 A bivariate random effects meta-regression model was used to fit a summary ROC 
(sROC) curve. Briefly, the bivariate model preserves the two-dimensional nature of diagnostic data 
in a single model. This model incorporates the correlation that may exist between sensitivity and 
specificity within studies due to possible differences in threshold between studies.
59
 AUC (Area 
Under the Curve) values between 0.70 and 0.79 were deemed as having moderate discriminative 
properties, and those with AUC values of ≥ 0.80 as having good discriminative properties. 
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Heterogeneity of results between studies were investigated qualitatively by examining the 
distribution of sensitivities and specificities in (ROC) space and variability of accuracy estimates 
across studies using the forest plot.
58
  Data was analysed using Metadisc and Stata softwares. 
 
Fig 1.2 summarises the HTA in maternal and perinatal medicine conducted as part of this PhD 
thesis. 
 
Fig 1.2. An overview of Health Technology Assessment of topics in maternal and perinatal 
medicine in the thesis 
 
Surveys (A), Review of reviews (B)
Delphi survey of tests in pre eclampsia , Review of reviews in maternal and fetal 
medicine
None or poor quality reviews
Conduct systematic review 
Good quality 
reviews with precise 
results
Recommendations  for practice
Systematic reviews of test 
accuracy (D)
Tests in pre eclampsia
Pulse oximetry for congenital 
heart disease in newborn
Systematic reviews of 
therapy (C)
Progesterone in preterm labour  
Anti epileptic drugs in pregnancy
Recommendations  for research
Prioritisation 
of research 
topic
Section A, B
Chapters 2-5 
Research
Section C
Chapters 6,7
Section D
Chapters 8-15
Conclusions
Chapter 16
Primary study
PREP, Pulse Ox,  SOAP
 
PREP – Prediction of Risks in Early onset Pre eclampsia 
Pulse Ox –Pulse Oximetry as a screening tool for detecting congenital heart disease in newborn 
SOAP – Study of Optimal Anti epileptic drug monitoring in Pregnancy 
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SECTION A 
DELPHI SURVEY 
 
In this section, I have undertaken a Delphi survey of experts to prioritise the list of tests in pre 
eclampsia that are considered to be predictive of adverse maternal and fetal outcomes 
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CHAPTER 2: THE DELPHI TECHNIQUE 
 
2.1 Abstract 
Background 
The Delphi technique involves the collection and aggregation of expert opinion. It straddles the 
divide between qualitative and quantitative methodologies. The cardinal features of Delphi method 
are the use of a number of questionnaire rounds, feed-back of responses, the opportunity for 
participants to modify their responses and anonymity of responses. 
 
Methods 
A valid Delphi process would consist of at least a three-iteration questionnaire survey. The purpose 
of the initial iteration is to identify broad issues related to the various components of the issue at 
hand. The second and subsequent rounds are more specific with the questionnaire seeking the rating 
or ranking of various items in terms of their significance and analysed quantitatively. Most 
feedback is numerical or statistical with some form of aggregated group response.  Statistical feed-
back often uses medians, usually accompanied by minima and maxima, quartiles and/or the inter-
quartile range. 
 
Conclusion 
The consensus-forging nature of the Delphi technique can be used to good effect in enabling 
evidence-based medical guidelines to become adopted by clinical groups. It is a useful tool for 
developing group consensus and can avoid many of the counterproductive pitfalls that can bedevil 
face-to-face meetings. 
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2.2 Background 
The Delphi technique involves the collection and aggregation of expert opinion.  It was initially 
used by the military to estimate the probable effects of massive atomic bombing but now has 
applications in economic and financial settings, civic planning and health care: very much a case of 
turning swords into ploughshares. 
 
Its original purpose was to “obtain the most reliable consensus of opinion of a group of experts… 
by a series of intensive questionnaires interspersed with controlled opinion feed-back”60, 
particularly in areas “where hard data was unavailable or too costly to obtain61”. The cardinal 
features of Delphi method are the use of a number of questionnaire rounds, feed-back of responses, 
the opportunity for participants to modify their responses and anonymity of responses. 
 
Delphis are about the harnessing and organising judgement, particularly in problems that are 
complex and require intuitive interpretation of evidence or informed guesswork. A Delphi can be 
used as an alternative to conventional meetings, avoiding problems arising from powerful 
personalities, group pressures and the effects of status. This is manifest more in the hierarchical 
structure of the health profession, where more junior practitioners may be reluctant to challenge the 
opinion of their seniors
62
. Its structure and sense of direction provides focus and avoids entropic 
and often counterproductive discussions and digressions that bedevil face-to-face group 
discussions.  
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2.3 Methods 
2.3.1 Conduct of a Delphi survey 
A valid Delphi process would consist of at least a three-iteration questionnaire survey, although 
decision about the number of rounds is largely pragmatic. The purpose of the initial iteration is to 
identify broad issues related to the various components of the issue at hand. A questionnaire 
consisting of open-ended questions is circulated to a panel of experts and opinion leaders. The 
responses to the open-ended questions are analysed qualitatively by sorting, categorising and 
searching for common themes. These responses are edited and then used to construct the second 
questionnaire. The second and subsequent rounds are more specific with the questionnaire seeking 
the rating or ranking of various items in terms of their significance and analysed quantitatively. As 
the researcher feeds back results from the previous rounds there tends to be convergence to a 
consensus of opinion
41
. A typical Delphi includes use of a number of questionnaire rounds, feed-
back of responses, the opportunity for participants to modify their responses and anonymity of 
responses.  
 
2.3.2 Methodological considerations 
What’s an expert? 
Some would argue that an expert is “any individual with relevant knowledge and experience of a 
particular topic”63.  This depends on the setting and objectives of the Delphi in question.   
Size of Panel 
There are no hard and fast rules.  Linstone
64
   suggests that “a suitable minimum panel size is 
seven” but panel sizes have ranged from 4 to 3000.  It seems therefore that the decision about panel 
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size an empirical and pragmatic one taking into consideration factors such as time and expense
65
. 
Representation is assessed by the qualities of the expert panel than its numbers
66
. 
Selection of the panel 
The Delphi technique straddles the divide between qualitative and quantitative methodologies; this 
is especially evident in the issue of how to select the panel. There is a danger of bias where experts 
are selected on the basis of acquaintance with researchers, which may be a difficult factor to 
address in intensely specialised areas
67
.  Some express concern about bias resulting from poor 
selection methodologies whilst others dismiss these concerns. The implication is that random 
sampling may not always be appropriate particularly in areas of clinical intervention  where it is 
more appropriate to select specialists in that area. It is sensible to describe what criteria were used. 
Anonymity of panelists 
Anonymity of individual responses is one of the key features said to characterise the Delphi
61
. It 
means that panelists will not know who made what response, although more extensive 
constructions of anonymity have been suggested, even to the point that the responses are 
anonymous to the researchers
68;69
. The advantage of anonymity is that it is a leveller of opinion, 
removing the effects of status, personalities and group pressures that can arise in meetings
69-71
.  
Questionnaire design and scoring methods 
Panelists‟ views have been recorded using a variety of scoring methods.  Linear numerical scales, 
such as described by Likert
72
, are often used.  Concern has been expressed about the validity of 
some of the scoring methods used and on the way the data have been aggregated. Delphi reports 
often give little information on the actual scoring and aggregation methods used and greater clarity 
in reports would be desirable.  
Feed-back 
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Feed-back with an opportunity to revise earlier responses is an important Delphic feature but it is 
also a potential weakness. The researcher should be impartial and provide feed-back in a reliable 
and valid way highlighting the degree of dissent and divergence amongst participants‟ views67. 
Furthermore, feed-back response depends not only on the feed-back but also by the respondents‟ 
reaction to it. 
Most feedback is numerical or statistical with some form of aggregated group response.  Sometimes 
these data can be supplemented by non-quantitative information such as justifications or other 
comments.  Statistical feed-back often uses medians, usually accompanied by minima and maxima, 
quartiles and/or the inter-quartile range. Participants should also be informed about the position of 
their scores in relation to the overall picture so that it gives them an opportunity to revise previous 
scores in view of the group response
66
. 
Number of rounds 
  A valid Delphi requires a minimum of two rounds (three if round one is open-ended). Feed-back 
to respondents and the opportunity to revise earlier responses are arguably defining features of 
Delphi.  This requires a minimum of two rounds. Beyond that, the number of rounds is disputed.  
Walker and Selfe
73 make the sensible point that “repeated rounds may lead to fatigue by 
respondents and increased attrition”.  Most studies use only two or three rounds. 
Consensus 
The Delphi was originally developed as means for gaining consensus though this is not always the 
case.  It has, nonetheless, been argued that the Delphi is “designed to force consensus”74. This 
might occur by the way the questionnaire data is presented or perhaps in the way it is analysed.  
Simple statistical summaries will conceal important variations in distribution, such as bimodal 
patterns that could demonstrate a lack of consensus
66
.  Mullen
75
 points out that the question of 
whether or not consensus should be sought depends: if the aim is to find the correct answer, as in a 
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positivist sense, outliers have to be considered as they might be right; when the aim is to obtain 
normative views, seeking consensus is appropriate.  
 
2.4 Scientific Merit 
One of the arguments against Delphi technique is that these studies mostly overlook reliability 
measurements and scientific validation of the findings
76
. However the role of Delphi comes into 
play to resolve a situation where no conclusive hard evidence is available, by drawing on, and 
sharing the knowledge and experience of experts. Therefore it should not be subject to the same 
validation criteria as hard science
77
. Alternate means have been suggested to express the validity 
and credibility of Delphi findings
66
. The findings of one study can be „tested‟ or confirmed in 
another study with a different sample as a means of validation
78
.  Inclusion of a clear decision trait 
that explains the appropriateness of the method selected to address a problem, choice of expert 
panel, data collection procedures, identification of justifiable consensus levels and means of 
dissemination and implementation are features that determine the credibility of the method
77
. 
 
2.5 Health Service Applications 
Since 1969, there have been over 1400 publications using this technique in a health care setting, 
most of which have been published in the last 10 years.  Its applications have included forecasting 
disease patterns and health funding requirements, addressing clinical problems, and education.   
 
Forecasting 
As a forecasting tool, researchers have used Delphi methodology to predict developments in a 
variety of health care areas, including child and maternal health. For example, Longhurst
79
 used a 
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Delphi to predict how improvements in nutrition, family income and prenatal care would impact on 
birth weight and subsequent intellectual development.   
 
Consensus in clinical problem-solving 
Delphi can be used as a way of obtaining consensus about tackling clinical problems and, in this 
context, is useful as a clinical management tool.  It has been particularly useful in the development 
of performance indicators, which is a notoriously controversial area
80
. This type of approach could 
be used to proactively determine performance indicators in a variety of clinical settings, including 
obstetric and gynaecological wards.  
 
Clinical guidelines 
The consensus-forging nature of the Delphi technique can be used to good effect in enabling 
evidence-based medical guidelines to become adopted by clinical groups.  In essence this approach 
involves the development of evidence-based guidelines which were then modified and finally 
ratified by a Delphi process.  This approach worked well in the multi-national context of European 
colposcopy whereby a set of evidence-based colposcopic clinical guidelines on treatment have been 
produced
81
.  Discussion and exploration of differences were an important part of this process and 
this was served well by the iterative methodology inherent in the Delphi process. Guidelines 
developed in this way need a process of validation with some ensuing modification, if needed. 
 
Education 
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In clinical education the Delphi technique has been used in a variety of ways which include 
forecasting and planning, and curriculum development.  
 
2.6 Conclusion 
As in any area of clinical practise, obstetrics and gynaecology generates an array of problems that 
are complex and not amenable to simple didactic analysis. In this context, the Delphi technique is a 
particularly useful tool for developing group consensus and can avoid many of the 
counterproductive pitfalls that can bedevil face-to-face meetings. 
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CHAPTER 3: PRIORITISATION OF TESTS FOR THE PREDICTION OF 
COMPLICATIONS OF PRE-ECLAMPSIA: A DELPHI SURVEY 
 
3.1 Abstract 
Background 
Pre eclampsia is associated with several maternal and fetal complications. Numerous tests, 
including items of history, examination findings and investigations are used to predict such 
complications in women with pre-eclampsia. At present there are no robust systematic reviews, or 
large studies on accuracy of tests that could predict complications in women with pre eclampsia.  
 
Method 
To identify the tests which include items of history, examination and investigations, that are 
clinically relevant in predicting maternal and fetal complications in women with pre-eclampsia 
using a two generational Delphi method   
 
Results 
Blood pressure was rated as the best predictor of complications with mean score (SD) of 4.7 (± 
0.47), followed by proteinuria 4.6 (± 0.5) and liver function tests (4.5, ± 0.52) (scale x to y 
anchored between 0 -5). 
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Conclusion 
The list of tests that have been identified and prioritised will form the basis for future systematic 
reviewing of literature in this field. 
 
Citation of paper published from this work 
Thangaratinam S, Ismail K, Sharp S, Coomarasamy A, O'Mahony F, Khan KS, O'Brien S; TIPPS 
(Tests in Prediction of Preeclampsia's Severity) Review Group. Prioritisation of tests for the prediction 
of preeclampsia complications: a Delphi survey. Hypertens Pregnancy. 2007; 26: 131-8. 
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3.2 Background 
Hypertensive disorders in pregnancy remain one of the largest causes of maternal and fetal 
mortality and morbidity.
82;83
 The commonest among them, pre-eclampsia, is associated with several 
complications.
82
 Clinical prediction of disease complications using a combination of patients‟ 
characteristics, symptoms, physical signs and tests, forms the basis of clinical care in this situation. 
Early prediction and identification of complications will be of benefit to patients by monitoring 
disease severity, use of antihypertensive therapy
84
, administration of anticonvulsants
85
, and 
steroids
86
. as well as allowing clinicians to avoid unnecessary interventions in low risk groups.
87;88
 
At present there are no systematic reviews or large studies on accuracy of tests that could predict 
complications in women with pre-eclampsia. There are a large number of tests in practice and 
research with considerable variation in their use. The need to identify clinically useful tests that 
predict maternal or fetal complications is the first step in determining the scope of the research in 
this broad field. We decided to use the Delphi method for the purpose of identifying and prioritising 
the relevant tests.  
 
3.3 Method 
The Delphi Technique 
A two generational Delphi method was used to prioritise the clinically relevant tests that are 
considered helpful in predicting maternal and fetal complications of pre-eclampsia. The purpose of 
the first iteration was to narrow down the large number of tests that might aid in the prediction of 
complications of pre-eclampsia. The second iteration was conducted to prioritise the eventual list of 
relevant tests to clinical practice, determined by feedback from the initial round with convergence 
of opinion.   
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Selection of experts 
The panel of experts was selected for their interest in the field of pre-eclampsia that included 
medical experts on the panel of APEC (Action on Pre-eclampsia) group and specialists with 
research interest in this area. They were selected for two reasons. Firstly as academics with special 
interest in this field, they have the knowledge and opinion of existing evidence. Secondly as 
practicing clinicians, they have the understanding of applicability and relevance of these tests to 
clinical practice. A total of twenty-five experts were included in the study, 24 from the United 
Kingdom and one from Australia.  
 
First Iteration 
We searched MEDLINE (1951-2004), EMBASE (1974-2004), Cochrane Library (2004:4) and 
MEDION (a database of diagnostic test reviews set up by Dutch and Belgian researchers) for 
relevant citations. We identified 33 tests that might aid in the prediction of maternal and fetal 
complications of pre-eclampsia. A structured list of these tests was sent along with a covering letter 
explaining the purpose of this survey.  The questionnaire was sent by e-mail and anonymity was 
maintained between panelists (Appendix 31). Two reminders were sent to non responders by e-
mail. In the first round, the experts were asked to rank the „tests‟ for their importance to clinical 
practice in predicting possible maternal and fetal complications on a 0 to 5 scale (0-unnecessary; 1-
not important; 2-slightly important; 3-moderately important; 4-very important; 5-essential). The 
mean score with standard deviation was calculated for each test. 
 
Second Iteration 
Tests that had a mean score 2.0 or more were included for rating in the second round. In this round, 
the experts were asked to reconsider their previous rating in view of the panel score (Appendix  32). 
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The new mean ratings were recalculated. Tests that scored 3.0 or more were considered to be 
clinically significant. 
    
3.4 Results 
First Iteration 
Eighteen experts responded to the questionnaire in the first round and fifteen reported their results. 
Rating was not performed on the grounds of clinical inadequacy by one pure academician and 
personal uncertainty in the Delphi method of survey by two experts. Twenty five tests from a total 
of 33 had a mean score of 2.0 or more in this round. Blood pressure was rated as the best predictor 
with mean score (SD) of 4.8 (± 0.41), followed by ophthalmologic findings, liver function tests and 
proteinuria with mean scores (± SD) of 4.3 (± 1.1), 4.3 (± 1.3) and 4.3 (± 1.3) respectively. Weight 
gain (1.3 ± 1.1), oedema (1.3 ± 0.97), urinary calcium excretion (1.5 ± 1.3), microalbuminuria (1.8 
± 1.5), maternal serum alpha feto protein (1.2 ± 1.2), imaging techniques of brain (1.5 ± 1.2), serum 
human chorionic gonadotrophin (1 ± 0.92) and fibronectin (0.8 ± 1) that scored as poor predictors 
were excluded for rating in the second round. 
 
Second Iteration 
There was a 73% (11/15) response to the second round questionnaire. Eleven experts reconsidered 
their previous score in view of the panel results and four of them changed their previous ratings for 
a total of twenty four items. Seventeen tests that had a mean score of 3 or more were included in the 
final list (Table 3.1).  Blood pressure and proteinuria were considered as the most important 
predictors of complications in pre-eclampsia with mean scores of 4.7 (± 0.47) and 4.6 (± 0.5) 
respectively followed by liver function tests (4.5, ± 0.52) and pre-eclampsia in the presence of pre-
existing medical conditions like hypertension, renal disease and diabetes (4.4, ± 0.81). All four of 
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the above tests were considered to be clinically significant predictors by the entire group.  Full 
blood count (4.3, ±0.9), renal function tests (4.1, ±0.94) and multiple pregnancy (3.7, ±0.79) were 
the other tests that were scored as significant predictors by all the experts. Only 64% of the group 
considered uric acid to be a moderately or very important predictor of complications.  Coagulation 
screen mean score of 3 (±1.6) was derived from the first iteration only as it was missed for inclusion 
in the second round list of tests.  Race, parity, obesity, family history of pre-eclampsia, deep tendon 
reflexes were considered to be not important or only slightly important predictors of adverse 
outcomes in pre-eclampsia.  
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No. Tests 
First Iteration Second Iteration 
Mean 
Standard 
deviation 
% ≥ 
2 
Mean 
Standard 
deviation 
% 
≥ 3 
1 Blood pressure 4.8 0.41 100 4.7 0.47 100 
2 
 
Proteinuria ( 24 hr collection, dipstick) 4.3 1.3 93 4.6 0.50 100 
3 
 
Liver function tests 4.3 1.3 93 4.5 0.52 100 
4 
 
Pre existing hypertension, renal disease, diabetes 4.1 1.1 93 4.4 0.81 100 
5 
 
Full blood count 4.1 1.3 93 4.3 0.90 100 
6 
 
History of lupus, thrombophilia, other auto immune 
diseases 3.9 1.5 93 4.3 1.0 91 
7 
 
Symptoms-headache, epigastric pain , nausea, visual 
disturbance 4.1 1.2 93 4.2 0.87 91 
8 
 
Papilloedema, Retinal changes 4.3 1.1 100 4.1 1.1 82 
9 
 
Renal function tests 4.1 1.2 93 4.1 0.94 100 
10 
 
Ultrasound including Doppler 3.7 1.6 87 4.0 1.2 82 
11 
 
Previous history of severe pre-eclampsia / Eclampsia 3.9 1.2 87 3.9 0.94 91 
12 
 
Oliguria 3.9 1.2 100 3.9 0.94 91 
13 
 
Clonus 3.5 1.1 100 3.9 0.83 91 
14 
 
Multiple pregnancy 3.4 1.3 93 3.7 0.79 100 
15 
 
Symphysio fundal height 3 1.3 87 3.2 0.75 82 
16 
 
Coagulation screen 3 1.6 80 3
* 
1.6
* 
- 
17 
 
Serum uric acid 2.8 1.8 67 3.1 1.7 64 
18 
 
Hypoalbuminaemia 2.7 1.5 73    
19 
 
Maternal age 2.7 1.7 60    
20 
 
Family history of pre-eclampsia 2.7 1.5 67    
21 
 
Exaggerated tendon reflexes 2.5 0.99 87    
22 
 
Parity 2.5 1.6 67    
23 
 
Race 2.3 1.2 80    
24 
 
Obesity 2.3 1.5 67    
25 
 
Thrombophilia screen 2.1 1.4 67    
 
Table 3.1. List of tests that are considered to be clinically important in predicting maternal and 
fetal complications of pre-eclampsia identified after first and second iterations of the Delphi survey 
* Score calculated from first iteration only 
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3.5 Discussion 
One of the questions remaining after establishing effectiveness of magnesium sulphate
85
, steroids
5
 
and anti-hypertensives
3
 in reducing maternal and fetal mortality and morbidity in women with pre-
eclampsia, is to identify those who will benefit most from these interventions. There are no 
guidelines, systematic reviews or large studies that provide evidence on the accuracy of various 
tests to predict complications of pre-eclampsia. Subsequently, we have embarked on the task of 
identifying and prioritising a list of such tests using the Delphi method. We plan to review the 
prioritised tests systematically in the near future. 
 
The Delphi consisted of an iterative methodology that allowed the participants to maintain 
anonymity while preventing domination by particular individuals who might otherwise be overly 
influential in a group decision.
69-71
 Communication via e mail was a cost effective, time saving 
exercise and had helped to overcome geographical boundaries. The feedback after successive 
rounds provided an opportunity to the respondents to reconsider their original opinion.
66
 Some 
clinical and biochemical tests like deep tendon reflexes, clonus and serum uric acid are often given 
importance in clinical practice, but have scored poorly in this survey. A subsequent systematic 
review conducted by us has identified uric acid as a poor predictor of adverse maternal and fetal 
outcomes in pre-eclampsia (Chapter 10), thus substantiating the results of this survey.  
 
The scientific merit and validity of such an exercise as the Delphi method that we used is often 
questioned.
76
 However this method is important in situations where no conclusive hard evidence is 
available, by attempting to provide answers by relying on and sharing the knowledge and 
experience of experts in the field.
77
 We acknowledge that there is the possibility that a panel with 
different composition might identify a different set of results.  
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3.6 Conclusion 
This exercise has identified the tests that can be prioritised from the numerous proposed tests, for 
the purpose of conducting systematic reviews of diagnostic accuracy of the tests that predict 
complications of pre-eclampsia. This will help to generate practice guidelines and specific 
recommendations for future research. 
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SECTION B 
REVIEW OF REVIEWS 
 
In this section, I have evaluated the methodological quality of all systematic reviews in 
maternal and fetal medicine 
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CHAPTER 4:  A REVIEW OF SYSTEMATIC REVIEWS IN MATERNAL 
MEDICINE 
4.1 Abstract 
Introduction 
In maternal medicine, research evidence is scattered making it difficult to access information for 
clinical decision making. Systematic reviews of good methodological quality are essential to 
provide valid inferences and to produce usable evidence summaries to guide management. This 
review assesses the methodological features of existing systematic reviews in maternal medicine, 
comparing Cochrane and non-Cochrane reviews in maternal medicine. 
 
Methods 
Medline, Embase, Database of Reviews of Effectiveness (DARE) and Cochrane Database of 
Systematic Reviews (CDSR) were searched for relevant reviews published between 2001 and 2006. 
We selected those reviews in which a minimum of two databases were searched and the primary 
outcome was related to the maternal condition. The selected reviews were assessed for information 
on framing of question, literature search and methods of review. 
 
Results 
Out of 2846 citations, 68 reviews were selected. Among these, 39 (57%) were Cochrane reviews. 
Most of the reviews (50/68, 74%) evaluated therapeutic interventions. Overall, 54/68 (79%) 
addressed a focussed question. Although 64/68 (94%) reviews had a detailed search description, 
only 17/68 (25%) searched without language restriction. 32/68 (47%) attempted to include 
unpublished data and 11/68 (16%) assessed for the risk of missing studies quantitatively. The 
reviews had deficiencies in the assessment of validity of studies and exploration for heterogeneity. 
When compared to Cochrane reviews, other reviews were significantly inferior in specifying 
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questions (OR 20.3, 95% CI 1.1–381.3, p = 0.04), framing focussed questions (OR 30.9, 95% CI 
3.7-256.2, p = 0.001), use of unpublished data (OR 5.6, 95% CI 1.9–16.4, p = 0.002), assessment 
for heterogeneity (OR 38.1, 95%CI 2.1, 688.2, p = 0.01) and use of meta-analyses (OR 3.7, 95% CI 
1.3–10.8, p = 0.02). 
 
Conclusion 
This study identifies areas which have a strong influence on maternal morbidity and mortality but 
lack good quality systematic reviews. Overall quality of the existing systematic reviews was 
variable. Cochrane reviews were of better quality as compared to other reviews. There is a need for 
good quality systematic reviews to inform practice in maternal medicine. 
 
Citation of published paper of this work 
Sheikh L, Johnston S, Thangaratinam S, Kilby MD, Khan KS. A review of the methodological 
features of systematic reviews in maternal medicine. BMC Med. 2007;5:10.   
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4.2 Introduction 
Maternal medicine has emerged as an increasingly important area for the obstetricians dealing with 
high risk pregnancies. It involves care of women with medical complications of pregnancy which 
may be specific to or predate the pregnancy.
89
 Approximately half of complex pregnancies are 
related to an abnormal fetal or obstetric factor, whereas medical diseases constitute the remainder 
of this high risk obstetric population. Scientific developments in internal or general medicine have 
led to newer diagnostic and therapeutic strategies to manage medical diseases. The physiological 
changes during pregnancy can affect not only the clinical presentation of a medical problem but 
may give rise to difficulties in diagnosing and managing these problems. In order to provide the 
best possible quality of care to women with complicated pregnancies obstetricians dealing with the 
high risk obstetric cases should have evidence based knowledge on the diagnostic, therapeutic and 
prognostic aspects of maternal medicine. 
 
As maternal medicine covers the issues related to pregnancy as well as general medicine, research 
evidence is scattered in the literature making it difficult to access information for clinical decision 
making. Systematic reviews provide a way forward as individual pieces of research can be 
collected within literature reviews and if appropriate subjected to meta-analysis.
90
 Good 
methodological quality is essential for these reviews to have valid inferences and to produce usable 
evidence summaries to guide the obstetric management.
91
 This study examines the methodological 
features of recently published systematic reviews in maternal medicine and specifically compares 
Cochrane to non-Cochrane reviews. 
 
  
63 
 
4.3 Methods 
To determine the quality of current systematic reviews in maternal medicine, we developed a priori 
protocol based on recommended methods.
50;92;93
  A computerised search of publicly available 
databases was conducted. Ovid Medline (1996 to 2006), Embase (1996 to 2006), Database of 
Reviews of Effectiveness and Cochrane Database of Systematic Reviews were searched for 
relevant reviews published between 2001 and 2006. Key word combinations like Pregnan$, 
Matern$, Gestation$, Obstetric$, Complication$, Systematic review$ and Meta analys$ were used 
for the search strategy in addition to word variants, subject headings and free text. The $ sign is a 
truncator used to capture any word that begin with the letters in front of the $ sign in the search 
terms used. Additionally common and specific medical problems related to pregnancy were 
searched using key words describing names of the disease such as Pre eclampsia, Hypertension, 
Diabetes, Cholestasis, Anaemia, Thrombocytopaenia, Thrombophilia, and Thromboembolism. A 
hand search of reference lists was conducted of all relevant articles to identify any missing reviews. 
The searches were limited to reviews between 2001 and 2006 due to increasing developments in the 
field of maternal medicine in recent years. Inclusion criteria required a minimum of two publicly 
available databases searched for a medical condition specific to or predating pregnancy and 
maternal factor as the primary outcome. We searched without language restrictions. All the reviews 
with fetal or neonatal factor as the primary outcome were excluded.  
 
Two reviewers independently extracted and assessed the data according to a checklist formulated as 
part of our protocol (Appendix 30). The methodological quality of each review was assessed by 
focussing on framing of the question, literature search and review methods scrutinising methods of 
literature search and data synthesis. The items assessed internal validity and explicitness of 
reporting, both of which are important issues in quality of reviews. Differences between reviewers 
were resolved by discussion. We computed rates of compliance with the items in our checklist and 
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compared Cochrane and non-Cochrane reviews. Odds ratios (OR) and their 95% confidence 
intervals (CI) were computed. All statistical analysis was performed using Stata 8.0 statistical 
package. 
 
4.4 Results 
The initial literature search resulted in 2846 citations. The study selection process is shown in 
Appendix 1. Of these 68 reviews
94-161
 fulfilled the inclusion criteria and were selected for detailed 
study.  A total of 39 (57%) Cochrane reviews
94-132
 and 29 (43%) non Cochrane reviews
133-161
 were 
included. Most of the reviews assessed therapeutic interventions (50/68, 74%), and the rest were 
reviews on prognosis (12/68, 17%) and diagnosis (6/68, 9%). The range of clinical topics dealt with 
by the reviews is shown in Fig 4.1. 
Fig 4.1. Review topics in maternal medicine
 
  
65 
 
 
The overall quality of the existing systematic reviews was variable.  The majority of the reviews 
(62/68, 91%) specified the question and 54/68 (79%) had a focussed question with clearly defined 
population and outcome measures. A large population of the reviews (64/68, 94%) had a detailed 
search description including databases searched and key words used. Almost half of the reviews 
(32/68, 47%) attempted to include unpublished data. However only 11/68 (16%) assessed the risk 
of missing studies quantitatively and 17/68 (25%) searched without language restriction. Almost all 
the reviews had good tabulation of results and characteristics of included studies (65/68, 96%). 
 
Fig 4.2 Methodological quality of Cochrane and non Cochrane reviews included 
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The quality of Cochrane and non Cochrane reviews is given in Fig 4.2. Cochrane reviews  had 
specified the questions more often than non Cochrane reviews
133-137;139-141;150;151;153-157
  (OR 20.3, 
95% CI 1.1–381.3, p = 0.04) and were also framed narrowly focussed questions specifying the 
population, interventions and comparisons, outcome of the study and the study design (OR 30.9, 
95% CI 3.7- 256.2, p = 0.001). Cochrane reviews attempted more often to include unpublished data 
in literature search (OR 5.6, 95% CI 1.9–16.4, p =0.002). Twelve out of 29 non-Cochrane 
reviews
134;136;139-141;150-152;154-157
 performed a meta-analysis, but there was good awareness of where 
this technique was valuable and where it was not applicable. Meta analysis technique (OR 3.7, 95% 
CI 1.3–10.8, p = 0.02) and assessment for heterogeneity (OR 38.1, 95%CI 2.1, 688.2, p = 0.01) was 
found to be employed significantly more often by Cochrane reviews. 
 
4.5 Discussion 
This study showed that the Cochrane reviews were of consistently high methodological quality and 
had a greater level of assessment for quality of included studies. They always did a meta-
analysis
95;96;99;105-111;113-126;130-132
 where applicable. This is reassuring for clinicians who rely on 
them for decision-making. It is possible that the restriction on the length of published non Cochrane 
reviews by journals could have influenced their quality scores. However this issue has been 
addressed by increase in the web publishing of additional material in the electronic format by many 
journals in recent years. 
 
This work has highlighted that literature searches in reviews are currently generally poor. A search 
that is not thorough risks giving biased inferences. We identified considerable room for 
improvement in certain methodological features of non Cochrane reviews. However all the selected 
reviews were similar in searches without language restriction and assessment for risk of missing 
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studies. Interestingly the use of reference list of the selected papers to identify any other eligible 
studies for inclusion in the review was found to be more frequent in non Cochrane reviews (OR 0.2, 
95% CI 0.1–0.7, p < 0.007). This could be a result of the generic search strategy employed by 
Cochrane reviews with unclear mention of the use of reference lists in individual reviews. Cochrane 
reviews were found more likely to attempt to include unpublished data compared to non Cochrane 
reviews (OR 5.6, 95% CI 1.9–16.4, p < 0.002). This attempt to avoid publication bias is significant 
as the odds of publication are higher if the results are found to be significant compared to studies 
with non-significant results.
162
 
 
This study identified areas of maternal medicine that lack good quality systematic reviews. The 
majority of the reviews were on hypertensive disorders
94;95;97;98;105-109;117-
120;123;134;139;141;144;150;151;155;156
 psychiatry
102;113;129;133;136-138;142;143;145;147;160;161
, or 
thromboembolism.
112;128;148-152;154
 Even among these commonly addressed areas, a very narrow 
spectrum of diseases was covered. For example reviews in psychiatry were solely focussed on 
depression during pregnancy and reviews in hypertension focussed mainly on pre eclampsia. 
Reviews for some very common medical problems during pregnancy were missing or of poor 
quality. We found very few reviews on diabetes mellitus
99;125;135;159
 and chronic hypertension and 
none on thyroid disorders.  
 
With advancement in neonatology and paediatric medicine, more and more women with congenital 
problems such as congenital heart disease and inherited metabolic diseases are reaching child 
bearing age and considering pregnancy. There is an urgent need to have some cumulative evidence 
on management of this high risk group in the best possible way. 
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This study has some potential limitations. With our strict criteria to include reviews conducted with 
two publicly available databases, it is possible that some of the good quality reviews in maternal 
medicine using single database are missed. Another limitation relates to maternal outcome as the 
main focus of our study. We excluded all those reviews in which association between maternal 
disease and perinatal outcome was assessed. Keeping in mind the primary goal of an obstetrician 
being directed towards achieving a healthy and safe outcome for both mother and fetus, good 
quality evidenced based information on medical problems during pregnancy can only be achieved 
by reviewing methodological features of all aspects of maternal medicine irrespective of the 
endpoint. Due to the absence of blinding of the reviewers to the source of the review it is difficult to 
completely rule out any resultant bias. 
 
4.6 Conclusion 
Evidence based healthcare continues to make important contributions to the well being of pregnant 
women. This study has identified areas in maternal medicine that lack good quality systematic 
reviews. Overall quality of the existing systematic reviews was variable, with Cochrane reviews 
better than other reviews. To achieve better understanding and provide high quality obstetric care 
for pregnant women with medical problems, it is important to ensure that systematic reviews in 
maternal medicine are conducted to cover a wider spectrum of diseases, and are reported at the 
highest possible quality. Deficiencies identified in the areas of prognostic / diagnostic review are 
covered in this thesis. 
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CHAPTER 5: A REVIEW OF SYSTEMATIC REVIEWS IN FETAL 
MEDICINE 
5.1 Abstract 
Introduction  
Systematic reviews of fetal medicine can serve as a tool for translation of research findings from a 
few expert centres to a wider healthcare specialty. The extent to which reviews of fetal medicine 
research are systematic and unbiased is not known. 
 
Methods  
We searched, without language restrictions, Medline, Embase, DARE, Cochrane Library (from 
database inception to 2005), bibliographies of known reviews and contacted experts to identify 
potentially relevant citations of literature for reviews of fetal medicine studies. The selected reviews 
were assessed for information on framing of question, literature search and methods of review.  
 
Results 
The search yielded 659 citations of which 84 reviews met the inclusion criteria. Most of the reviews 
were in the field of fetal pathology (49/84, 59%). A majority of reviews (58/84, 69%) specified the 
question to be answered but only half (44/84, 52%) addressed a focussed question. Although 57/84 
(68%) reviews had a detailed search description, only 32/84 (38%) searched without language 
restriction. 45/84 (54%) searched in multiple databases and 27/84 (32%) assessed for the risk of 
missing studies.  There was no difference in quality between reviews of fetal pathology, screening 
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for aneuploidy, fetal growth and fetal therapy, except with respect to specifying the question 
(p<0.03), search without language restriction (p<0.004), assessment of risk of missing studies 
(p<0.006) and study quality assessment (p<0.002) where reviews of fetal growth performed better 
than other domains. 
 
Conclusion  
Our study reflects the paucity of good quality reviews in fetal medicine research. Existing reviews 
tend to be poor in reporting of methodological features. Particularly not enough attention is paid to 
assessment of validity of included studies and means to improving reliability of results through 
appropriate use of meta-analysis. There is a need for conducting further reviews and for rigour 
when reviewing fetal medicine research.  
 
Citation of published paper of this work 
Ellen M Knox, Thangaratinam S, Mark D Kilby, Khalid S Khan. A review of the methodological 
features of systematic reviews in fetal medicine. Eur J Obstet Gynecol Reprod Biol 2009. 146: 121-
128   
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5.2 Introduction 
Fetal medicine can broadly be described as the assessment, management and treatment of diseases 
or conditions affecting the fetus. Fetal medicine focuses on the “fetus as the patient” the same way 
as a newborn is managed by a neonatologist.
163
 Once the fetus has been found to be at risk, 
interventions aimed at improving neonatal outcome can be employed. The management of many 
fetal conditions diagnosed prenatally has been transformed by the advances in the field of fetal 
imaging, genomics, minimally invasive techniques and in utero fetal therapy.
164
  However, there is 
concern that current fetal medicine research is often restricted to single centres, that it is 
observational in nature and that individual results are imprecise. The specialist nature of this area 
has required experience to be centralised, however, this is a rapidly expanding subspecialty area. It 
is important that any new advances in fetal medicine are validated in research prior to being 
introduced as “usual practice”. Practices in this field have become established without serious 
multicentre trials, although there are some exceptions.
165;166
 Current policy making in this field 
relies on the evidence that is constrained by paucity of systematic reviews collating findings of 
existing research.  
 
Erroneously, some think that reviews should be limited to collating randomised evidence. The high 
risk nature of interventions, especially in the domain of in utero therapy, makes it difficult to 
conduct randomised controlled trials (RCTs) in fetal medicine, resulting in very few published 
RCTs. Current practice is, thus, largely based on evidence from observational studies often carried 
out in single centres with imprecise estimates i.e wide confidence intervals due to small sample 
size. The deficiencies due to imprecision can be overcome by collating studies in high quality 
systematic reviews. There has been increasing application of this approach in summarising 
observational research to better understand the value of health technologies and to translate findings 
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of preliminary research for further research
 
or for wider application.
167;168
 However, the extent and 
the quality of systematic reviews of fetal medicine studies are unknown. We therefore determined 
what evidence existed for current practice and the foundations for that evidence by undertaking a 
systematic review of all systematic reviews relevant to fetal medicine and examining their 
methodology. 
 
5.3 Methods 
To determine the quality of current systematic reviews in fetal medicine, we developed a priori 
protocol based on recommended methods.
50;93
  
We searched from database inception to 2005, MEDLINE, EMBASE, DARE and the Cochrane 
library using the terms fetus, fetal diseases, therapy and applying a sensitive search filter for 
systematic reviews. In addition, reference lists were hand searched for additional reviews. There 
were no language restrictions. The electronic searches were examined and the full manuscripts of 
all the potentially relevant citations were obtained. Fetal maternal medicine specialists in the United 
Kingdom were also asked for knowledge of any additional papers in the literature or in press. 
Inclusion criteria required a minimum of one publicly available database searched for studies 
specific to feal medicine. Fetal medicine was defined as the assessment management or treatment 
of diseases and conditions affecting the fetus. For example, a paper examining the relationship 
between uterine artery Doppler and subsequent preclampsia was excluded but if the outcome 
measure was stillbirth it was included. We subgrouped reviews into those relating to fetal 
pathology, fetal screening for aneuploidy, fetal growth and fetal therapy. 
 
We extracted and assessed the data according to a checklist formulated as part of our protocol. The 
methodological quality of each review was assessed by focussing on framing of the question, 
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literature search and review methods scrutinising methods of literature search and data synthesis. 
The items assessed internal validity and explicitness of reporting, both of which are important 
issues in quality of reviews. These included study quality assessment, tabulation of findings, 
assessment for heterogeneity, and assessment of risk of missing studies quantitatively or 
graphically with funnel plots and use of meta-analysis where appropriate. Differences between 
reviewers were resolved by discussion. All reviews were classified as being therapeutic, prognostic, 
diagnostic or etiological in nature and we compared the quality between the four reviews in the 
above domains.   
 
5.4 Results 
The initial literature search resulted in 659 citations. Of these 121 reviews fulfilled the inclusion 
criteria and were selected for detailed study (Appendix 3).  A further 12 papers were obtained from 
reference lists. Forty nine reviews were rejected because there was no systematic literature search 
of at least one database (n= 6) or the reviews were found to be pertaining to maternal rather than 
fetal medicine (n= 43). The details of the 84 included reviews are shown in Appendix 14. 
 
The results of methodological quality of the included reviews are provided in Fig 5.1. Although the 
majority of reviews (58/84, 69%) specified the question to be answered, they had a narrow focus 
with clearly defined population and outcome measures in 52% (44/84). Most of the reviews (57/84, 
68%) had a detailed search description including databases searched and key words used with 54% 
(45/84) using multiple databases to search for relevant studies. Only 38% (32/84) searched without 
language restriction. Assessment of heterogeneity was performed in 39% (33/84) of the reviews. 
Less than half the reviews (45%, 38/84) performed study quality assessment and only 32% (27/84) 
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performed assessment for risk of missing studies quantitatively or by funnel plots. Meta analysis 
was performed in 40% of reviews (34/84).  
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Fig 5.1. Quality of existing systematic reviews in various domains of fetal medicine
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Most of the systematic reviews were in the field of fetal pathology (49/84, 59%) followed by fetal 
growth (13/84, 21%), fetal therapy (11/84, 10%) and fetal aneuploidy (11/84, 10%).  Reviews of 
fetal growth were generally of the best quality, although heterogeneity was assessed in only 61% 
(8/13) of studies (Fig 5.1). Fetal growth reviews performed significantly better than reviews in 
other areas in question specification (p<0.03), search without language restriction (p<0.004), 
a sessment of risk of missing studies (p<0.006) and study quality assessment (p<0.002). There was 
no difference in other quality items (Fig .1).  
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Of the 84 included reviews, only 15 were Cochrane reviews. Due to the smaller number of the 
Cochrane reviews, we refrained from attempting a comparison between Cochrane and non 
Cochrane reviews of fetal medicine unlike the maternal medicine reviews in Chapter 4.  
 
5.5 Discussion 
We found that even with a lenient definition for systematic reviews, reviews of fetal medicine 
studies were relatively infrequent considering the large amount of research that goes on in this field 
(Appendix 2).  Reviews that addressed the rapidly advancing field of fetal therapy were particularly 
few. Overall the reporting of methodological features amongst reviews was poor, although reviews 
in the fetal growth domain performed better than those in other domains. 
 
From our study, a number of lessons have emerged for reviewers of fetal medicine research. Firstly, 
when interrogating databases for reviews of fetal medicine research, searches could be restricted if 
the majority of the findings are kept confidential by the centres that initiated the work. In this 
situation, systematic reviews are likely to be flawed, particularly if clear evidence of publication 
bias can be demonstrated. The proportion of the work that is published in a form that is available to 
the public (rather than just being available to experts and the regulatory authorities) is unknown. 
However, assessments for risk of missing studies scarcely featured in the reviews we assessed. 
Special efforts (contact with experts, regulatory bodies, etc) will be needed to retrieve unpublished 
data. This is one of most important challenges for reviewers of fetal medicine studies.  
 
Secondly, validity or quality of the studies included in a review is a key issue in avoiding biased 
influences. Despite its importance this issue was often not assessed in the reviews we studied 
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thereby risking erroneous conclusions. As many fetal medicine studies are observational in nature, 
reviewers would have to develop quality checklists carefully adapting existing tools for validity 
assessment. Finally, one key objective of such reviews is to improve precision of results to generate 
narrower confidence intervals around point estimates. In our study, the proportion of reviews that 
included meta-analysis or statistical pooling was small, but the actual number of times this 
approach was feasible or appropriate remains unknown. Disturbingly, we found that data synthesis 
among the reviews included in our study usually ignored methods to assess heterogeneity so that 
the suitability of combining results in meta-analysis could not be evaluated. Another related issue is 
that of use of appropriate methods for pooling results of small sized observational studies. Standard 
statistical approaches typically used in reviews of larger to medium sized studies may produce 
biased summaries when applied to pooling of studies with paucity of data.
167 
 
5.6 Conclusion 
This study reflects the poor state of current reviews in fetal medicine research. It suggests the need 
for focusing attention on conducting good quality reviews and meta-analyses to generate valid 
inferences. It highlights the fact that systematic reviews should be an essential prerequisite to 
guidelines on fetal medicine practice and further research in this field.  
  
77 
 
SECTION C 
SYSTEMATIC REVIEWS OF EFFECTIVENESS 
 
In this section, I have systematically reviewed the therapeutic studies and summarised the 
evidence of effectiveness by meta analyses, in the areas of: a) preterm labour by evaluating 
the use of progesterone in preventing pre term delivery and b) epilepsy in pregnancy by 
comparing the effects of regular monitoring of serum lamotrigine compared to management 
based on clinical features only in reducing seizures 
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CHAPTER 6: PROGESTERONE FOR THE PREVENTION OF PRETERM 
BIRTH: A SYSTEMATIC REVIEW OF EFFECTIVENESS 
6.1  Abstract  
Background 
Adequate concentration of progesterone in the myometrium reduces the risk of uterine activity. 
Progestagens can be used as agents to prevent preterm delivery. 
 
Methods 
Systematic review of literature evaluating the effectiveness of progesterone in reducing preterm 
births and neonatal mortality and morbidity with conventional and cumulative meta analysis. The 
effectiveness of progesterone across women at various risks of preterm birth was evaluated by 
L‟Abbe plots. 
 
Results 
The systematic review of literature identified nine randomised trials that evaluated the effects of 
progestational agents in the prevention of preterm delivery. These studies were of variable quality. 
Meta-analyses showed reductions in delivery rates before 37 weeks (OR 0.42, 95% CI 0.31 to 0.57) 
and 34 weeks (OR 0.51, 95% CI 0.34 to 0.77) as well as in respiratory distress syndrome (OR 0.55, 
95% CI 0.31 to 0.96) with progestational agents. A cumulative meta-analysis showed that the 
treatment benefit for the outcome of delivery before 37 weeks exceeded conventional level of 
statistical significance in 1975 (p<0.01); by 1985, the p-value was <0.001, and by 2003, it was 
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<0.0001.  Another cumulative meta-analysis in which the studies were added to the pooled analysis 
by decreasing quality score showed significant benefit was shown even when the analysis was 
limited to just the highest quality trials  (OR 0.47,  95% CI 0.33, 0.66, p<0.0001).  An exploration 
of the applicability of the effects across various baseline risks using an L‟abbe plot found that the 
benefit was consistent across a range of risks.  
 
Conclusion 
Women at high risk of preterm birth should be recommended progestational agent therapy. 
 
Citation of paper arising from this work 
Coomarasamy A, Thangaratinam S, Gee H, Khan KS. Progesterone for the prevention of preterm 
birth: a critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol. 2006; 129: 111-8.  
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6.2 Background 
Basic science evidence suggests that adequate concentration of progesterone in the myometrium 
counteracts the stimulatory activity of prostaglandins, lowers the concentration of oxytocin 
receptors, and inhibits the formation of gap junctions, raising the possibility of use of progestagens 
as agents to prevent preterm delivery.
169
 Over many decades, several randomised trials have shown 
a role for the use of progestational agents in this context, although this has not resulted in their use 
in clinical practice. The reasons for the lack of use could be related to a perceived concern about the 
quality of the trials assessing these agents, as well as ignorance of the totality of existing evidence. 
Systematic reviews can help with both assessment of quality and presentation of the totality of 
evidence, although this is conditional to a large extent on the robustness with which the reviews are 
carried out.  
 
A recent meta-analysis of randomised trials of progestational agents found it to be effective in 
reducing the risk of preterm delivery below 37 weeks.
170
 However, it did not report on the quality 
of the included studies, nor explore the effect of the quality on the inferences. Moreover, the study 
failed to report on outcomes such as delivery rates before 34 weeks, which is a clinically more 
relevant endpoint than the 37 weeks threshold. This is because delivery before 34 weeks‟ gestation 
accounts for three-quarters of neonatal mortality and one-half of long term neurological impairment 
in children.
171
 Additionally, before clinicians could recommend, and women accept, progestational 
agent therapy, the applicability of the evidence and the safety of the drug need to be established.   
 
A systematic review with conventional as well as cumulative meta-analyses was therefore carried 
out, firstly to explore the size and significance of the effects as trials accumulated over time, and 
secondly to evaluate the impact of quality of trials on effects. Furthermore, the applicability of the 
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evidence to women at various baseline risks is assessed, and the evidence for safety of 
progestational agents is reviewed. 
 
6.3 Methods 
We searched MEDLINE (1966-2004), EMBASE (1980-2004), Cochrane Library (2004:3), and 
SCISEARCH (1974-2004) for relevant citations. A combination of Medical Subject Headings 
(MeSH) and textwords were used to generate two subsets of citations, one indexing progesterone 
(„progesterone‟, „progestational hormones‟, „progestational agents‟ and „progest$‟) and the other 
indexing preterm birth („preterm‟, „premature‟, „early labo(u)r‟ and „pret$‟ ). These subsets were 
combined using „AND‟ to generate a subset of citations relevant to our research question. The 
reference lists of all known primary and review articles were examined to identify cited articles not 
captured by electronic searches. Articles frequently cited were used in the Science Citation Index to 
identify additional citations. 
 
Studies were selected if the target population was women with risk factors for preterm birth, the 
therapeutic intervention was progesterone or a progesterone metabolite (synthetic progestagens 
were excluded), and the studies were of randomised design.  Studies in which the population was 
exclusively multiple pregnancies were excluded.  
 
The selected studies were assessed for methodological quality using the components of study 
design that are related to internal validity.
172
 Information on the adequacy of randomisation, 
concealment, blinding, description of withdrawals, and follow-up rates was sought. Odds ratios 
from individual studies were pooled using fixed and random effects models.
173;174
 Heterogeneity of 
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treatment effects was evaluated graphically using forest plot and statistically using Chi-square test. 
Exploration of the causes of heterogeneity was planned using variation in features of the 
population, intervention, outcome and study quality. To assess for publication bias, a funnel-plot 
analysis was performed, using Egger‟s test to evaluate for asymmetry.175  
 
In addition to conventional meta-analysis, cumulative meta-analysis was performed in which the 
meta-analysis is updated whenever a new relevant trial becomes available for inclusion in the 
review.
176
 Such analysis allows the retrospective identification of the point in time when a 
treatment effect reached conventional levels of statistical significance.
177
 In another cumulative 
meta-analysis, analysis was started with the highest quality studies, and lesser quality studies were 
added progressively, to explore the effect of study quality on the results. 
 
In some trials of progesterone, the baseline risks in the control arms may be high, raising the issue 
of whether the evidence of effectiveness applies to populations in which the baseline risks may be 
substantially lower. Although there are several issues to be considered when assessing applicability 
and, ultimately, assessment of applicability is a clinical judgement, the concern over baseline risks 
were explored by evaluating the size of effects across a range of baseline risks using L‟Abbe plot.  
The L‟Abbe plot graphs the event rate in the control group (i.e., the baseline risk) against the event 
rate in the treatment group, thus allowing a visual assessment of homogeneity of effects across a 
range of baseline risks.
178
  
 
The systematic review of randomised trials of progestational agents may not show any evidence of 
harm.  Moreover, as trials generally involve patients studied for a short period, they are not likely to 
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detect delayed adverse events.
179
 We, therefore, conducted a review for safety of non-synthetic 
progestational agents using the following words and their word variants in MEDLINE (1966 – 
2004) and EMBASE (1988 – 2004) bibliographic databases: („progesterone‟ OR „progestational 
hormones‟ OR „progestational agents‟ OR „progest$‟) AND („adverse effects‟ OR „complications‟ 
OR „side effects‟ OR „harm‟) AND “pregnancy”. 
 
6.4 Results 
6.4.1 Systematic review of effectiveness of progestational agents 
We identified 1430 relevant citations from the search in databases. Full copies of seventy studies 
were retrieved for detailed evaluation. Nine studies with 1048 patients were identified for inclusion 
in the review after examination of the full manuscripts of studies that satisfied the selection criteria. 
The effect of 17 hydroxy progesterone caproate was assessed in five studies,
180-184
 vaginal 
progesterone suppositories in two studies,
185;186
 oral progesterone in one study
187
 and intramuscular 
progesterone pellets in one study.
188
 The quality of the studies is presented in Appendix 12, where 
each study is scored for quality using Moher‟s criteria.  
 
Pooling of the results from the studies showed a significant benefit of progestational agents in 
reducing preterm delivery before 37 weeks (OR 0.42, 95% CI 0.31 to 0.57, Fig. 6.1 a). A 
significant benefit was also observed for the clinically more relevant outcome of delivery before 34 
weeks (OR 0.51, 95% CI 0.34 to 0.77, Fig. 6.1 b). No heterogeneity was identified for both results 
(p values of 0.59 and 0.10 for deliveries before 37 weeks and 34weeks respectively). 
There was a significant reduction in respiratory distress syndrome (RDS) with the use of 
progestagens (OR 0.55, 95% CI 0.31 to 0.96, Fig. 6.1 c). The results were again homogenous 
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(p=0.425). Funnel plot analysis indicated that publication and related biases were unlikely (Egger‟s 
test, p=0.384). 
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Figure 6.1:  Meta-analysis of randomised trials evaluating the effectiveness 
of progestational agents in the reduction of a) delivery before 37 weeks, b) delivery before 34 
weeks, and c) respiratory distress syndrome 
 
6.4.2 
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0.14 (0.03,0.72)Johnson, 1975 7.0
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0.66 (0.18,2.36)Noblot, 1991 4.5
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6.4.2 Cumulative Meta-analysis by time 
Cumulative meta-analysis by year of study showed that the beneficial effect of progestational 
agents in reducing pre term delivery before 37 weeks‟ gestation exceeded conventional level of 
statistical significance in 1975 (p<0.01); by 1985, the OR was 0.29(95 % CI 0.14, 0.6) with very 
high level of statistical significance (p<0.001); and by 2003, the statistical significance was 
impressively high at p<0.0001 (Fig 6.2). There has been a gradual narrowing of confidence 
intervals with increasing statistical certainty of benefit around a point estimate of about 60% 
reduction in the odds of pre term delivery with progestational agents. 
Fig 6. 2.  Cumulative meta-analyses by year of study of randomised trials evaluating the 
effectiveness of progestagens in preventing delivery before 37 weeks 
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6.4.3 Cumulative Meta-analysis by study quality 
Cumulative meta-analysis in which the studies were ranked by decreasing quality score showed that 
statistically significant benefit was shown even when we limited the analysis to the highest quality 
studies with the maximum quality score of 5 (OR 0.47,  95% CI 0.33, 0.66, p<0.001, Fig 6.3). 
Addition of the poorer quality trials simply improved the precision, but did not alter the inferences 
drawn from the highest quality studies alone. 
Fig 6.3. Cumulative meta-analysis by quality score of randomised trials evaluating the 
effectiveness of progestagens in preventing delivery before 37 weeks 
Odds Ratio
0.1 1 10
Study (year)
p<0.03
p<0.001
p<0.000110621Papiernik
(1970)
9631Swyer (1953)
8502Yemini (1985)
7702Johnson (1975)
7202Le Vine (1964)
6645Noblot (1991)
6205Meis (2003)
1575da Foncesca
(2003)
Quality
score
Pts
Favours progestagen Favours control
OR (95% CI)
(0.31-0.58)0.42
(0.32-0.61)0.44
(0.31-0.59)0.43
(0.32-0.63)0.45
(0.34-0.66)0.47
(0.33-0.66)0.47
(0.32-0.65)0.46
(0.17-0.94)0.40
 
6.4.4 Variation in effectiveness across different baseline risks 
The L'Abbe plot which graphed event rate in the treated group against the control group for the 
outcome of delivery before 37 weeks, is presented in Fig 6.4.  This scatter plot shows that the 
magnitude of benefit from progestational agents does not change across a range of baseline risks (x-
axis in Fig 4).  This supports the applicability of the findings to a wide range of populations with 
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varying baseline risks. Naïve regression analyses based on the  L‟Abbe plots were not done as they 
could suffer from regression to mean bias.  
Fig 6.4   L'Abbe plot of effect of progestational agents with varying baseline risk 
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6.4.5 Safety of progestational agents 
Our systematic review did not show any evidence of harm from progestagen therapy. We identified 
a Cochrane review of RCTs and a meta analysis of observational studies evaluating the harm from 
progestagen treatment.
189;190
 The Cochrane review  evaluated progestagens for various indications 
such as prevention of miscarriages and stillbirth and identified 14 trials consisting of 1988 women, 
and found no evidence of harm to mother or baby, thus confirming our review findings. The 
systematic review of observational studies of first trimester sex hormone exposure identified 14 
studies, consisting of 65,567 women. This included 7 cohort and 7 case control stuies. The sex 
hormone in several of these 14 studies was progestagens alone or with other steroids. No harm, 
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particularly any external genital malformation (OR 1.09; 95% CI 0.90, 1.32), was found in this 
review. 
 
However, a recent case control study suggested an association between progestagens and genital 
abnormalities, especially hypospadias.
191
  This study had a small number of cases, a weak case 
control design and included use of progestagens in early pregnancy, thus making the evidence 
unlikely to be relevant to the later use of progestagens in the prevention of preterm birth. The 
extensive review by Brent et al has firmly ruled out any association between the use of 
progestagens and nongenital malformations.
192
 
 
6.5 Discussion 
This review shows that progestational agents have a large treatment effect in reducing the risk of a 
number of clinically relevant outcomes, especially delivery rates before 34 weeks and respiratory 
distress syndrome. The results were homogenous, and significant regardless of the statistical 
approach used for meta-analysis.  In addition, there was no evidence of publication and related 
biases from funnel plot analysis. The cumulative meta analysis of randomised trials shows that a 
significant benefit of progestagens in reducing preterm delivery was evident from 1975, and 
subsequent studies have increased our confidence to such a striking level that statistical uncertainty 
could not be cited as a reason for not using progestational agents.  Reduced confidence in the 
quality of the older trials has been thought to be one of the reasons for not using progestagens. 
However, this could no longer be a reason as the findings from the highest quality recent 
randomised controlled trials concur with the older studies.  
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Studies whose populations were exclusively women with multiple pregnancies were not included. 
Earlier reviews showed that the consistent beneficial effect of progesterone was not observed in 
women with multiple pregnancies. It might be that there are important factors other than what could 
be influenced by progestational agents that contribute to preterm birth in multiple pregnancies, and 
our review evidence is limited to singletons - a theory that needs further research. The exclusion of 
multiple pregnancies in two of the recent, good quality, large randomised trials that showed 
significant benefit of progestagens lends support for this hypothesis. 
 
In the existing review of progestational agents to prevent preterm birth, the authors have reported 
average Numbers Needed to Treat (NNT) calculated from the pooled meta-analyses results.  Such 
analyses can be seriously misleading, as NNT are sensitive to changing baseline risks – the lower 
the risk, the higher the NNT, and the lower are our and women‟s expectations of benefit from 
treatment. Conversely, the higher the baseline risk, the lower the NNT, and the higher are our and 
women‟s expectations of benefit from therapy, and the more inclined we would be to recommend, 
and women to accept therapy.  NNT will, therefore, need to be tailored according to baseline risks. 
We have, therefore, given a range of NNT appropriate for various baseline risk for the several 
outcomes in Appendix 16. 
 
There is no clear consensus on the dosage, route, or the release formulation, as well as the period of 
treatment with progestational agents.  However, the largest high quality study used intramuscular 
17 hydroxy progesterone caproate at a dose of 250 mgs weekly started between 16 to 20 weeks and 
continued until 36 weeks or delivery – this study was also associated with large treatment effects. 
Two other studies also used intramuscular 17 hydroxy progesterone caproate at same dosage as 
above, and found large treatment effects. Another regime used in one of the recent and high quality 
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study that again showed large treatment effects was vaginal progesterone suppositories of 100mg 
every night.  We recommend either of these regimens. There is substantial evidence for the safety 
of progestagens on the fetus and has not shown any adverse effect.  
 
6.6 Conclusion 
The very large treatment effects in clinically important outcomes of delivery before 34 weeks (50% 
reduction in odds) and respiratory distress syndrome (45% reduction in odds) cannot, and should 
not be ignored. Reluctance to use a very effective and safe therapy, which is based on level 1a 
evidence, is likely to cause untold amount of harm, similar to the harm caused by the delay in the 
introduction of streptokinase therapy after myocardial infarction, or steroids in preterm birth.  
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CHAPTER 7: A SYSTEMATIC REVIEW OF EFFECTIVENESS OF 
LAMOTRIGINE DOSAGE BASED ON SERUM LEVELS COMPARED TO 
CLINICAL FEATURES IN REDUCING SEIZURES IN PREGNANCY 
7.1 Abstract 
Background: Epilepsy is one of the significant causes of indirect maternal deaths in pregnancy. 
Both seizures during pregnancy and AED (Anti Epileptic Drug) exposure in utero influence the 
poor outcomes in children born to mothers with epilepsy. Lamotrigine (LTG) is the first choice for 
AED in women of child-bearing age.  In pregnancy, serum levels of lamotrigine fall with resulting 
increase in seizures.  There is clinical equipoise with clinicians either increasing the dose of LTG 
based on serum levels or based on clinical features alone. There is a need to systematically review 
the available evidence assessing the effectiveness of the 2 dosage regimens on maternal and fetal 
outcomes to inform clinical practice.  
 
Methods: We searched MEDLINE (1966–2009) and EMBASE (1980–20098), for relevant 
citations on the effectiveness of different dose regimes of LTG in pregnancy.  Study selection, 
quality assessment and data extraction were carried out by 2 independent reviewers. We calculated 
the relative risk (RR) and the rates of seizures for maternal and fetal outcomes.  
 
Results:  Five studies with a total of 101 pregnant women with epilepsy were included to evaluate 
the effectiveness of the different LTG regimes on seizure control in pregnancy. Two studies 
assessed the effectiveness of LTG dose management based on serum levels and two evaluated LTG 
dosage based on clinical features alone. One study compared the effectiveness of both regimens on 
seizure deterioration. The combined rate of seizure deterioration was 0.40 (95% CI 0.26 to 0.55) in 
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women with LTG dosage based on serum levels compared to 0.73 (95% CI 0.56 to 0.86) in those 
managed by clinical monitoring alone. 
 
Conclusion: LTG dose management based on serum levels in pregnancy appears to be better in 
reducing seizures than dose management based on clinical features alone. The included studies are 
small, heterogeneous, non randomised and not controlled thereby limiting recommendations for 
clinical practice from the review. 
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7.2 Background  
Epilepsy affects 0.5-1% of general population.
18
 Approximately one third of people receiving 
AEDs are of reproductive age.
19;20
 There is a 10-fold increase in mortality among pregnant 
women with epilepsy which greatly exceeds the two to three-fold mortality rate observed in all 
people with epilepsy.
21
 In 2000-2002, 13 maternal deaths in the UK were attributed to 
epilepsy.
22
 These were invariably a direct consequence of seizures. There is one in 250 
pregnancies exposed to AEDs .
23;24
 AED exposure in-utero is associated with congenital 
malformations.
25
  Fetal risk is related to the number of AEDs, AED type and probably AED 
dose. Furthermore, there are concerns about the long-term neurological development of children 
exposed to AEDs in-utero. There is a general consensus that the risks of uncontrolled convulsive 
seizures in the mother outweigh the potential teratogenic risk of the medication, and most 
women with active epilepsy are advised to continue with medication during pregnancy.
18
 The 
effects of seizures extend into daily living resulting in loss of driving licence, negative impact on 
employment and relationships and reduced Quality of Life (QoL).
26
 The triennial Confidential 
Enquiries into Maternal Deaths in the UK reported concerns about epilepsy management during 
pregnancy.
22
 
 
Seizure control is important during pregnancy. Uncontrolled epilepsy, with generalised tonic-
clonic convulsions, carry risks of harm including miscarriage, fetal hypoxia and acidosis, and 
fetal loss.
27-29
 The reasons for fetal loss are not entirely understood but are more likely to be 
related to maternal seizures than to fetal exposure to AEDs.
29;30
 This is supported by the finding 
of fetal heart rate decelerations during maternal seizures.
31
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There is clear evidence that blood levels of various anti-epileptic drugs fall in women with epilepsy 
due to physiological changes in pregnancy altering AED pharmacokinetics and AED 
concentrations. There is decreased gastric tone and motility, increased plasma volume, increased 
renal clearance and albumin levels and protein binding.193-196Among the newer AEDs, levels of 
Lamotrigine (LTG) have been shown to fall significantly in pregnancy. A significant decrease in 
the ratio of Lamotrigine concentration-to-dose by 65% has been observed in second and third 
trimesters compared to pre-conception baseline levels
197
. This has been correlated with significant 
increase in seizure activity by up to 75% in pregnancy.
198
  
 
In pregnancy, therapeutic drug monitoring could guide adjustment of AED dosage to achieve good 
seizure control while minimising fetal exposure. If possible, it is advisable to establish the total and 
free pre pregnancy AED concentrations at which the seizures are well controlled in the woman as a 
baseline. Regular monitoring of LTG levels has been advocated in each trimester and shortly after 
delivery, with adjustment of dosage to avoid seizure precipitation during pregnancy and to avoid of 
toxicity after birth. A fall in serum levels in pregnancy is diagnosed by comparing to the patient‟s 
pre pregnancy levels at which they had good seizure control. The risk of seizures associated with a 
fall in levels is discussed with the woman and the dose of AED is increased appropriately. 
Although reference ranges for levels of AEDs including LTG exist, the therapeutic range, i.e. the 
optimal serum LTG level for seizure control varies between individuals. The therapeutic range may 
lie outside the reference range in some individuals with increase in risk of toxicity when the 
therapeutic range lies above the reference range for the individual.
199
 Regular and frequent serum 
monitoring reduces the above risks. Most often in clinical practice, the pre pregnancy levels are not 
available. The earliest tested level in pregnancy i.e. the booking is then considered to be the 
baseline level. There is uncertainty about the degree of fall in levels at which an increase in dose of 
LTG is essential. Monitoring of serum AED levels including LTG in each trimester and after 
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delivery has been recommended by the American Academy of Neurology based on consensus as a 
good practice.
200
 In the UK however, the SIGN (Scottish Intercollegiate Guidelines Network) 
guideline does not recommend regular AED monitoring in pregnancy due to paucity of evidence.
201
 
 
 Existing practice on the dosage of lamotrigine in pregnancy is based on the preference of 
individual clinicians. The management of women with epilepsy on LTG is aimed at achieving 
seizure control on the lowest possible dose and number of AEDs. Current practice in most units 
is based on the clinical features, with increase in dose of LTG if there is an impending risk of 
seizures or actual aggravation of seizures. Routine LTG serum level monitoring is not done 
except in the following states: suspicion of non compliance, risk of toxicity or uncontrolled 
seizures.  Given the significant reduction in LTG levels in pregnancy some clinicians advocate 
routine dose escalation of LTG based on serum levels, even in the absence of seizures, to reduce 
the risk of their occurrence.   There are no systematic reviews that have evaluated the 
effectiveness of the two alternative regimes and looked at maternal and fetal outcomes including 
neurodevelopmental outcomes and major congenital malformations in babies.  
 
7.3 Method 
We searched MEDLINE (1966–2009) and EMBASE (1980–2009) for relevant citations. A 
combination of Medical Subject Headings (MeSH) and text words were used to generate for subsets 
of citations, one indexing Lamotrigine („Lamotrigine‟ and „Lamictal‟) another indexing pregnancy 
(„pregnancy‟); the third indexing epilepsy („epilepsy‟) and the final indexing dose response 
relationship („dose increase‟, „increase dose‟, „decrease dose‟ and „dose decrease‟). These subsets 
were combined using „AND‟ to generate a subset of citations relevant to our research question. The 
reference lists of all known primary and review articles were examined to identify cited articles not 
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captured by electronic searches. Articles frequently cited were used in the Science Citation Index to 
identify additional citations.  
 
Studies which evaluated the effectiveness of LTG dosage in pregnant women with epilepsy based 
on serum levels  or clinical features alone  were selected in a two-stage process. First, the electronic 
searches were scrutinised and full manuscripts of all citations that were likely to meet the 
predefined selection criteria were obtained.  Secondly, final inclusion or exclusion decisions were 
made by 2 reviewers after examination of these manuscripts. Studies which met the predefined and 
explicit criteria regarding population, intervention, outcomes and study design were selected for 
inclusion in the review. When disagreements occurred, they were resolved by consensus. In cases 
of duplicate publication, the most recent and complete versions were selected. There were no 
language restrictions.   
 
Studies were selected if the target population was pregnant epileptic women; the therapeutic 
intervention was LTG (or a combination of LTG and other antiepileptic drugs) and the studies 
mentioned dose escalation versus dose maintenance therapy. The outcomes studied were seizure 
frequency, the presence or absence of seizures, maternal quality of life and fetal risks.   
  
All manuscripts meeting the selection criteria were assessed for their methodological quality. The 
selected studies were assessed for methodological quality using the components of study design 
that are related to internal validity. Quality was defined as the confidence that the study design, 
conduct and analysis minimised bias in the estimation of therapeutic effectiveness. Based on 
existing checklists, quality assessment involved scrutinising study design and relevant features of 
the population, intervention and outcomes of the study. A study was considered to be of good 
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quality if it used a prospective design, randomised patients, consecutive enrolment, blinding, 
adequate description of intervention, outcome and adequate follow up. We calculated the relative 
risk (RR) of seizures in both regimes and maternal and fetal outcomes. Data was obtained on the 
dose of LTG, and adverse maternal and fetal effects. 
 
7.4 Results 
Appendix 4 summarises the process of literature identification and selection. We identified 389 
relevant electronic citations. After screening the titles and abstracts, 359 were rejected, and 33 were 
considered for detailed evaluation study selection. Finally 5 primary articles met the selection 
criteria for inclusion in the review with a total of 101 women (Appendix 18).
194;202-205
 The included 
studies consisted of pregnant women with epilepsy treated with on Lamotrigine alone or 
Lamotrigine in combination with other anti-epileptic drugs. The quality of the included studies is 
provided in Appendix 13.  
 
Three studies evaluated the effectiveness of LTG dosage regime based on serum levels in reducing 
seizure frequency.
194;203;204
  Three studies reported on the effectiveness of LTG dosage regime 
based on clinical features alone.
202;203;205
 One study provided comparative data on seizure frequency 
in both the cohorts, LTG dosage based on serum levels and clinical features alone.
203
 Patients 
involved in 2 studies were treated with other AED in addition to LTG. The therapeutic drug 
monitoring was reported as LTG plasma concentration (mmol/l)/LTG dose (mg) ratio, apparent 
clearance equal to the dose (mg/kg/d) / level (mg/l) or Ratio to Target Concentration (RTC total 
LTG / target LTG). The LTG RTC threshold for increasing seizure frequency was reported as 0.65, 
with a true positive rate (TPR) of 83.3% and a low false positive (FPR) of 4.2%.  Increasing the 
RTC threshold to 0.78 gave a TPR of 100% and a FPR of 25%. 
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The rates of seizure increase in the  groups that managed LTG dose based on serum levels were0.39 
(95% CI 0.23 - 0.57),
194
 0.45 (95% CI 0.17 - 0.77)
204
 and 0.33 (95% CI 0.00 - 0.98).
203
 In the  
group that managed LTG dose on the basis of clinical features alone, the rates of seizure increase 
were 0.75 (95% CI 0.43 - 0.95),
202
 0.92   (95% CI 0.62 - 1.00)
205
 and 0.54 (95% CI 0.25 - 0.81).
203
  
The combined rate of seizure deterioration was 0.40 (95% CI 0.26 to 0.55) in women with LTG 
dosage based on serum levels compared to 0.73 (95% CI 0.56 to 0.86) in those managed by clinical 
monitoring alone. (Fig 7.1) 
Fig 7.1. Rates of increase in seizure in pregnant women with dose LTG management based on 
serum levels compared to management based on clinical features  
Petrenaite 2005
Pennel 2008
Ohman 1008
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Chi - square = 0.18; df =  2 (p = 0.9136)
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There was one incidental pregnancy loss in the included studies.
198
 Maternal toxicity was reported 
in 1 study after delivey.
206
 No association was found between small for gestational age, fetal and 
neonatal death, neonatal intensive care unit admissions or low Apgar scores.  There was one 
congenital malformation (renal hydronephrosis, resolved by 4 months), one newborn diagnosed 
with a heart murmur (resolved early) and two premature deliveries.
206
 
 
7.5 Discussion 
The data from existing studies suggest that LTG dosage based on serum levels escalation is 
associated with decreased seizure frequency and that dosage based on clinical features alone is 
associated with an increase in seizures.   
 
This systematic review included a detailed search of the major medical databases studies on the 
basis of their quality and relevance to this subject to provide information on the dosage regime of 
LTG on maternal seizures and fetal outcome. It has systematically collated and evaluated the 
quality of existing evidence in this area. The limitations of this review arise from the characteristics 
of the included studies. The studies were small, not randomised, nor controlled, with heterogeneous 
results and there was imprecision with small numbers of women, making findings unreliable. There 
is insufficient evidence on other outcome measures like neurodevelopmental outcome in the 
offspring and maternal quality of life. The inclusion of other AEDs in addition to LTG means that 
seizure deterioration and subsequent control could be confounded by the fall in levels of other 
drugs, their interaction with LTG and their effectiveness in seizure control. Furthermore the studies 
are heterogeneous in the identification and classification of fall in serum levels of LTG that 
necessitate an increase in dosage of LTG. There is no consistent evidence on the dosage of LTG 
that needs to be increased to prevent a seizure when there is a fall in serum levels.  
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Management of LTG dosage in pregnancy can be guided by „Individual Therapeutic Level‟. This is 
the level at which there is good seizure control with minimum toxicity.
207
 The individual 
therapeutic level can be identified from pre pregnancy levels of LTG at which there was good 
seizure control. The dose adjustment was based on pre pregnancy serum levels in the 3 studies. 
Information of the sampling time from the last dose intake is necessary to maximise the benefit of 
dose management based on serum levels. Heterogeneity and lack of information on the sampling 
time when evaluating a drug like LTG with relatively short half life can affect the results.  
 
One of the major concerns in increasing the dose of LTG in pregnancy is its potential short term 
and long term adverse effect on the fetus. A variety of adverse effects have been reported on 
infants born to women with epilepsy either treated or untreated, including intrauterine growth 
retardation, major and minor malformations and postnatal developmental delay.
18
 The overall 
major congenital malformation rate for all AED exposed cases was 4.2% (95% Confidence 
Interval: 3.6%-5.0%).
208
 The average frequency of major congenital malformations in cohorts of 
women using AED monotherapy only ranges between 1.03% and 4.5%.
209-212
 The risk is highest 
in the first trimester during organogenesis. For LTG (n=647) the mean daily dose was found to 
be significantly higher for those with a major congenital malformation than for those without a 
major congenital malformation (respectively, 352.4 mg and 250.6 mg; p=0.005).
212
 The North 
American Antiepileptic Drug (NAAED) Pregnancy Registry of 684 women on LTG 
monotherapy did not find dose related adverse effects.
213
 Data related to dose from the LTG 
Pregnancy Registry found no increase in major defects with daily doses up to 400 mg; data for 
doses of 400 mg or more were insufficient to confirm or refute a dose effect.
210
 There were 176 
exposures at doses of 400 mg or more included in a recent report by the LTG Pregnancy 
Registry Advisory Committee with data from 2287 pregnant patients on LTG monotherapy.
214
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This includes 39 exposures in the range of 601 – 1200 mg. The Committee considered the data 
reassuring, providing no evidence of a dose effect. The available data suggest that any dose 
effect that might exist on malformation is likely to be small. Long-term follow up of children 
exposed to LTG in utero has been limited, so that more subtle effects on the subsequent 
neurological and cognitive development of children have been poorly studied. Besides exposure 
to LTG, neurodevelopment may also be affected by variables such as seizure type and frequency 
or severity during pregnancy, maternal age and IQ, genetics, and socioeconomic status. 
215;216
   
 
Large randomised studies sufficiently powered to investigate the use of AEDs including LTG in 
pregnancy and the optimal dosage regimen to maximise seizure control and minimise short term 
and long term adverse effects to the mother and fetus are needed. Such a study will determine, 
among pregnant women with epilepsy on AEDs, whether AED dose adjustment based on serum 
AED levels (intervention) reduces the risk of seizure deterioration compared to management 
based on clinical features only (control). There are several ways in which loss of seizure control 
can be defined and analysed. There is no consensus on the best approach.
217
 The standard 
approaches to analysis assume normal distribution, but the data are likely to be highly skewed. 
This is because a large proportion (50-60%) of patients will remain seizure free throughout 
pregnancy.
218
  
 
An optimal study design is needed to ensure statistical efficiency, feasibility and validity. Early 
randomisation of women to either therapeutic drug monitoring or not, i.e. AED dose 
management with serum AED level monitoring or without in a study would be similar to that of 
a trial comparing two testing protocols.
219
 In this situation, only women in the intervention group 
whose serum AED levels fall will be in a position to benefit from intervention that follows 
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testing. This will reduce the size of effect than can be discovered and will introduce statistical 
inefficiency with the need to recruit very large numbers, otherwise the study would be 
underpowered risking type II error.
219
  An alternative design could have both clinicians and 
patients blind in all groups using placebos. However, this may pose problems with logistics and 
acceptability. Pregnant women enter the pregnancy on various AED types, doses, combinations 
and preparations (generic and branded). The requirements for dummy dosing with identical 
placebos in different shapes, sizes and colours with central provision of drug supplies for 
participating centres would present an enormous logistic challenge apart from being 
prohibitively expensive. Furthermore, clinicians may be reluctant to participate if they were 
blinded to the intervention group. Such a study would thus be unfeasible. The key issue is to 
design the study in such a way so as to achieve blinding. A trial design where eligible pregnant 
women with epilepsy will be consented early to enrol in a comprehensive cohort study of 
therapeutic drug monitoring of antiepileptic drugs (AEDs) throughout pregnancy will ensure that 
both women and clinicians will be initially blinded to the serum AED levels. Those women who 
have a fall in serum AED levels will be randomised to either management based on serum levels 
in the intervention group (Group A) or management based on clinical features only in the control 
group (Group B). Women with stable serum AED levels will form the non-randomised cohort 
(Group C) to be followed-up in a manner identical to the randomised cohort. The clinicians and 
women cannot be blinded in the intervention group (Group A). However, both clinicians and 
women in Groups B and C can be kept blinded to whether serum AED levels have fallen or not, 
thereby minimising the risk of performance and measurement bias in the control group.  
 
Such a design with early consent and randomisation only when the serum levels fall, will ensure 
that the data on all the randomised patients will contribute to estimation of the effect, enhancing 
the statistical power to detect a difference. Follow-up of the non-randomised cohort will make it 
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possible to blind the control group. Additional information collected from the non-randomised 
group will provide useful data for decision-analytic modelling. In order to accrue the large 
number of pregnancies necessary for a reliable evaluation, the trial will need the participation of 
a number of centres managing pregnant women with epilepsy. To make this practicable, the trial 
procedures need to be kept simple, with the minimal extra workload placed on the participating 
clinicians and centres, beyond that required to test and treat the mothers. 
 
7.6 Conclusion 
Existing evidence collated in our review seem to favour LTG dosage in pregnancy based on serum 
levels. Concerns about the quality of the studies with substantial imprecision in the results make it 
difficult to make any firm recommendations. A large well conducted randomised study 
incorporating patient acceptability data and cost economic evaluation will help clinicians and 
pregnant women with epilepsy on AEDs like LTG make decisions on the preferred choice of 
dosage regimen.  
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SECTION D 
SYSTEMATIC REVIEWS OF TEST ACCURACY 
 
 
In this section, I have systematically reviewed the test accuracy studies and summarised the 
evidence of accuracy by meta analyses, in the field of: 1) maternal medicine by evaluating the 
accuracy of proteinuria, uric acid, liver function tests, symptoms and blood pressure in 
predicting adverse maternal and fetal outcomes in women with pre eclampsia and 2) 
perinatal medicine in newborn by assessing the accuracy of pulse oximetry as a screening test 
in the detection of congenital heart disease (CHD) in newborn 
 
  
106 
 
CHAPTER 8:  TESTS FOR PREDICTING COMPLICATIONS OF             
PRE-ECLAMPSIA: A PROTOCOL FOR SYSTEMATIC REVIEWS 
8.1 Abstract 
Background 
Pre-eclampsia is associated with several complications. Early prediction of complications and 
timely management is needed for clinical care of these patients to avert fetal and maternal mortality 
and morbidity. There is a need to identify best testing strategies in pre eclampsia to identify the 
women at increased risk of complications.  
 
Method 
An extensive search was performed in MEDLINE (1951–2004), EMBASE (1974–2004) including 
manual searches of bibliographies of primary and review articles. The detailed search  revealed 
19,500 citations. Two reviewers were proposed to independently select studies and extracted data 
on study characteristics, quality and accuracy. Accuracy data will be used to construct 2 × 2 tables. 
Data synthesis will involve assessment for heterogeneity and appropriately pooling of results to 
produce summary Receiver Operating Characteristics (ROC) curve and summary likelihood ratios. 
Bivariate analysis will be performed to assess sensitivity and specificity. 
 
Results and Discussion 
The protocol led to the development of reviews that generated information on the accuracy of tests 
in predicting complications in women with pre-eclampsia. 
 
 
  
107 
 
Citation of paper from this work 
Thangaratinam S, Coomarasamy A, Sharp S, Ismail KMK, Khan KS for the TIPPS (Tests in 
Prediction of Pre-eclampsia‟s Severity) review group Tests for predicting complications of pre-
eclampsia: A protocol for systematic reviews of the literature BMC Pregnancy Childbirth 2008.  
8:38  
  
108 
 
8.2 Background 
Hypertension is a common medical complication of pregnancy, affecting about 6–8% of all 
pregnancies.
220
 Hypertensive disorders in pregnancy consist of a group of disorders that include 
pre-eclampsia, latent or chronic essential hypertension, a variety of renal diseases, and transient 
(gestational) hypertension. The definitions used to distinguish these disorders differ, leading to 
uncertainty about their prevalence, natural history and response to treatment. Pre eclampsia is 
associated with several complications
221
 and remains one of the largest single cause of maternal and 
fetal mortality and morbidity.
222;223
  They have been reported to account for 14% of direct maternal 
deaths and 18% of fetal or infant deaths.
222;223
 
 
Once the diagnosis of pre-eclampsia is established, timely management is of the essence to avoid or 
minimise mortality and morbidity. Clinical prediction of disease complications using a combination 
of patients' characteristics, symptoms, physical signs and investigations all of which we consider 
tests, forms the basis of clinical care in these situations.
139
 Therefore, there is a need for guidance 
regarding the best testing strategies with which to predict the development of complications in pre-
eclampsia. As well as allowing clinicians to avoid unnecessary interventions in low risk groups, this 
would allow high-risk groups to benefit from monitoring of disease severity, use of 
antihypertensive therapy, administration of anticonvulsants, and antenatal corticosteroids.
140;224
 
 
8.3 Methods 
A systematic quantitative overview of studies of complications of pre-eclampsia was conducted to 
obtain summary estimates of accuracy of all available tests. The proposed methodology was in line 
with the guidance of the NHS Centre for Reviews and Dissemination
172
 and that of the Cochrane 
Methods Working Group on Screening and Diagnostic tests.
55
 The investigation was be carried out 
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in the following recommended steps: (i) Question formulation, (ii) Study selection and 
identification, (iii) Study quality assessment, (iv) Data extraction and (v) Data synthesis.  Our 
strategy for each of these steps was be based on a prospective protocol, which is outlined below:   
 Table 8.1: Structured questions in the systematic review of tests predicting complications in 
women with pre eclampsia 
 
Question 
Components    
Population Pregnant women with pre eclampsia 
Tests  
History 
Parity; Race; Maternal age; Previous severe pre eclampsia/Eclampsia; Family history of 
pre eclampsia/eclampsia; Obesity; Weight gain; Pre existing  hypertension, renal disease, 
diabetes, lupus, thrombophilia, other auto immune diseases; Multiple pregnancy; 
Symptoms-headache, epigastric pain, nausea, visual disturbance or combination of 
symptoms 
Examination 
 
Blood pressure; Peripheral oedema; Exaggerated tendon reflexes; Clonus; Papilloedema; 
Retinal changes; Oliguria; Symphysio fundal height; Oxygen saturation 
Investigations Biochemical: Serum uric acid, Urine dipstick (Bedside Urinalyses), Urine Protein: 
Creatinine Ratio (PCR), Urine Albumin Creatinine Ratio (ACR), 24 hour urine protein; 
Urinary calcium excretion; Hypoalbuminaemia; Microalbuminuria; Fibronectin, Renal 
and liver function tests; Ultrasound: Growth , liquor volume, doppler ( uterine, 
umbilical artery, middle cerebral artery, venous) bio Physical Profile; 
Haematological: Anti thrombin III; Platelet count; Haemoglobin; Fibrinogen; 
Thrombophilia screen; Maternal serum Alpha feto protein (MSAFP); Serum Human 
Chorionic Gonadotropin (HCG); Computerised Tomography; Magnetic Resonance 
Imaging 
Outcome 
 
 
Maternal 
Eclampsia; Pulmonary oedema; Cerebral Haemorrhage; Hepatic, renal, haematological 
complications; Cardiac arrest; Abruption; Thromboembolism; stroke;  Psychiatric 
problems; Complications of labour and delivery; Maternal death; Need for 
hospitalisation; Day care unit visits; Use of intensive care; Ventilation and dialysis 
Fetal 
Intra uterine growth restriction; Prematurity; Abnormal pH  at birth or antenatal; 
Abnormal  Apgar; Hypoxic Ischemic Encephalopathy; Perinatal death; Long term 
effect:learning disabilities, Developmental and special needs after discharge; Need for 
neonatal intensive care admission; Mechanical ventilation and duration of hospital stay 
Study design Systematic review of test accuracy studies 
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8.3.1 Question Formulation 
The tests to be considered by the review are specified in the form of structured questions in Table 
8.1. A priority list had been generated based on importance to clinical practice using a modified 
Delphi survey.
17
  An exhaustive list of the tests and outcomes in the prediction of pre eclampsia  
were sent to experts in the field. Each one of the issues were rated according to their importance to 
clinical practice and ranked accordingly. The reviews will focus on the prioritised tests obtained 
from the survey.  
 
8.3.2 Study Identification and Selection 
 A thorough search protocol was developed by which literature was identified via the general 
bibliographic databases including MEDLINE and EMBASE and a specialist database MEDION. 
The latter is a database of diagnostic test reviews set up by Dutch and Belgian researchers. 
Reference lists of articles obtained by iterative search will be checked as an adjunct to other 
methods.
225
 Language restrictions will not be applied. A comprehensive database of relevant articles 
will be constructed. The search will be updated every year to enable inclusion of current evidence in 
the reviews. A search term combination was constructed after exhaustive planning and piloting of 
possible search concepts capturing the relevant population, tests and outcomes. Our search terms 
and flow chart of strategy are shown in Appendices 5 and 20. An initial search in Medline yielded 
11711 citations. The search strategy was adapted for searching in Embase to obtain a total of 19500 
citations. From this citation set, studies will be selected for inclusion in the review in a two-stage 
process.  
 
In the first stage the electronic searches will be scrutinised by two independent reviewers and full 
manuscripts of all citations that are likely to meet the predefined selection criteria will be obtained. 
All available reports, irrespective of language will be included to reduce bias.
226
 Subsequent final 
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inclusion or exclusion decisions will be made on examination of these manuscripts. In cases of 
duplicate publication, the most recent and complete versions will be selected. Two reviewers will 
then independently select the studies, which meet predefined and explicit criteria regarding 
population, tests, outcomes and study design (Table 8.1).  These criteria will be piloted using a 
sample of papers and agreement between reviewers will be measured.  When disagreements occur, 
the two reviewers will meet and if necessary the issue will be resolved by consensus involving a 
third reviewer. 
 
8.3.3 Study Quality Assessment 
A review of papers meeting the eligibility criteria will be conducted by the same reviewers who 
judged eligibility, but this time rating the methodological quality of the primary research. 
Methodological quality is a reflection of the degree to which the study design, conduct and analysis 
has minimised bias in addressing the research question. This ensures a high level of internal validity 
(i.e. the degree to which the results of an observation are correct for the patients being studied). The 
potential sources of bias and variability arising from spectrum composition and other variations in 
test protocol or the use of reference standard in individual studies will be considered when 
interpreting the results.
227
 In addition to using study quality as possible explanation for differences 
in results, the extent to which primary research met methodological standards is important per se for 
assessing the strength of any conclusions that are reached.
172
 We will evaluate elements of study 
design which are likely to have a direct relationship to bias and variability in a test accuracy 
study.
172;226-232
  
 
8.3.4 Data Extraction  
The extraction of study findings will be conducted in duplicate using a pre-designed and piloted 
data extraction form to avoid any errors. Two authors will independently extract information from 
  
112 
 
each article in order to construct 2×2 tables of the diagnostic test result and outcomes. Any 
disagreement will be resolved by consensus.  Given the extent of insufficient reporting in the 
medical literature, we propose to obtain missing information from investigators whenever possible.  
It is otherwise impossible to distinguish between what was done but not reported and what was not 
done.  To avoid introducing bias, unpublished information will be obtained in writing, and will be 
coded in the same fashion as published information with equal regard for inter-coder agreement.  In 
addition to using multiple coders to insure the reproducibility of the overview, sensitivity analyses 
around important or questionable judgements regarding the inclusion or exclusion of studies, the 
validity assessments and data extraction will be performed. 
 
8.3.5 Data Synthesis   
We will explore causes of variation in results from study to study (heterogeneity), synthesise results 
from individual studies (meta-analysis) if appropriate
172;230
 and assess for the risk of publication 
bias.  Heterogeneity of results between studies will be graphically assessed looking at the 
distribution of rates, sensitivities and specificities in the ROC (Receiver Operating Characteristics) 
curve and likelihood ratios using Forest plots. To explore causes of heterogeneity we will conduct a 
sensitivity analysis by subgroups to see whether variations in population characteristics, tests, 
outcomes and study quality affect the estimate accuracy.  Conclusions regarding the typical estimate 
accuracy will be interpreted cautiously if there is significant heterogeneity.  Individual factors 
explaining heterogeneity will also be analysed using meta-regression to determine their unique 
contribution allowing for other factors. We will conduct meta-analyses to generate summary 
estimates of likelihood ratios (LRs), diagnostic odds ratios (ratio of LRs) and area under receiver 
operating characteristic (ROC) curves as appropriate. 
230;233;234
 To visualise data we will plot for 
each model combinations of sensitivity and specificity in receiver operating characteristic (ROC) 
plots.
233
 In a ROC plot the upper left corner is the ideal position in an ROC curve because it reflects 
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the highest sensitivity and the lowest false positive rate. A bivariate random effects meta-regression 
model will be used to fit a summary ROC (sROC) curve. Briefly, the bivariate model preserves the 
two-dimensional nature of diagnostic data in a single model. This model incorporates the 
correlation that may exist between sensitivity and specificity within studies due to possible 
differences in threshold between studies.
59
 AUC values between 0.70 and 0.79 are deemed as 
having moderate discriminative properties, and those with AUC values of ≥ 0.80 as having good 
discriminative properties. 
 
The risk of publication bias is expected to be high in reviews of test accuracy.
235
  Analysis for 
assessing the risk of publication bias will be carried out by producing funnel plots of accuracy 
estimates against corresponding variances.  In the absence of publication bias it is to be expected that 
the point estimates will fill a funnel shape in the plot.  Large gaps in the funnel indicate a group of 
possible „missing‟ publications.  These omissions are due to small studies showing limited accuracy 
and are unlikely to be missing at random.  This phenomenon will also be statistically evaluated using 
Egger's test.  
 
8.4 Discussion 
In the same way as systematic reviews of effectiveness of treatments in obstetrics have been 
pursued over the last decade, research on test accuracy also needs systematic reviewing.
236;237
 One 
of the questions remaining after establishing effectiveness evidence for magnesium sulphate, 
steroids and anti hypertensives is to identify those who will benefit most from these 
interventions.
238;239
 Relying on the inclusion and exclusion criteria of the trials alone is not 
sufficient for determining who should and shouldn't get these treatments. Women at high risk of 
complications of pre-eclampsia are likely to benefit most whilst in low risk women, therapy may 
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cause more harm than good. Therefore, what is required is the prediction of risk of complications 
(such as eclampsia) of pre-eclampsia. 
 
8.5 Conclusion 
This project will collate and synthesise the available evidence regarding the value of the tests for 
predicting complications of pre-eclampsia. The systematic overviews will assess the quality of the 
available evidence and provide estimates of rate (or risk) of complications of pre-eclampsia given 
various patient characteristics and other findings. It will identify a set of tests that have maximal 
predictive value to aid in therapeutic decision-making. This will help to formulate practice 
recommendations and specific recommendations for future research. 
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CHAPTER 9:  PROTEINURIA AS A PREDICTOR OF COMPLICATIONS IN 
PRE-ECLAMPSIA 
9.1 Abstract 
Background 
Proteinuria is one of the essential criteria for the clinical diagnosis of pre-eclampsia. Increasing 
levels of proteinuria is considered to be associated with adverse maternal and fetal outcomes. We 
aim to determine the accuracy with which the amount of proteinuria predicts maternal and fetal 
complications in women with pre-eclampsia by systematic quantitative review of test accuracy 
studies. 
 
Methods 
We conducted electronic searches in MEDLINE (1951 to 2007), EMBASE (1980 to 2007), the 
Cochrane Library (2007) and the MEDION database to identify relevant articles and hand-search of 
selected specialist journals and reference lists of articles. There were no language restrictions for 
any of these searches. Two reviewers independently selected those articles in which the accuracy of 
proteinuria estimate was evaluated to predict maternal and fetal complications of pre-eclampsia. 
Data were extracted on study characteristics, quality and accuracy to construct 2×2 tables with 
maternal and fetal complications as reference standards. 
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Results 
Sixteen primary articles with a total of 6749 women met the selection criteria with levels of 
proteinuria estimated by urine dipstick, 24-hour urine proteinuria or urine protein:creatinine ratio as 
a predictor of complications of pre-eclampsia. All 10 studies predicting maternal outcomes showed 
that proteinuria is a poor predictor of maternal complications in women with pre-eclampsia. 
Seventeen studies used laboratory analysis and eight studies bedside analysis to assess the accuracy 
of proteinuria in predicting fetal and neonatal complications. Summary likelihood ratios of positive 
and negative tests for the threshold level of 5g / 24h were 2.0 (95% CI 1.5, 2.7) and 0.53 (95% CI 
0.27, 1) for stillbirths, 1.5 (95% CI 0.94, 2.4) and 0.73 (95% CI 0.39, 1.4) for neonatal deaths and 
1.5 (95% 1, 2) and 0.78 (95% 0.64, 0.95) for Neonatal Intensive Care Unit admission. The area 
under the curve (AUC) for adverse maternal and fetal outcomes are 0.63 (95% CI 0.22, 0.91) and 
0.59 (95% CI 0.36, 0.79) respectively. 
 
Conclusion 
Measure of proteinuria is a poor predictor of either maternal or fetal complications in women with 
pre-eclampsia. 
 
Citation of paper from this work 
Thangaratinam S, Coomarasamy A, O'Mahony F, Sharp S, Zamora J, Khan KS, Ismail KM. 
Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. 
BMC Med 2009 Mar 24; 7:10  
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9.2 Background 
Proteinuria is one of the essential criteria for the clinical definition of pre-eclampsia. It is part of the 
fundamental investigations performed by healthcare professionals in primary and secondary care to 
monitor disease severity and predict complications in women with pre-eclampsia. Urinalysis by 
visual reagent strip tests is widely performed in antenatal clinics and in the community by various 
health professionals. Total protein estimation in a 24-hour urine sample is also frequently used to 
assess the severity of pre-eclampsia in patients admitted to the hospital. More recently, spot urine 
protein:creatinine ratio has been used to provide an accurate quantification of 24-hour 
proteinuria.
240
 Estimation of the accuracy of the predictive value of proteinuria by any of the above 
methods in predicting maternal and fetal complications will aid in clinical management by 
identifying the highest risk women who may need aggressive management, and the lower risk 
women in whom unnecessary interventions may be avoided. 
 
Proteinuria occurs due to renal glomerular endotheliosis, a manifestation of widespread endothelial 
damage in pre-eclampsia.
241
 The association between proteinuria and adverse fetal outcomes was 
first highlighted by Page and Christianson.
242
 Since then, increased excretion of protein in women 
with pre-eclampsia has been generally associated with adverse maternal and fetal outcomes.
243;244
 
However, the primary diagnostic studies that evaluate the association between increase in the levels 
of proteinuria and maternal and neonatal outcomes have not generally been conducted with 
sufficiently large sample size to provide precise accuracy estimates. Moreover, they vary widely in 
their definition of pre-eclampsia, maternal and fetal outcomes, the method used for measurement 
and optimal cut-off levels of proteinuria. There are no systematic reviews exploring the accuracy of 
proteinuria to predict complications of pre-eclampsia. We therefore conducted a comprehensive 
systematic review to obtain precise estimates of likelihood ratios of adverse maternal and fetal 
complications for various cut-off levels of proteinuria in women with pre-eclampsia. 
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9.3 Methods 
The review was carried out with a prospective protocol using widely recommended methods 
described in Chapter 8, Section 8.3.  
 
9.4 Results 
9.4.1 Literature identification and study quality 
Appendix 6 summarises the process of literature identification and selection. There were 16 
primary articles that met the selection criteria including a total of 6749 women.
240;245-260
 Eight 
articles reported estimation of proteinuria by laboratory method only
246;247;249;252;254;255;259;260
, five 
by bedside dipstick urinalysis only
248;250;251;256;258
, two by either of the above methods
253;257
 and one 
by spot urine protein: creatinine ratio.
240
  
 
The salient features (population subgroups, test characteristics and reference standards) of each 
individual study are provided in Appendix 21.  The definition of pre-eclampsia differed widely 
between the studies. The test threshold in individual studies for laboratory estimation varied from 
0.3g/24h to 10g/24h, or was reported as an increase in proteinuria by 2g/24h between two 
measurements. The cut-off levels for bedside urinalysis using visual reagents ranged from 1+ to 4+ 
of proteinuria. One study evaluated the accuracy of spot urine protein: creatinine ratio for threshold 
levels of 500mg/ mmol and 900mg/ mmol in the prediction of maternal and fetal complications.
240
 
The methodological quality of the included studies is given in Appendix 14. 
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9.4.2 Proteinuria to predict maternal outcomes 
Table 9.1 summarises the accuracy estimates of various threshold levels of proteinuria in predicting 
adverse maternal outcomes. 
 
Three primary studies evaluated the accuracy of proteinuria in predicting eclampsia in 5 2x2 tables 
for cut off levels of 5g/24h, 10g/24h and an increase by 2g in 24 hours.
249;252;255
  The LR of positive 
test ranged from 1.7 (95% CI 0.94, 3.1) to 2.7 (95% CI 1.1, 6.2) respectively. The negative LR 
ranged from 0.54 (95% CI 0.06, 5.2) to 0.62 (95% CI 0.28, 1.4). The highest specificity 0.81 (95% 
CI 0.75, 0.86) was observed for cut off of 10g / 24 h and the highest sensitivity 67% was observed 
for cut offs of 5g / 24 h and an increase of 2g in 24 h. 
 
Three primary studies estimated the accuracy of proteinuria in predicting placental abruption using 
a cut-off of increase in level more than 2g/24h.
246;249;255
 The sensitivity of the 2 x 2 tables ranged 
between 0.29 (95% CI 0.19, 0.41) and 0.60 (95% CI 0.15, 0.95). The specificity varied from 0.59 to 
0.77. Three of the 4 tables had specificity less than 70% and none had sensitivity above 60%. 
 
HELLP syndrome prediction was evaluated in three primary studies.
249;252;255
 The sensitivity was 
less than 50% in all the studies with specificity more than 60% in all the studies. The LR of positive 
test ranged from 0.9 to 1.2. The negative LR varied from 0.96 to 1.1. 
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Table 9.1. Accuracy of proteinuria in the prediction of adverse maternal outcomes  
in women with pre eclampsia 
 
 
 
 
 
 
 
 
 
 
The area under the curve (AUC) for adverse maternal outcomes is 0.63 (95% CI 0.22, 0.91) (Fig 
9.1). 
 
 
 
 
 
Study Year Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
      
Eclampsia      
Newman 2002 >5g 0.67(0.22,0.96) 0.60(0.54,0.67) 1.7(0.94,3.1) 0.55(0.18,1.7) 
Hall 2002 >5g 0.50(0.07,0.93) 0.76(0.71,0.80) 2.1(0.76,5.6) 0.66(0.25,1.8) 
Newman 2002 >10g 0.50(0.12,0.88) 0.81(0.75,0.86) 2.7(1.14,6.2) 0.62(0.28,1.4) 
Schiff 1996 inc>2g 0.50(0.00,1.0) 0.67(0.51,0.75) 1.4 (0.19,10.0) 0.79(0.11,5.6) 
Hall 2002 inc>2g 0.67(0.01,1.0) 0.62(0.50,0.73) 1.7(0.54,5.6) 0.54(0.06,5.2) 
      
Abruption      
Buchbinder 2002 >5g 0.60(0.15,0.95) 0.59(0.49,0.69) 1.46(0.69,3.1) 0.69(0.23,2.0) 
Hall 2002 >5g 0.29(0.19,0.41) 0.77(0.71,0.82) 1.25(0.81,1.9) 0.93(0.79,2.0) 
Schiff 1996 inc>2g 0.40(0.05,0.85) 0.64(0.51,0.76) 1.11(0.36,3.4) 0.94(0.45,2.0) 
Hall 2002 inc>2g 0.30(0.07,0.65) 0.59(0.45,0.72) 0.74(0.27,2.0) 1.2(0.75,1.9) 
      
HELLP      
Newman 2002 >5g 0.47(0.302,0.65) 0.61(0.54,0.69) 1.22(0.82,1.81) 0.86(0.62,1.2) 
Hall 2002 >5g 0.22(0.06,0.45) 0.76(0.70,0.80) 0.91(0.37,2.2) 1.03(0.80,1.3) 
Newman 2002 >10g 0.22(0.10,0.39) 0.81(0.74,0.87) 1.17(0.59,2.3) 0.96(0.80,1.2) 
Schiff 1996 inc>2g 0.33(0.10,0.65) 0.63(0.49,0.76) 0.9 (0.38,2.2) 1.06(0.68,1.7) 
Hall 2002 inc>2g 0.33(0.00,1.0) 0.60(0.48,0.72) 0.84(0.09,8.2) 1.11(0.35,3.5) 
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Fig 9.1. Area under the curve for predicting adverse maternal outcome by proteinuria in pre 
eclampsia 
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9.4.3 Proteinuria to predict fetal outcomes 
Fetal, neonatal and perinatal mortality 
Thirteen studies reported prediction of fetal, neonatal and perinatal mortality using both laboratory 
and bedside testing for proteinuria.
240;246;247;252;254-256;260;261
 The largest study, involving 3260 
patients that estimated the prediction of stillbirths in pre-eclampsia was conducted by Taylor et al 
using urine dipstick method.
262
 The highest specificity (0.91, 95% CI 0.87, 0.94) was observed for 
cut off levels of PCR 500 mg/mmol for perinatal mortality. The highest sensitivity (1, 95% CI 0.29, 
1) was reported for stillbirths for levels of 5g/24h proteinuria. (Table 9.2) 
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Table 9.2. Accuracy of proteinuria in the prediction of adverse fetal outcomes in women with 
pre eclampsia 
 
Study Year Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Small for 
gestational age      
Lao 1988 1+ 0.68(0.43,0.87) 0.52(0.40,0.64) 1.4(0.95,2.1) 0.61(0.30,1.24) 
Odegaard 2000 2+ 0.84(0.68,0.94) 0.40(0.30,0.42) 1.3(1.1,1.5) 0.45(0.21,1.0) 
Brown 1996 2+ 0.75(0.67,0.81) 0.18(0.15,0.21) 0.9(0.83,1.0) 1.39(1.01,1.91) 
Odegaard 2000 3+ 0.46(0.30,0.63) 0.76(0.70,0.81) 1.9(1.3,2.8) 0.72(0.53,0.97) 
Furukawa 2006 3+ 0.50(0.33,0.67) 0.61(0.45,0.76) 1.3(0.8,2.1) 0.82(0.55,1.23) 
Waugh 2005 0.5g/24hBCA 0.47(0.30,0.65) 0.73(0.65,0.79) 1.7(1.11,2.7) 0.73(0.52,1.01) 
Waugh 2005 0.3g/24hBCA 0.68(0.50,0.83) 0.30(0.23,0.38) 0.96(0.75,1.24) 1.09(0.63,1.86) 
Buchbinder 2002 5g/24h 0.63(0.25,0.92) 0.60(0.49,0.69) 1.55(0.86,2.79) 0.63(0.25,1.56) 
      
Neonatal death      
Newman 2002 5g/24h 0.56(0.21,0.86) 0.61(0.53,0.67) 1.4(0.77,2.59) 0.74(0.35,1.54) 
Buchbinder 2002 5g/24h 1.0(0.03,1.0) 0.59(0.49,0.68) 1.80(0.79,4.1) 0.43(0.04,4.75) 
Fleigner 1975 5g/24h 0.50(0.01,0.99) 0.59(0.48,0.69) 1.21(0.30,4.95) 0.85(0.21,3.44) 
Hall 2002 5g/24h 0.10(0.00,0.45) 0.75(0.70,0.80) 0.40(0.06,2.61) 1.20(0.97,1.49) 
Newman 2002 10g/24h 0.33(0.08,0.70) 0.81(0.75,0.86) 1.75(0.67,4.62) 0.82(0.52,1.31) 
Hall 2002 inc>2g 0.00(0.00,0.71) 0.59(0.47,0.70) 0.31(0.02,4.14) 1.48(0.98,2.25) 
Perinatal 
mortality  
Fleigner 1975 5g/24h 0.64(0.35,0.87) 0.62(0.51,0.73) 1.71(1.06,2.75) 0.57(0.28,1.18) 
Brown 1996 2+ 0.40(0.12,0.74) 0.19(0.16,0.22) 0.49(0.23,1.05) 3.18(1.88,5.37) 
Paladini 1970 1g/l 0.54(0.43,0.65) 0.44(0.38,0.50) 0.96(0.77,1.21) 1.05(0.80,1.37) 
Paladini 1970 2g/l 0.36(0.25,0.47) 0.64(0.59,0.70) 1.01(0.72,1.40) 1.0(0.83,1.20) 
Chan 2004 
PCR 500mg/ 
mmol 0.50(0.01,0.99) 0.91(0.87,0.94) 5.32(1.28,22.15) 0.55(0.14,2.21) 
      
Intra uterine 
death      
Buchbinder 2002 5g/24h 1.0(0.29,1.0) 0.60(0.50,0.70) 2.16(1.40,3.35) 0.21(0.02,2.82) 
Fleigner 1975 5g/24h 0.67(0.35,0.90) 0.62(0.51,0.72) 1.76(1.09,2.85) 0.54(0.24,1.22) 
Hall 2002 5g/24h 0.50(0.01,0.99) 0.76(0.71,0.80) 2.06(0.51,8.35) 0.66(0.17,2.64) 
Taylor 1954 1+ 0.65(0.59,0.71) 0.51(0.49,0.52) 1.31(1.19,1.45) 0.69(0.59,0.82) 
Taylor 1954 3+ 0.36(0.30,0.42) 0.84(0.83,0.86) 2.26(1.89,2.72) 0.77(0.70,0.84) 
      
Neonatal intensive 
care unit 
admission      
Newman 2002 5g/24h 0.44(0.36,0.52) 0.73(0.57,0.85) 1.60(0.96,2.67) 0.78(0.62,0.97) 
Buchbinder 2002 5g/24h 0.52(0.33,0.70) 0.62(0.50,0.73) 1.35(0.87,2.11) 0.78(0.52,1.17) 
Hall 2002 5g/24h 0.24(0.17,0.32) 0.52(0.42,0.62) 0.50(0.35,0.71) 1.47(1.19,1.80) 
Newman 2002 10g 0.26(0.19,0.34) 0.95(0.87,1.0) 5.59(1.79,17.45) 0.77(0.69,0.87) 
Hall 2002 inc>2g 0.50(0.26,0.74) 0.64(0.50,0.77) 1.40(0.78,2.50) 0.78(0.47,1.28) 
Lao 1988 1+ 0.70(0.35,0.93) 0.49(0.38,0.61) 1.38(0.87,2.19) 0.61(0.23,1.61) 
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Neonatal deaths were evaluated in five studies for cut-off levels of 5g/24h (n=3),
246;247;252
 10g/24h 
(n=1)
252
 and increase by 2g in 24h (n=1).
261
 The specificity was more than 60% in 3 of the 5 studies 
and the sensitivity was more than 60% in 1 study. 
 
The threshold levels of proteinuria to predict perinatal deaths were 1g/l, 2g/l and 500 mg/ mmol. 
The positive LR was 5.3 (95% CI 1.3, 22.1) and the negative LR was 0.55 (95% CI 0.14, 2.2) for 
cut-off levels of 500mg/ mmol.
240
 
 
Small for gestational age 
Small for gestational age is the commonest outcome reported in 8 2x2 tables. Three primary studies 
assessed the accuracy of bedside urinalysis for cut-offs of 1+, 2+ and 3+ of proteinuria in urine 
dipstick.
248;250;253
 The likelihood ratio of laboratory estimates of proteinuria levels of 0.3g/24h and 
0.5g/24h were 0.96 (95% CI 0.75, 1.2) and 1.7 (95% CI 1.1, 2.7) for positive test and 1.09 (95% 
0.63, 1.9) and 0.73 (95% CI 0.52, 1) for negative test respectively, using the benzethonium chloride 
assay (BCA).
259
 The sensitivity was higher for levels of proteinuria less than 3+ or 0.5 g/24h 
compared low cut off levels. The specificity was high with increasing levels of proteinuria for 
predicting small for gestational age fetus. 
 
Neonatal Intensive Care Unit (NICU) admission 
NICU admission was assessed as an outcome in 6 2x2 tables.
246;250;252;261
 The highest specificity 
(0.95, 95% CI 0.87,1.0) and positive likelihood ratio (5.59, 95% CI 1.79,17.45) were observed for 
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levels of 10g/24h proteinuria. Urine dipstick of 1+ had the highest sensitivity (0.70, 95% CI 0.35, 
0.93) in predicting NICU admission. 
The area under the curve (AUC) for adverse fetal outcomes is 0.59 (95% CI 0.36, 0.79) (Fig 9.2). 
Fig 9.2. Area under the curve for predicting adverse fetal outcome by proteinuria in pre 
eclampsia 
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9.5 Discussion 
Proteinuria has usually been associated with increase in maternal and fetal mortality and 
morbidity.
244
 Our review has shown that the magnitude of proteinuria in women with pre-eclampsia 
is a poor predictor of the major maternal and fetal complications. 
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For prediction of adverse fetal outcomes, the only statistically significant results were observed for 
positive test result with LR+ ranging from 1.3 to 2.3 for cut-off levels of 5g/24h, 1+ and 3+ 
proteinuria in the prediction of stillbirths.
246;247;256;261
 Furthermore, we need to take into account that 
three of these five test accuracy studies were conducted more than 30 years ago.
247;256
 The test was 
found to be a poor predictor of neonatal and perinatal deaths with no significant LRs for positive or 
negative test. The test performed poorly as evidenced by the increase in adverse events noticed in 
the test negative group compared with the test positive group, as noticed in some studies.
254;259;261
 
The overall low value of abnormal test and high value of normal test implies that the test is of „very 
little‟ clinical value. 
 
The validity of our review findings depends on the methodology of the systematic review and the 
quality of the individual studies included.
232
 An extensive literature search was performed in 
relevant databases without any language restrictions to minimize the possibility of missing any 
studies. Methodological deficiencies such as verification bias and differential use of reference 
standards did not apply to the studies in the review, ensuring inclusion of studies of acceptable 
quality. 
 
The methodological problems facing reviews of this nature are daunting. A significant limitation of 
this review is the heterogeneity noticed between individual studies with regards to population, 
definition of pre-eclampsia, method of performing the test, test thresholds, frequency of testing, 
interval between the test and outcome, and reference standards. The lack of information regarding 
the temporal relation between test findings and outcomes observed and possibility of confounding 
by other risk factors contributing to maternal and fetal complications may influence the observed 
predictive value of proteinuria for maternal and fetal complications. The wide confidence intervals 
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observed for the various outcomes are a reflection of the statistical uncertainty around the results 
due to the small sample size in many studies. Meta-analysis of studies using individual patient data 
may conquer many of the difficulties identified. 
 
9.6 Conclusion 
This systematic review has shown that estimation of levels of proteinuria in women is not a 
clinically useful test to predict fetal or maternal complications. The results of this review calls into 
question the commonly used practice of making clinical decisions in women with pre-eclampsia 
based on the severity of proteinuria. It has highlighted the need for large, well-designed prospective 
studies on this important question with the hope to expand future research. 
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CHAPTER 10: SERUM URIC ACID AS A PREDICTOR OF 
COMPLICATIONS IN PRE ECLAMPSIA                                                                                                
10.1 Abstract 
Background 
Uric acid is considered to be a clinical indicator of severity of disease in pre eclampsia. Through the 
systematic review we aim to determine the accuracy with which serum uric acid predicts maternal 
and fetal complications in women with pre eclampsia. 
 
Methods 
We conducted electronic searches in MEDLINE (1951-2004), EMBASE (1980-2004), the 
Cochrane Library (2004:4) and the MEDION database to identify relevant articles. A hand-search 
of selected specialist journals and reference lists of articles obtained was then carried out. There 
were no language restrictions for any of these searches. Two reviewers independently selected 
those articles in which the accuracy of serum uric acid was evaluated to predict maternal and fetal 
complications of pre eclampsia. Data were extracted on study characteristics, quality and accuracy 
to construct 2 x 2 tables with maternal and fetal complications as reference standard. 
 
Results  
There were 18 primary articles that met the selection criteria, including a total of 3675 women. The 
sensitivity of uric acid was higher than specificity in 9/15 (60%) and 13 /20 (65%) 2x2 tables 
predicting adverse maternal and fetal outcomes respectively. The area under the curve for adverse 
maternal and fetal outcomes were 0.75 (95% CI 0.46, 0.92) and 0.69 (0.39, 0.86) respectively. 
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Conclusion 
 Serum uric acid is a moderate predictor of adverse outcomes in pre eclampsia with better 
performance for maternal than fetal outcomes.  
 
Citation of paper from this work 
Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS; Tests in Prediction of Pre-
eclampsia Severity review group. Accuracy of serum uric acid in predicting complications of pre-
eclampsia: a systematic review. BJOG. 2006;113:369-78.  
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10.2 Background 
Hyperuricemia is one of the characteristic findings in pre-eclampsia. In clinical practice, uric acid 
determination is considered to be a part of the workup in patients with pre-eclampsia to monitor 
disease severity and aid management of the patients. The association between raised serum uric acid 
and pre-eclamptic pregnancy was first reported in 1917.
263
 Reduced uric acid clearance secondary 
to reduced glomerular filtration rate, increased reabsorption and  decreased secretion may be the 
reasons for elevated serum uric acid levels in women with pre-eclampsia.
264;265
 The 
pathophysiologic mechanisms of pre-eclampsia comprising of increased trophoblastic tissue 
shedding, endothelial dysfunction, reduced blood flow in the feto-maternal unit have also been 
hypothesized as the underlying cause of hyperuricemia in this condition.
266
 
 
 Several studies have reported a positive correlation between elevated maternal serum uric acid 
levels and adverse maternal and fetal outcomes.
267-270
 However, these primary diagnostic studies 
have not generally been conducted with large enough sample size to provide precise accuracy 
estimates and they vary widely in their definition of pre-eclampsia, maternal and fetal outcomes, 
and optimal cut off levels of uric acid in predicting maternal and fetal complications. There are no 
systematic reviews exploring the accuracy of uric acid to predict complications of pre-eclampsia. 
We therefore conducted a comprehensive systematic review to obtain precise estimates of maternal 
serum uric acid levels to predict maternal and fetal complications in women with pre-eclampsia. 
 
10.3 Methods 
The review was carried out with a prospective protocol using widely recommended methods as 
described in Chapter 8, section 8.3.  
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10.4 Results 
10.4.1 Literature identification and study quality 
Appendix 7 flow chart summarises the process of literature identification and selection. 
There were 18 primary articles that met the selection criteria including a total of 3675 
women.
245;251;265;267;268;271-283
 Each study‟s salient features according to the population subgroups, 
test characteristics and reference standards are provided in Appendix 22. The definition of pre-
eclampsia differed widely between the studies (2x2 tables). The most common cut off of uric acid 
was 6mg/dl (350 µmol/ l). The commonest maternal and fetal outcomes assessed were severity of 
hypertension and small for gestational age respectively. The methodological quality of the included 
studies is given in Appendix 14. 
 
10.4.2 Uric acid to predict maternal outcomes 
Eclampsia was evaluated as an outcome in three studies using a cut off level of 6mg/dl.
265;267;283
 
The sensitivity ranged between  0.36 (95% CI 0.17, 0.59) and 0.92 (95% CI 0.64, 1.0) and 
specificity from 0.54 (95% CI 0.44, 0.65) to 0.95 (95% CI 0.83, 1.0). 
 
Six studies estimated the accuracy of uric acid levels more than or equal to 6mg/dl in predicting 
severe hypertension. The sensitivity and specificity were more than 70% in 5/8 and 4/8 studies 
respectively. Caesarean section was studied as an outcome using 3 cut offs, 6mg/dl, 5mg/dl and 8.5 
mg/dl. The sensitivity and specificity were more than 60% in 3 of the four studies. The positive LR 
varied from 1.33 (95% CI 0.58, 3.04) to 2.64 (95% CI 1.44, 4.83) and the negative LR from 0.19 
(95% CI 0.03, 1.25) to 0.97 (95% CI 0.88, 1.06). 
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Two studies evaluated the prediction of HELLP syndrome using 7.6 mg/dl and 9mg/dl threshold 
levels. The LRs for predicting HELLP syndrome with a threshold of 7.6 mg/dl were 1.6 (95% CI 
0.84, 2.9) and 0.90 (95% CI 0.76, 1.1) and with a threshold of 9mg/dl were 1.9 (95% CI 0.85, 4.2) 
and 0.92 (95% CI 0.81, 1.0).  
Table 10.1 Accuracy of uric acid in the prediction of adverse maternal outcomes  
in women with pre eclampsia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The AUC for predicting adverse maternal outcome was 0.75 (95% CI 0.46, 0.92). (Fig 10.1) 
Study Year Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
      
Eclampsia      
Fadel 1969 6mg/dl 0.36(0.17,0.59) 0.95(0.83,1.0) 7.27(1.69,31.30) 0.67(0.49,0.93) 
Yassaee 2003 6mg/dl 0.92(0.64,1.0) 0.54(0.44,0.65) 2.03(1.54,2.67) 0.14(0.02,0.94) 
Lancet 1956 6mg/dl 0.84(0.70,0.93) 0.57(0.52,0.62) 1.94(1.65,2.29) 0.29(0.15,0.54) 
      
Caesarean Section       
Liedholm 1984 6mg/dl 0.89(0.52,0.10) 0.59(0.33,0.82) 2.16(1.17,3.99) 0.19(0.03,1.25) 
Yassaee 2003 6mg/dl 0.70(0.56,0.81) 0.73(0.57,0.85) 2.55(1.53,4.25) 0.42(0.27,0.64) 
Odendaal 1996 8.7mg/dl 0.12(0.07,0.18) 0.91(0.82,0.96) 1.33(0.58,3.04) 0.97(0.88,1.06) 
Dequiedt 1979 5mg/dl 0.80(0.44,0.98) 0.70(0.51,0.84) 2.64(1.44,4.83) 0.29(0.08,1.01) 
      
Severe 
Hypertension       
Williams 2002 7.6mg/dl 0.25(0.16,0.38) 0.86(0.79,0.91) 1.79(0.99,3.24) 0.87(0.74,1.02) 
Liedholm 1984 6mg/dl 0.80(0.52,0.96) 0.73(0.39,0.94) 2.93(1.08,7.96) 0.28(0.09,0.81) 
Voto 1988 6 mg/dl 0.60(0.39,0.79) 0.82(0.73,0.89) 3.33(1.97,5.65) 0.49(0.30,0.80) 
Lancet 1956 6mg/dl 0.69(0.60,0.77) 0.60(0.54,0.65) 1.70 (1.43,2.04) 0.52(0.39,0.69) 
Connon 1968 6mg/dl 0.95(0.75,0.10) 0.51(0.41,0.61) 1.94(1.55,2.41) 0.10(0.01,0.67) 
Brown 1996 6mg/dl 0.76(0.69,0.82) 0.46(0.43,0.50) 1.42 (1.27,1.58) 0.52(0.39,0.68) 
Seitchik 1953 6mg/dl 1.00(0.16,1.0) 0.92(0.62,0.10) 7.22(1.48,35.34) 0.19(0.02,2.38) 
Peralta Pedero 
2004 3 mg/dl 0.78 (0.7,0.84) 0.32(0.21,0.45) 1.1(0.94,1.4) 0.7(0.44,1.1) 
      
HELLP      
Williams 2002 7.6mg/dl 0.24(0.13,0.37) 0.85(0.78,0.90) 1.6 (0.84,2.90) 0.90(0.76,1.06) 
Williams 2002 9 mg/dl 0.16(0.08,0.29) 0.91(0.85,0.96) 1.9(0.85,4.2) 0.92(0.81,1) 
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Fig 10.1 Area under the curve for predicting adverse maternal outcome by uric acid in pre 
eclampsia 
 
 
 
10.4.3 Uric acid to predict fetal outcomes 
Seven studies evaluated the accuracy of uric acid to predict stillbirth or neonatal deaths for various 
threshold levels (Table 10.2). The positive LR was between 1.05 (95% CI 0.83, 1.33) and 3.12 
(95% CI 2.14 ,4.56). The negative LR ranged from 0.07 (95% CI 0.01, 1.11) to 0.94 (95% CI 0.83, 
1.05). The sensitivity was above 70% in 5 of the 7 studies and specificity more than 70% in 2/7 
studies. 
 
 
 
  
133 
 
 
Table 10.2 Accuracy of uric acid in the prediction of adverse fetal outcomes in women with 
pre eclampsia 
Study Year Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Still birth or 
neonatal death       
Varma 1982 5.5mg 0.86(0.42,1.00) 0.73(0.66,0.79) 3.12(2.14,4.56) 0.20(0.03,1.21) 
Yassaee 2003 6mg 0.96(0.68,1.00) 0.55(0.44,0.65) 2.13(1.65,2.75) 0.07(0.01,1.11) 
Odendaal 1996 8.7mg 0.15(0.07,0.27) 0.91(0.85,0.95) 1.62(0.76,3.47) 0.94(0.83,1.05) 
Mathews 1980 6mg 0.67(0.22,0.96) 0.65(0.47,0.80) 1.89(0.91,3.90) 0.52(0.16,1.64) 
Dequiedt 1979 5mg 0.91(0.41,1.00) 0.66(0.49,0.80) 2.66(1.59,4.44) 0.14(0.01,1.97) 
Brown 1996 6mg 0.70(0.35,0.93) 0.42(0.38,0.45) 1.20(1.80,1.81) 0.72(0.28,1.86) 
Sagen 1984 6mg 0.92(0.47,1.00) 0.12(0.05,0.23) 1.05(0.83,1.33) 0.64(0.04,9.84) 
      
Small for 
gestational age       
Williams 2002 7.6mg/dl 0.17(0.08,0.31) 0.81(0.74,0.87) 0.89(0.44,1.80) 1.03(0.88,1.19) 
Varma 1982 60 inc 0.52(0.37,0.67) 0.77(0.70,0.84) 2.30(1.54,3.43) 0.62(0.45,0.85) 
Voto 1988 6mg/dl 0.31(0.11,0.59) 0.74(0.65,0.82) 1.22(0.55,2.70) 0.93(0.65,1.31) 
D‟Anna 2000 6mg/dl 0.86(0.74,0.93) 0.28(0.14,0.47) 1.19(0.94,1.51) 0.52(0.23,1.17) 
Yassaee 2003 6mg/dl 0.70(0.56,0.81) 0.73(0.57,0.85) 2.55(1.53,4.25) 0.42(0.27,0.64) 
Odendaal 1996 8.7mg/dl 0.09(0.04,0.15) 0.87(0.79,0.92) 0.65(0.31,1.39) 1.05(0.96,1.15) 
Dequiedt 1979 5mg/dl 0.75(0.35,0.97) 0.66(0.48,0.81) 2.19(1.19,4.02) 0.38(0.11,1.29) 
Sagen 1984 6mg/dl 1.0(0.90,1.0) 0.21(0.10,0.37) 1.26(1.06,1.50) 0.07(0.00,1.10) 
Brown 1996 6mg/dl 0.71(0.63,0.78) 0.45(0.41,0.49) 1.29(1.14,1.45) 0.65(0.50,0.84) 
      
Intra uterine 
death      
Varma 1982 5. 5mg/dl 1.0(0.16,1.00) 0.71(0.64,0.77) 2.88(1.66,5.00) 0.23(0.02,2.95) 
Yassaee 2003 6mg/dl 1.00(0.74,1.00) 0.55(0.44,0.65) 2.13(1.66,2.74) 0.07(0.01,1.07) 
Odendaal 1996 8.7mg/dl 0.17(0.04,0.41) 0.90(0.85,0.93) 1.60(0.53,4.83) 0.93(0.75,1.15) 
Dequiedt 1979 5mg/dl 1.00(0.48,1.00) 0.66(0.49,0.80) 2.65(1.62,4.34) 0.13(0.01,1.83) 
 
Uric acid showed moderate sensitivity and specificity (>70%) in 60% (5/8) of the studies. Four 
studies evaluated the accuracy of uric acid to predict intra uterine death, with high sensitivity 
(>90%) in 75% of the studies. The high specificity was observed in 25% of the studies. The AUC 
for adverse fetal outcome was 0.69 (95% CI 0.39, 0.86) as seen in Fig 10.2. 
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 Fig 10.2 Area under the curve for predicting adverse fetal outcome by uric acid in pre 
eclampsia 
0
.2
.4
.6
.8
1
S
e
n
s
it
iv
it
y
0.2.4.6.81
Specificity
Study estimate
HSROC curve
95% confidence
region
95% prediction
region
AUC         Area under the curve
AUC=0.69 (95% CI 0.39, 0.86)
 
10.5 Discussion 
This review presents the best available evidence so far in addressing the question of significance of 
uric acid levels as a predictor of maternal and fetal complications in pre-eclampsia. Although uric 
acid as a marker may be of value in detecting pre-eclampsia,
284
 it has been identified as a poor 
predictor of any complications of pre-eclampsia. The provision of likelihood ratios stratified by the 
severity of pre-eclampsia and test thresholds will enable clinicians to understand the poor clinical 
value of this test in predicting complications in women with pre-eclampsia.  
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The validity of our review findings depends on the methodology of the systematic review and the 
quality of the individual studies included.
55;232
 An extensive literature search was performed in 
relevant databases without any language restrictions to minimise the possibility of missing any 
studies. Methodological deficiencies like verification bias, differential use of reference standards 
and case control design did not apply to the studies in the review ensuring inclusion of acceptable 
quality studies. A significant limitation of this review is the heterogeneity noticed between 
individual studies with regards to population, definition of pre-eclampsia, test thresholds, frequency 
of testing, interval between the test and outcome, and reference standards. This led us to analyse 
data within subgroups defined by severity of pre-eclampsia and threshold levels, resulting in the 
inclusion of a small number of studies in the subgroup meta-analyses.  
 
Caution is needed in interpreting quantitative estimation of uric acid levels in relation to outcome. 
Apart from the variations in the methods for estimating uric acid levels, levels of uric acid could be 
raised due to the use of anti-hypertensives.
275
 The outcomes could also be influenced by the 
different therapeutic interventions such as use of antenatal steroids in reducing respiratory distress 
syndrome
285
 and anti-hypertensives
286
 that might help to reduce fetal and maternal complications. 
Moreover, it is not possible to be certain of the finding where only a small number of studies exist 
in a subgroup, due to imprecision.  
 
Our review has consistently observed poor performance of uric acid in predicting various maternal 
and fetal outcomes, across various studies, settings and population. The consistency of such poor 
performance of uric acid in predicting complications in those with pre-eclampsia cannot be ignored. 
The predictive value of a positive test was particularly poor for some fetal outcomes like stillbirths 
and neonatal deaths. The confidence intervals of the pooled LRs for a positive result extended to 1 
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or less than 1, suggesting the possibility of finding the same or more number of complications in 
those with normal urate levels compared to raised levels. The same anomaly was seen for a 
negative test result in predicting stillbirths and neonatal deaths (Table 10.2). 
10.6 Conclusion 
Given our results, uric acid does not seem to be a significant predictor of individual adverse 
maternal or fetal outcomes. The predictive capability is slightly better for composite adverse 
maternal outcome than fetal outcomes.  
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CHAPTER 11:  LIVER FUNCTION TEST AS A PREDICTOR OF 
COMPLICATIONS IN PRE ECLAMPSIA  
11.1 Abstract 
Background 
Liver function tests are considered to be markers of severity of pre eclampsia. This review aims to 
determine the accuracy with which liver function tests (LFTs) predict maternal and fetal 
complications in women with pre-eclampsia. 
 
Methods 
 We performed systematic quantitative review of test accuracy studies. We conducted electronic 
searches without language restrictions in Medline (1951-2008), Embase (1980-2008), the Cochrane 
Library (2008) and MEDION databases and hand-searched specialist journals and reference lists of 
known relevant articles.  Two reviewers independently selected articles and extracted data on study 
characteristics, quality and accuracy to construct 2 X 2 tables with maternal and fetal complications 
as separate reference standards. A bivariate model estimated area under summary Receiver 
Operating Characteristic curve (AUC), sensitivity and specificity.  
 
Results 
There were 13 primary articles selected including a total of 2813 women in 49 2 x 2 tables, 30 
assessing maternal adverse outcomes and 19 assessing adverse fetal outcomes. LFTs assessed 
included AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), LDH (Lactate 
dehydrogenase), GGT (Gamma glutamyltransferase) and bilirubin. Studies usually did not provide 
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results of each analyte separately. The commonest maternal outcome assessed was eclampsia and 
the commonest fetal outcome evaluated was neonatal death. For predicting adverse maternal 
outcome, the Area Under the Curve (AUC) was 0.79 (95% CI 0.51, 0.93). For predicting adverse 
fetal outcomes the AUC was 0.65 (95% CI 0.26, 0.9). Sensitivity of the test was poor for both 
maternal and fetal outcomes with higher specificity. 
 
Conclusion 
LFTs performed moderately in predicting adverse fetal and maternal outcomes in women with pre 
eclampsia. Increased liver enzymes increase the probability of maternal and fetal complications, but 
normal liver enzymes do by no means rule out disease.   
 
 
 
 
  
139 
 
11.2 Background 
Liver enzymes, aspartate aminotransferase (AST) or serum glutamic oxalocetic transaminase 
(SGOT) and alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) are 
often raised in pre-eclampsia. The clinical manifestations of liver involvement are right upper 
quadrant or epigastric pain, elevated liver enzymes, and in severe cases, subcapsular hemorrhage or 
hepatic rupture. Hemolysis, Elevated Liver functions, and Low Platelets (HELLP) syndrome is 
diagnosed in 10 – 20 % of women with severe pre-eclampsia. Liver function tests (LFTs) are part of 
the routine workup to monitor disease severity to aid management of the patients.  
 
Several studies have reported a positive correlation between elevated maternal serum liver enzyme 
levels and adverse maternal and fetal outcomes.
287-289
 However, these studies have not generally 
been conducted with large enough sample size to provide precise accuracy estimates and they vary 
widely in their definition of pre-eclampsia and maternal and fetal outcomes. There are no 
systematic reviews exploring the accuracy of liver enzymes to predict complications of pre-
eclampsia. We therefore conducted a comprehensive systematic review to obtain precise estimates 
of maternal serum liver enzyme levels to predict maternal and fetal complications in women with 
pre-eclampsia. 
 
11.3 Methods 
The review was carried out with a prospective protocol
290
 using widely recommended methods as 
described in Chapter 8, Section 8.3.  
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11.4 Results 
11.4.1 Literature identification and study quality 
Appendix 8 flow chart summarises the process of literature identification and selection. There were 
13 primary articles that met the selection criteria, consisting of 42 2 x 2 tables including a total of 
2813 women.
251;287;289;291-300
 Each study‟s salient features are provided in Appendix 23. 
Methodological quality of included studies (Appendix 14) showed that the index tests and reference 
standard (maternal and fetal outcomes) were adequately described in 3 (23 %) and 5 (38 %) out of 
13 studies respectively. Five of the 13 studies were prospectively conducted and none of the studies 
were blinded for outcome measurement.
287;291;294-296
  
 
11.4.2 Liver function tests to predict maternal outcomes 
 Thirteen primary studies evaluated accuracy of liver function tests (LFT) to predict adverse 
maternal outcomes in 30 2x2 tables.
251;275;287;289;291-297;299;300
 Eclampsia was the commonest reported 
adverse outcome. The accuracy of LFT to predict adverse maternal outcome ranged from 0.04 
(95% CI 0, 0.34) to 0.95 (95% CI 0.63, 1) for sensitivity and from 0.17 (95% CI 0.14, 0.20) to 0.97 
(95% CI 0.93, 0.99) for specificity respectively. The highest sensitivity of 0.95 (95% CI 0.63, 1) 
was noted for raised levels of either LDH (600 U/l) or AST (70 U/l) or ALT (70 U/l) to predict 
DIC.
293
  The highest specificity of 0.97 (95% CI 0.93, 0.99) was observed for increased levels of 
AST or ALT for prediction of eclampsia.
291
 The best predicted likelihood ratio of a positive test 
was 9.11 (95% CI 3.26, 25.45)
291
 and best predicted likelihood ratio of a negative test was 0.12 
(95% CI 0.01, 1.77)
295
  for raised levels of ALT or AST (Table 11.1). The AUC for predicting any 
adverse maternal outcome was 0.79 (95% CI 0.51, 0.93) (Fig 11.1).  
 
 
 
  
141 
 
Table 11.1 Accuracy of liver function tests in the prediction of adverse maternal outcomes in 
women with pre eclampsia 
Study Year Test Cut off 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
 
Eclampsia 
 
Borglin 1958 
AST/ALT Increased 0.67(0.02,1) 0.74(0.54,0.89) 2.6(0.70,9.4) 0.45(0.05,4.4) 
Crisp 1959 AST 70 0.93(0.52,1) 0.55(0.41,0.69) 2.1(1.5,3) 0.12(0.01,1.8) 
Romero 1988 AST 2SD 0.71(0.29,0.96) 0.80(0.75,0.85) 3.6(2.1,6.1) 0.36(0.11,1.2) 
Aali  2004 AST/ALT 500/300 0.27(0.13,0.46) 0.97(0.93,0.99) 9.1(3.3,25.5) 0.75(0.61,0.93) 
Audibert 1996
* 
LDH/AST/ALT 
600/70/70
0 
0.27(0.11,0.50) 0.73(0.66,0.78) 1(0.49,2.0) 1.0(0.77,1.31) 
Abramovici 1999* AST 70 0.13(0.05,0.26) 0.86(0.76,0.93) 0.94(0.37,2.4) 1(0.87,1.2) 
Haddad 2000* LDH/AST/ALT 600/70/70 0.56(0.21,0.86) 0.51(0.37,0.65) 1.1(0.59,2.2) 0.87(0.40,1.90) 
Woldesellasie 2005  AST 43 0.82(0.48,0.98) 0.16(0.10,0.23) 0.97(0.73,1.3) 1.2(0.31,4.3) 
Woldesellasie 2005 ALT 60 0.04(0,0.34) 0.97(0.92,0.99) 1.3(0.07,23.4) 0.99(0.87,1.1) 
Woldesellasie 2005 LDH 180 0.70(0.35,0.93) 0.84(0.77,0.90) 4.5(2.5,8) 0.36(0.14,0.92) 
 
Pulmonary 
oedema 
      
Romero 1988 AST 2SD 0.67(0.09,0.99) 0.79(0.74,0.84) 3.2(1.4,7.5) 0.42(0.08,2.1) 
Audibert 1996* LDH/AST/ALT 600/70/70 0.50(0.19,0.81) 0.73(0.67,0.79) 1.9(0.97,3.6) 0.68(0.37,1.3) 
Haddad 2000* LDH/AST/ALT 600/70/70 0.67(0.22,0.96) 0.52(0.38,0.65) 1.4(0.74,2.6) 0.64(0.2,2.1) 
 
Adverse maternal 
outcome 
      
Martin Jr 1999* AST 150 0.70(0.63,0.77) 0.48(0.43,0.53) 1.4(1.2,1.5) 0.62(0.48,0.8) 
Martin Jr 1999* LDH 1400 0.72(0.65,0.79) 0.49(0.44,0.54) 1.4(1.2,1.6) 0.57(0.44,0.74) 
Martin Jr 1999* ALT 100 0.66(0.59,0.73) 0.47(0.42,0.52) 1.2(1.1,1.4) 0.72(0.57,0.91) 
Girling 1997 
AST/ALT/Bil/G
GT 
30/32/14/
41 
0.93 (0.52,1) 0.57(0.37,0.76) 2.2 (1.4,3.5) 0.12 (0.01,1.7) 
Menzies 2007 ALT/AST 40/55 0.33(0.22,0.45) 0.80(0.77,0.84) 1.7(1.2,2.4) 0.83(0.71,0.99) 
Menzies 2007 LDH 600 0.62(0.49,0.74) 0.60(0.56,0.64) 1.6(1.3,1.9) 0.63(0.46,0.86) 
 
Abruption 
      
Odendaal 2000* LDH 350 0.07(0.02,0.16) 0.96(0.88,0.99) 1.7(0.41,6.7) 0.97(0.89,1.1) 
Audibert 1996* LDH/AST/ALT 600/70/70 0.40(0.16,0.68) 0.73(0.67,0.79) 1.5(0.78,2.9) 0.82(0.54,1.2) 
Haddad 2005* LDH/AST/ALT 600/70/70 0.40(0.05,0.85) 0.49(0.36,0.63) 0.79(0.26,2.4) 1.2(0.57,2.6) 
 
Maternal death 
      
Audibert 1996* LDH/AST/ALT 600/70/70 0.67(0.02,1) 0.73(0.67,0.78) 2.5(0.78,7.8) 0.46(0.05,4.4) 
Abramovici 1999* AST 70 0.80(0.12,1) 0.83(0.71,0.92) 4.8(2.1.11.1) 0.24(0.02,2.8) 
Yucesoy 2005 AST/ALT/LDH Increased 0.86(0.23,1) 0.85(0.78,0.90) 5.6(3.19,9.7) 0.17(0.01,2.2) 
Disseminated 
Intravascular 
Coagulation 
      
Audibert 1996* LDH/AST/ALT 600/70/70 0.95(0.63,1) 0.76(0.70,0.81) 3.9(3.0,5.1) 0.06(0.00,0.94) 
Haddad 2000* LDH/AST/ALT 600/70/70 0.89(0.33,1) 0.62(0.47,0.75) 2.3(1.44,3.7) 0.18(0.01,2.5) 
 
Intra Cranial 
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*severe pre eclampsia; ALT: Alanine transaminase; AST: Aspartate transaminase; LDH: Lactate dehydrogenase; 
GGT: Gamma glutamyltransferase; Bi:Bilirubin; SD: Standard Deviation  
Fig 11.1 Area under the curve for predicting adverse maternal outcomes by liver function 
tests in pre eclampsia 
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11.4.2 Liver function tests to predict fetal outcomes 
Five primary studies evaluated accuracy of LFT to predict adverse fetal outcomes in 19 2x2 
tables.
287;289;292;296;297
 The commonest reported adverse fetal outcome was neonatal death in 3 
studies.
287;289;292
  The sensitivity and specificity of LFT to predict adverse fetal outcome ranged 
from 0.11 (95% CI 0, 0.67) to 0.82 (95% CI 0.60, 0.95) and from 0.51 (95% CI 0.59, 0.73) to 0.88 
Haemorrhage 
Audibert 1996* LDH/AST/ALT 600/70/70 0.67(0.02,1) 0.73(0.67,0.78) 2.3(1.44,3.71) 0.46(0.05,4.4) 
 
Acute renal 
failure 
      
Audibert 1996* LDH/AST/ALT 600/70/70 0.80(0.12,1) 0.73(0.67,0.79) 3.0(1.56,5.75) 0.27(0.02,3.3) 
Haddad 2000* LDH/AST/ALT 600/70/70 .1 (0.03, 1) 0.51(0.38,0.64) 1.5(0.66,3.5) 0.49(0.04,5.5) 
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(95% CI 0.83, 0.92) respectively. The best likelihood ratios of positive and negative tests for 
adverse fetal outcome were 5.18 (95% CI 3.66, 7.31) and 0.22 (95% CI 0.09, 0.52) for levels of 
AST increased by 2 or more standard deviation (Table 11.2). The AUC for predicting any adverse 
fetal outcome was 0.65 (95% CI 0.26, 0.9) (Fig 11.2). 
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Table 11.2 Accuracy of liver function tests in the prediction of adverse fetal outcomes in 
women with pre eclampsia 
 
*severe pre eclampsia; ALT: Alanine transaminase; AST: Aspartate transaminase; LDH: Lactate dehydrogenase; 
GGT: Gamma glutamyltransferase; Bi:Bilirubin; SD: Standard Deviation  
 
 
 
Study Year Test Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Intra uterine death 
Yucesoy 2005 AST/ALT/LDH Inc 0.71(0.29,0.96) 0.86(0.79,0.91) 4.9(2.7,9) 0.33(0.1,1.1) 
Haddad 2000* LDH/AST/ALT 
600/70/ 
70 0.63(0.24,0.91) 0.52(0.38,0.65) 1.3(0.71,2.4) 0.72(0.29,1.8) 
Neonatal death 
Romero 1988 AST 2SD 0.5(0.16,0.84) 0.80(0.75,0.84) 2.5(1.2,5.1) 0.63(0.31,1.3) 
 Abramovici 1999* AST 70 0.5(0.19,0.81) 0.68(0.6,0.74) 1.5(0.8,3) 0.74(0.4,1.4) 
Haddad 2000* LDH/AST/ALT 
600/70/ 
70 0.38(0.09,0.76) 0.5(0.35,0.65) 0.75(0.29,1.9) 1.25(0.68,2.3) 
Intra Uterine Growth Restriction 
 Abramovici 1999* AST 70 0.39(0.25,0.54) 0.68(0.6,0.74) 1.2(0.8,1.9) 0.9(0.7,1.1) 
Romero 1988 AST 2SD 0.48(0.34,0.63) 0.85(0.8,0.89) 3.2(2,4.9) 0.61(0.47,0.8) 
Respiratory Distress Syndrome 
Abramovici 1999* AST 70 0.51(0.38,0.64) 0.74(0.66,0.81) 1.9(1.3,2.8) 0.67(0.51,0.88) 
Romero 1988 AST 2SD 0.82(0.6,0.95) 0.84(0.79,0.89) 5.2(3.6,7.3) 0.22(0.09,0.53) 
Haddad 2000* LDH/AST/ALT 
600/70/ 
70 0.46(0.31,0.61) 0.40(0.12,0.74) 0.76(0.42,1.4) 1.4(0.6,3) 
Intra ventricular haemorrhage 
Romero 1988 AST 2SD 0.6(0.15,0.9) 0.80(0.74,0.84) 3(1.4,6.3) 0.5(0.17,1.5) 
Haddad 2000* LDH/AST/ALT 
600/70/ 
70 0.33(0.01,0.91) 0.51(0.37,0.65) 0.68(0.13,3.5) 1.3(0.56,3) 
Abramovici 1999* AST 70 0.11(0,0.67) 0.66(0.59,0.73) 0.33(0.02,4.5) 1.3(0.96,1.9) 
Necrotising Enterocolitis 
Abramovici 1999* AST 70 0.2(0,0.88) 0.66(0.59,0.73) 0.59(0.05,7.1) 1.2(0.64,2.3) 
Haddad 2000* LDH/AST/ALT 
600/70/ 
70 0.5(0.07,0.93) 0.52(0.38,0.66) 1(0.38,2.9) 0.96(0.35,2.6) 
Bronchopulmonary dysplasia 
Abramovici 1999* AST 70 0.68(0.43,0.87) 0.70(0.63,0.77) 2.3(1.6,3.4) 0.45(0.23,0.88) 
Mechanical ventilation 
Abramovici 1999* AST 70 0.47(0.35,0.59) 0.74(0.66,0.82) 1.8(1.3,2.7) 0.71(0.56,0.9) 
Preterm birth 
Romero 1988 AST 2SD 0.5( 0.37,0.63) 0.88(0.83,0.92) 4.2(2.7,6.5) 0.57(0.44,0.73) 
Adverse outcome 
Girling 1997 
AST/ALT/Bi/GG
T 
30/32/14/
41 0.86(0.23, 1) 0.5 (0.32,0.68) 1.7(0.99,3) 0.27(0.02,3.8) 
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Fig 11.2 Area under the curve for predicting adverse fetal outcomes by liver function tests in 
pre eclampsia 
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11.5 Discussion 
In women with preeclampsia, LFTs had at best moderate prediction of maternal and fetal 
complications.  The test specificity, however, was better than sensitivity. This meant that with a 
positive test result one could be more confident about predicting poor outcome than one could 
about ruling out complications with a negative result.   
 
Our review is the first to systematically collate and appraise the existing evidence on the predictive 
accuracy of LFTs in women with pre eclampsia. The validity of our findings depends on the 
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methodological quality of the systematic review and the quality of the included studies. We 
conducted an extensive search of literature with no language restrictions to minimise the risk of 
missing studies and used contemporary statistical methods. There were limitations in the included 
studies. Firstly, the definition of pre eclampsia differed between different studies. Secondly, very 
few studies provided details of the test methods and the gestation of testing. Information on 
gestational age may help in better interpretation of the predictive role of the test as women with 
early onset pre eclampsia with increased risk of maternal and fetal complications, where decision 
making often involves complex balancing of maternal benefits against fetal risks. Thirdly, no 
details were available on the temporality between the test results and the final maternal or fetal 
outcome. It is possible that the outcome could have been modified by time or any interventions like 
anti hypertensives, magnesium sulphate, corticosteroids (treatment paradox).
236
 Fourthly, the 
definition of adverse outcome measures differed between the studies and was often not sufficiently 
described in detail. Contacting authors did not increase the number of included studies. Despite 
these provisos this is the best available summary of the available studies. 
 
The role of a predictive test in clinical practice depends on the prevalence and severity of the 
outcome, the cost and acceptability of the test, and the interventions available to reduce or prevent 
the complications. Currently, pre-eclampsia accounts for about one-fifth of antenatal admissions, 
two-thirds of referrals to day assessment units and a quarter of obstetric admissions to intensive 
care units.
301
  Although the rate of complications is relatively low in pre eclampsia, when present 
they are often associated with significant maternal and fetal mortality and morbidity. Clinicians 
need to identify the women at risk of severe complications who need effective interventions like 
magnesium sulphate, anti hypertensives and corticosteroids delivery to reduce or prevent risks of 
complications to mother or baby. LFTs are currently routinely performed in most obstetric units as 
part of the admission battery of tests in women with pre eclampsia. A Delphi survey of 
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international experts showed that LFTs are considered to be the third important predictor of 
maternal and fetal complications after blood pressure and proteinuria.
17
   
 
Current national and international classifications of severity of pre eclampsia are hampered by the 
unknown disease aetiology. However, uteroplacental ischemia causing activation of the 
endothelium seems to play a major role. Endothelial dysfunction is considered to underlie many of 
the clinical symptoms of pre-eclampsia like hypertension, increased vascular permeability resulting 
in oedema and proteinuria, and expression of inflammatory parameters leading to coagulopathy.
302-
304
 These changes also cause ischemia of target organs, such as brain, liver, kidney and placenta. 
Fibrin deposition, periportal haemorrhage, ischemic lesions and microvesicular fat deposition are 
histological findings observed in the livers of preeclamptic women.
305
 Our published reviews have 
shown the accuracy of uric acid and proteinuria in predicting maternal and fetal complications in 
women with pre eclampsia.
306;307
 This paper adds further evidence to inform this subject.  
 
For women with raised liver enzymes, the test sensitivity to predict adverse maternal outcome was 
relatively poor with point estimates more than 50% in only half the included studies. The test 
performed better with regards to specificity with point estimates more than 70% in 18 of the 30 2 x 
2 tables. The test performance in predicting adverse fetal outcomes were similar with the specificity 
of the test was better than sensitivity.  
 
11.6 Conclusion 
Through this review we have highlighted the moderate ability of abnormal LFT in correctly 
identifying women at increased risk of maternal and fetal complications.  However, given the 
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uncertainties in the data, making clinical recommendations or developing prediction rules for using 
LFTs is not possible without good quality large prospective studies. These studies should especially 
focus on the sub group of women with early onset pre eclampsia where monitoring has a critical 
role in prolonging gestation.  
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CHAPTER 12: SYMPTOMS AS A PREDICTOR OF COMPLICATIONS IN  
PRE ECLAMPSIA 
12.1  Abstract 
Background 
Symptoms such as severe headache, visual disturbances, nausea and vomiting and epigastric pain 
are believed to be clinical markers of impending complications in pre-eclampsia.  The objective of 
this review is to determine the accuracy of maternal symptoms in predicting complications in 
women with pre-eclampsia. 
 
Methods 
Systematic quantitative review of test accuracy studies was undertaken.  We conducted electronic 
searches in Medline (1951-2009), Embase (1980-2009), the Cochrane Library (2009) and the 
MEDION database and hand-searches of selected specialist journals and reference lists of known 
articles to identify relevant papers without language restrictions.  Two reviewers independently 
selected articles in which the accuracy of symptoms including headache, visual disturbances, 
nausea and vomiting and epigastric pain were correlated with development of maternal and fetal 
complications in pre-eclampsia.  We extracted data on study characteristics, quality and accuracy.  
We constructed 2 x 2 tables for the prediction of a composite endpoint of maternal and fetal adverse 
outcomes.  We summarised accuracy with a bivariate model estimating sensitivity, specificity and 
area under summary Receiver Operating Characteristic (AUC) curve. 
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Results 
Six primary articles with 2573 women were included.  The AUC for predicting complications with 
symptoms of headache, epigastric pain and visual disturbances were 0.58 (95% CI 0.24, 0.86), 0.70 
(95% CI 0.3, 0.93) and 0.74 (95% CI 0.33, 0.94).  The sensitivity and specificity of headache to 
predict adverse maternal outcomes were 0.54 (95% CI 0.27, 0.79) and 0.59 (95% CI 0.38, 0.76) 
respectively.  The sensitivity of epigastric pain and visual disturbances are 0.34 (95% CI 0.22, 0.5) 
and 0.27 (95% CI 0.07, 0.65) with a specificity of 0.83 (95% CI 0.76, 0.89) and 0.81 (95% CI 0.71, 
0.88) respectively.  The sensitivity and specificity of nausea and vomiting to predict adverse 
outcomes were 0.24 (95% CI 0.21, 0.27) and 0.87 (95% CI 0.85, 0.89) respectively. 
 
Conclusion 
The presence of symptoms is useful for identifying women at risk of complications in primary and 
secondary care.  This information should be employed judiciously to direct laboratory 
investigations.   
 
Citation of paper arising from this work 
Thangaratinam S, Gallos I, Meah N, Usman S, Ismail KMK, Khan KS. How accurate are 
maternal symptoms in predicting impending complications in women with pre- 
eclampsia? A systematic review. (Acta Obstet et Gynecol in press) 
 
 
  
151 
 
12.2 Background 
Maternal symptoms of headache, vomiting, visual disturbances or epigastric pain in pregnancy may 
be the only pointers to underlying pre eclampsia that was not detected previously. An early warning 
system may employ maternal symptoms to raise an alert for diagnosis of pre eclampsia by 
measurement of blood pressure and proteinuria. In women known to have pre eclampsia, history of 
symptoms is obtained routinely in antenatal setting but the absence of quantitative information 
about their accuracy limits their use in decision making. A Health Commission‟s report identified 
that early warning symptoms for maternal complications in pre eclampsia were not recognised in 2 
of 10 maternal deaths.
308
 Failure to recognise symptoms as a marker of severity of pre-eclampsia is 
an established reason for medical negligence cases against health professionals.
309
  The low 
awareness of the importance of symptoms in women with pre-eclampsia outside the antenatal 
setting may be due to absence of clear collated summaries of the evidence. 
 
Symptoms such as severe headache, visual disturbances, epigastric pain, nausea and vomiting have 
a physiological basis.  Headaches have been attributed to cerebral oedema or vasospasm of cerebral 
arteries.
310;311
 Visual disturbances have been linked to impeding blood flow and ischemic injury 
secondary to vasospasm of retinal arteries.
312
 Epigastric pain, nausea and vomiting are thought to 
reflect hepatic involvement and is postulated to result from obstructed blood flow in the hepatic 
sinusoids, mainly the periportal areas subsequent to vascular constriction caused by fibrin like 
deposits.
313
   
 
Several studies have shown varying degrees of correlation between symptoms in pre eclamptic 
patients and presence of adverse maternal and fetal outcomes.
251;314;315
 Current guidelines consider 
symptoms to be a surrogate marker of disease severity.
316-318
   They may contribute to decisions 
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leading to delivery or admission to high dependency unit, when present alongside other abnormal 
tests. These guidance are not always evidence based.  For example, the recommendations on the 
value of maternal symptoms in predicting complications are poorly referenced
318
 or not referenced 
in the guidelines.
317
  There are no systematic reviews on the accuracy of symptoms in predicting 
adverse outcomes in pre-eclampsia.  We therefore conducted such a comprehensive systematic 
quantitative review evaluating the role of symptoms in women diagnosed to have pre eclampsia.    
 
12.3 Methods 
 
The review was carried out with a prospective protocol
290
 using widely recommended methods as 
described in Chapter 8, Section 8.3.  
 
12.4 Results 
12.4.1 Literature identification and study quality 
The flow chart in Appendix 9 summarises the process of literature identification and selection.  
There were 6 primary articles that met the selection criteria,
288;315;319-322
 consisting of 22 2 x 2 tables 
including a total of 2573 women.  Each study‟s salient features are provided in Appendix 24.  
Methodological quality of included studies in Appendix 14 showed that the index tests was 
adequately described in 5 out of 6 studies (83 %) and reference standard adequately described in all 
the studies.   Only two studies (30%) were prospectively conducted and none of the studies were 
blinded for outcome measurement.  
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The symptoms assessed in the included studies were headache, epigastric pain, visual symptoms 
and vomiting.  The adverse maternal outcomes reported were HELLP syndrome, eclampsia, severe 
pre-eclampsia, abruption and postpartum adverse outcome.  None of the studies reported fetal 
outcome.  The sensitivity and specificity of individual studies for various symptoms and outcomes 
are provided in Table 12.1.  The summary sROC curve by bivariate model was fitted for headache, 
epigastric pain and visual disturbances that have more than 4 2x2 table data as shown in Fig 12.1. 
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a. Headache 
 
 
 
AUC = 0.58 (95% CI 0.24, 0.86) 
c. Epigastric pain 
 
 
 
AUC = 0.70 (95% CI 0.30, 0.93) 
Fig 12.1 Area Under the curve (AUC) for symptoms in predicting adverse maternal outcomes 
in women with pre eclampsia 
 
 
 
 
 
b. Visual symptoms 
 
 
 
AUC = 0.74 (95% CI 0.33, 0.94) 
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12.4.2 Headache as a predictor of adverse maternal outcome 
 
All 6 studies
 
evaluated the accuracy of headaches in predicting adverse maternal 
outcomes.
288;315;319-322
 The pooled sensitivity and specificity of headache as a test to predict adverse 
outcomes were 0.54 (95% CI 0.27, 0.79) and 0.59 (95% CI 0.38, 0.76) respectively.  The summary 
positive and negative likelihood ratios were 1.3 (95% CI 0.96, 1.7) and 0.79 (95% CI 0.54, 1.2) 
respectively (Table 12.1).  The highest sensitivity of 0.98 (95% CI 0.87, 1) was reported for the 
prediction of eclampsia.  The test had the highest specificity for prediction of HELLP syndrome 
0.87 (95% CI 0.82, 0.92). The AUC for any adverse maternal outcome was 0.58 (95% CI 0.24, 
0.86) (Fig 12.2a). 
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Table 12.1. Sensitivity, Specificity and Likelihood ratios for predicting adverse maternal 
outcomes in women with pre-eclampsia using clinical symptoms 
 
Study Year Outcome 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) LR + (95% CI) LR - (95% CI) 
Headache      
Witlin 1999 Abruption 0.61    (0.42 - 0.77)  0.53 (0.48 -0.58)  1.3 (0.97 - 1.7)  0.74 (0.48 - 1.1)  
Ben Salem 2003 Eclampsia
* 
0.98   (0.87 - 1.00)  0.27(0.17 - 0.38)  1.3 (1.1 - 1.5)  0.09(0.01- 0.66)  
Witlin 1999 Eclampsia* 0.63    (0.46 - 0.77)  0.56(0.51 - 0.61)  1.4 (1.1 - 1.9)  0.67 (0.44 - 1.0)  
Black 2007 
Severe pre-
eclampsia* 0.46    (0.33 - 0.59)  0.68(0.52 - 0.82)  1.4  (0.85 - 2.5)  
0.79 (0.58 - 
1.1)  
Harms 1991 HELLP* 0.16    (0.03 - 0.40)  0.87(0.82 - 0.92)  1.3  (0.41 - 3.8)  0.96 (0.79 - 1.2)  
Martin 1999 HELLP* 0.58    (0.55 - 0.62)  0.32(0.26 - 0.39)  0.86 (0.76 - 0.96)  1.3 (1.0 - 1.6)  
Menzies 1997 
Adverse 
outcome* 0.36   (0.25 – 0.48) 0.71(0.67– 0.74) 1.2  (0.89 – 1.7) 0.90 (0.75 – 1.1) 
Summary 
estimate 
Adverse 
outcome 0.54  (0.27 – 0.79) 0.59(0.38– 0.76) 1.3 (0.96 – 1.7) 0.79 (0.54 – 1.2) 
Visual 
symptoms      
Ben Salem 2003 Eclampsia
* 
0.85   (0.71 - 0.94)  0.66(0.54 - 0.76)  2.5  (1.8 - 3.5)  0.22 (0.1 - 0.47)  
Witlin 1999 Eclampsia* 0.35    (0.21 - 0.52)  0.80(0.75 - 0.83)  1.7  (1.1 - 2.7)  0.82(0.65 - 1.0)  
Witlin 1999 Abruption 0.27    (0.13 - 0.46)  0.78(0.74 - 0.82)  1.3  (0.7 - 2.3)  0.93 (0.75 - 1.2)  
Black 2007 
Severe pre-
eclampsia* 0.34    (0.22 - 0.47)  0.80 (0.65 - 0.91)  1.7  (0.85 - 3.6)  0.82(0.65 - 1.0)  
Harms 1991 HELLP* 0.05    (0.00 - 0.26)  0.94(0.89 - 0.97)  0.87  (0.12 - 6.4)  1.01 (0.90 - 1.1)  
Menzies 1997 
Adverse 
outcome* 0.18   (0.10 – 0.29) 0.82(0.79– 0.85) 0.99  (0.59 – 1.7) 1.0  (0.89 – 1.1) 
Summary 
estimate 
Adverse 
outcome 0.27 (0.07 – 0.65) 0.81(0.71– 0.88) 1.4 (0.67 – 3.1) 0.89 (0.64 – 1.3) 
Nausea and 
vomiting      
Martin 1999 HELLP
* 
0.24   (0.21 - 0.27)  0.85(0.79- 0.90)  1.6  (1.1 - 2.3)  0.9 (0.84 - 0.96)  
Harms 1991 HELLP* 0.47    (0.24 - 0.71)  0.92(0.87 - 0.96)  6.2  (3.1 - 12.3)  0.57(0.37- 0.88)  
Witlin 1999 Eclampsia* 0.20    (0.09 - 0.36)  0.86(0.82 - 0.89)  1.4 (0.72 - 2.7)  0.93(0.80 - 1.1)  
Summary 
estimate 
Adverse 
outcome 0.24 (0.21 – 0.27) 0.87(0.85– 0.89) 2.3 (1-5.4) 0.87 (0.74 – 1) 
Epigastric pain      
Martin 1999 HELLP
* 
0.31   (0.28 - 0.35)  0.87(0.81 - 0.91)  2.4  (1.7 - 3.6)  0.79 (0.73 - 0.85)  
Witlin 1999 Eclampsia* 0.18   (0.07 - 0.33)  0.75(0.71 - 0.79)  0.71  (0.35 - 1.4)  1.1 (0.94 - 1.3)  
Witlin 1999 Abruption 0.33    (0.18 - 0.52)  0.76(0.72 - 0.80)  1.4  (0.84 - 2.3)  0.87 (0.68 - 1.1)  
Black 2007 
Severe pre-
eclampsia* 0.42    (0.30 - 0.56)  0.66(0.49 - 0.80)  1.2  (0.74 - 2.1)  0.88(0.64 - 1.2)  
Harms  1991 HELLP* 0.68    (0.43 - 0.87)  0.92(0.87 - 0.95)  8.3 (4.7 - 14.7)  0.34(0.18-0.67)  
Menzies 1997 
Adverse 
outcome* 0.25    (0.16 -0.37) 0.84(0.81– 0.87) 1.6  (1 – 2.4) 0.89 (0.78 – 1.0)  
Summary 
estimate 
Adverse 
outcome 0.34 (0.22 – 0.5) 0.83(0.76– 0.89) 2.1 (1 – 4.2) 0.79 (0.6 – 1) 
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12.4.3 Visual disturbances as a predictor of adverse maternal outcome 
Six studies reported the accuracy of visual disturbances to predict maternal 
complications.
288;315;319;320;322 
The summary sensitivity and specificity were 0.27 (95% CI 0.07, 
0.65) and 0.81 (95% CI 0.71, 0.88) respectively (Table 12.1).  The pooled positive and negative 
likelihood ratios for adverse maternal outcome were 1.4 (95% CI 0.67, 3.1) and 0.89 (95% CI 0.64, 
1.3) respectively.  Visual disturbance had the highest sensitivity of 0.85 (95% CI 0.71, 0.94) in 
predicting eclampsia. The maximum specificity of 0.94 (95% CI 0.89, 0.97) was for HELLP 
syndrome.  The AUC for any adverse maternal outcome was 0.75 (95% CI 0.3, 0.95) (Fig 12.2b).   
   
12.4.4 Epigastric pain as a predictor of adverse maternal outcome 
Epigastric pain was evaluated in 6 studies to assess prediction of eclampsia, HELLP syndrome, 
abruption, severe pre-eclampsia and adverse composite maternal outcome.
288;315;320-322
 The 
summary sensitivity and specificity for adverse maternal outcome were 0.34 (95% CI 0.22, 0.5) and 
0.83 (95% CI 0.76, 0.89) respectively.  The pooled positive and negative likelihood ratios were 2.1 
(95% CI 1, 4.2) and 0.79 (95% CI 0.6, 1) (Table 12.1).   The maximum sensitivity and specificity of 
0.68 (95% CI 0.43, 0.87) and 0.92 (95% CI 0.87, 0.95) respectively for HELLP syndrome was 
observed in the study by Harms et al. The AUC for any adverse maternal outcome was 0.70 (95% 
CI 0.3, 0.93) (Fig 12.2c).   
 
12.4.5 Vomiting as a predictor of adverse maternal outcome 
Vomiting was evaluated in 3 studies.
288;315;321
  The highest sensitivity and specificity were 0.47 
(95% CI 0.24, 0.71) and 0.92 (95% CI 0.87, 0.96) for HELLP syndrome. The summary sensitivity 
and specificity were 0.24 (95% CI 0.21, 0.27) and 0.87 (95% CI 0.85, 0.89) respectively (Table 
12.1). 
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12.5 Discussion 
Among women with pre-eclampsia, symptoms of visual disturbance and epigastric pain were 
moderately good predictors of maternal complications.  Their predictive accuracy was better than 
headache as a test.  The symptoms overall had high specificity than sensitivity.  Thus, the presence 
of symptoms is clinically more useful for ruling in complications in comparison to their absence for 
ruling out complications.   
 
The data from the largest study by Martin et al show that headache had poor specificity for 
predicting eclampsia in comparison to epigastric pain and vomiting for HELLP syndrome.
321
 
Patients with class 1 HELLP syndrome indicating a worsening of condition were 4 times more 
likely to have symptoms of epigastric pain or vomiting compared to class 3 HELLP.  One of the 
largest population based surveys to date on eclampsia, BEST in UK, reported that 50% of women 
with eclampsia had headache preceding convulsions, visual disturbances in 19% and another 19% 
complained of epigastric pain.
314
 Antepartum cases of eclampsia were slightly more likely to be 
preceded by prodromal symptoms than intrapartum or postpartum cases (RR 1.48 (95% CI 1.26, 
1.73).  This increase was also noticed for eclampsia occurring before term than term.  However 
there is no comparative data to ascertain the incidence of symptoms in women without eclampsia.   
 
The sensitivity and specificity of headache was low overall in the review except in the case control 
study by Ben Salem et al with 98% sensitivity for headache.
319
  It is possible that with 60% of 
women with eclampsia having the first episode at home, recall bias may have influenced the 
reporting of symptoms prior to the episode.
319
 The large prospective study by Menzies et al showed 
that although the specificity was over 80% for visual symptoms and epigastric pain the sensitivity 
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only ranged between 18 and 25%.
322
 It reflects the overall pattern of the test performance with 
relatively higher specificity than sensitivity for adverse outcomes.   
 
Our review has been the first to systematically collate and quantify the predictive value of 
symptoms through a prospective protocol.
290
 We have employed an extensive search strategy to 
ensure that all relevant studies have been captured. The importance that clinicians attach to the 
symptoms has been determined through our Delphic survey of experts. We have used the composite 
maternal adverse outcome as reference standard that had been obtained by Delphic consensus and 
shown to be robust through piloting and validation.   
 
The review is constrained by the heterogeneity in the definition of population, limitation in details 
of the tests and outcome and lack of data on the time elapsed between onset of symptoms and 
adverse events.  Furthermore, the predictive accuracy may be affected by the presence of other risk 
factors and the effect of any interventions (treatment paradox).   Clinical symptoms although 
routinely elicited in the management of any patient with pre-eclampsia are poorly reported in the 
literature.  There is insufficient information on the gestational age of patients to assess the 
performance of the test according to gestation.  Due to the paucity of the data we were restricted 
from undertaking further analysis by meta-regression to study the effects of other abnormal tests 
like blood pressure, proteinuria, liver function etc, the time interval between the symptoms and 
outcome and any interventions on the accuracy of symptoms.   
 
12.6 Conclusion 
Evidence from this review suggests that presence of symptoms is more useful in their ability to 
predict complications compared to their absence in confidently excluding adverse events.  
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However, the findings are limited due to a relatively small number of heterogeneous studies.  This 
highlights the need for large prospective studies in this area to enable clinicians to confidently 
evaluate the added value of symptoms in the management of patients with pre-eclampsia. 
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CHAPTER 13: BLOOD PRESSURE AS A PREDICTOR OF 
COMPLICATIONS IN PRE ECLAMPSIA  
13.1 Abstract 
Background 
Blood pressure is considered to be the most predictive of complications in women with pre 
eclampsia compared to the other tests.  
 
Methods 
We performed systematic quantitative review of test accuracy studies. We conducted an electronic 
search in MEDLINE (1951-2009), EMBASE (1980-2009), the Cochrane Library (2009) to identify 
relevant articles. A hand-search of selected specialist journals and reference lists of articles 
obtained was then carried out. There were no language restrictions for any of these searches. 
Studies were selected independently by two reviewers if blood pressure profile was evaluated to 
predict maternal and fetal complications of pre eclampsia. Data was extracted on study 
characteristics, quality and accuracy to construct 2 X 2 tables with maternal and fetal complications 
as reference standard. 
 
Results 
There were 8 primary articles in the review including a total of 2304 women. For the prediction of 
eclampsia, abruption, renal, neurological and liver impairment, mean arterial pressure (MAP) ≥ 140 
mmHg or BP ≥ 170/110 had high specificity (more than 80%) and low sensitivity (<50%). The area 
under the curve (AUC) for any adverse maternal outcome was 0.68 (95% CI 0.29, 0.92). The 
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specificity for adverse fetal outcomes was more than 70% in 11/15 (73.3%) studies and sensitivity 
was more than 70% in 6/15 (40%) studies. 
 
Conclusion 
Blood pressure is a moderate predictor of adverse maternal and fetal outcomes, with severe 
hypertension more predictive of fetal complications than maternal complications. 
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13.2 Background 
An increase in blood pressure (BP) is one of the essential criteria in the diagnosis of pre-eclampsia. 
It is the commonest test performed in primary and secondary care and is a frequent cause of referral 
and admission to obstetric units. There is currently no consensus on the levels of BP needing 
intervention in the form of delivery or anti-hypertensives. Although there are primary studies 
evaluating the predictive role of BP on maternal and fetal complications, there are no systematic 
reviews that collate the evidence on the significance of this important test. With the recent stress on 
outpatient management of women with mild pre-eclampsia, there is a need to identify the BP 
threshold above which there is increased likelihood of significant maternal and fetal complications 
that  will enable us to identify the appropriate group of patients that need early intervention. It will 
also avoid unnecessary referral and treatment in the low risk group. We therefore conducted a 
comprehensive systematic review to obtain precise estimates of maternal levels of BP to predict 
maternal and fetal complications in women with pre-eclampsia. 
 
13.3 Methods 
The review was carried out with a prospective protocol
290
 using widely recommended methods as 
described in Chapter 8, Section 8.3.  
 
13.4 Results 
13.4.1 Literature identification and study selection 
The flow chart in Appendix 10 summarises the process of literature identification and selection. 
There were 8 primary articles that met the selection criteria including a total of 2304 
women.
245;280;315;322-326
 Each study‟s salient features according to the population subgroups, test 
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characteristics and reference standards are provided in Appendix 25. The definition of pre-
eclampsia differed widely between the studies. The test thresholds were reported as systolic and 
diastolic BP readings or as Mean Arterial Pressure (MAP) in individual studies. Adverse maternal 
outcomes were reported in 20 2 x 2 tables (Table 13.1) and adverse fetal outcomes in 15 2 x 2 
tables (Table 13.2). The methodological quality of the included studies is given in Appendix 14.  
 
13.4.2 Blood pressure and maternal outcome 
Four studies (2 x 2 tables) assessed the risk of eclampsia for threshold levels of MAP from 105 
mmHg to 160 mm Hg. The positive likelihood ratio for MAP 105 to 160 mm Hg in the prediction 
of eclampsia ranged from 0.96 (95% CI 0.87, 1.0) to 2.3 (95% CI 0.8, 6.3) respectively.  The 
negative likelihood ratio for the same outcome varied from 2.3 (95% CI 0.70, 7.9) to 0 .94 (95% CI 
0.85, 1.0) for levels of MAP of 105 and 160 mm Hg respectively. The accuracy of BP in predicting 
abruption was reported in 4 studies. Two studies assessed the rate of caesarean section for various 
threshold levels of BP. The positive likelihood ratios for BP of 170/110 and 160/110 were 2.5 (95% 
CI 1.8, 3.5) and 2.6 (95% CI 1.8, 3.6) respectively. The negative likelihood ratios for the above cut 
offs were 0.28 (95% CI 0.16, 0.5) and 0.74 (95% CI 0.67, 0.82) respectively.  
 
The sensitivity of BP in predicting any adverse maternal outcome was more than 70% in 6/20 
(30%)  studies and the specificity was more than 70% in 9/20 (45%) of the studies for various 
threshold levels of BP (Fig 13.1). For the prediction of eclampsia, abruption, renal, neurological 
and liver impairment, MAP ≥ 140 mmHg or BP ≥ 170/110 had high specificity (more than 80%) 
and low sensitivity (<50%).  The area under the curve (AUC) for any adverse maternal outcome 
was 0.68 (95% CI 0.29, 0.92). 
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Table 13.1. Accuracy of blood pressure in the prediction of adverse maternal outcomes  
in women with pre eclampsia 
Study Year Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Eclampsia      
Witlin 1999 MAP >105 0.93(0.80,0.98) 0.03(0.02,0.05) 0.96(0.87,1.05) 2.34(0.70,7.86) 
Witlin 1999 MAP>120 0.78(0.62,0.89) 0.25(0.21,0.30) 1.04(0.87,1.24) 0.89(0.49,1.63) 
Witlin 1999 MAP>140 0.28(0.15,0.44) 0.82(0.77,0.85) 1.49(0.86,2.56) 0.89(0.73,1.08) 
Witlin 1999 MAP>160 0.10(0.03,0.24) 0.96(0.93,0.97) 2.25(0.80,6.33) 0.94(0.85,1.05) 
      
Abruption      
Witlin 1999 MAP >105 0.88(0.72,0.97) 0.02(0.01,0.04) 0.90(0.79,1.02) 6.26(1.99,19.70) 
Witlin 1999 MAP>120 0.67(0.48,0.82) 0.24(0.20,0.28) 0.87(0.68,1.12) 1.41(0.84,2.35) 
Witlin 1999 MAP>140 0.18(0.07,0.36) 0.80(0.76,0.84) 0.92(0.43,1.94) 1.02(0.86,1.21) 
Witlin 1999 MAP>160 0.06(0.01,0.20) 0.95(0.93,0.97) 1.25(0.31,5.12) 0.99(0.90,1.08) 
      
Inpatient admission      
Peek 1995 170/110 0.60(0.48,0.71) 0.60(0.46,0.72) 1.49(1.04,2.12) 0.67(0.48,0.95) 
      
Caesarean section (CS)       
Peek 1995 170/110 0.81(0.68,0.91) 0.68(0.57,0.78) 2.52(1.80,3.54) 0.28(0.16,0.50) 
Xiong 1999 160/110 0.36(0.31,0.42) 0.86(0.81,0.90) 2.57(1.83,3.61) 0.74(0.67,0.82) 
Elective CS      
Peek 1995 170/110 0.85(0.68,0.95) 0.60(0.50,0.69) 2.10(1.60,2.76) 0.25(0.11,0.58) 
Emergency CS      
Peek 1995 170/110 0.75(0.51,0.91) 0.53(0.44,0.62) 1.60(1.16,2.19) 0.47(0.22,1.03) 
Forceps      
Peek 1995 170/110 0.46(0.19,0.75) 0.48(0.39,0.58) 0.89(0.49,1.65) 1.11(0.65,1.90) 
      
Renal impairment      
Brown 1996 170/110 0.45(0.32,0.58) 0.81(0.78,0.84) 2.40(1.74,3.28) 0.68(0.54,0.85) 
      
Thrombocytopenia      
Brown 1996  170/110 0.44(0.33,0.55) 0.82(0.79,0.85) 2.42(1.81,3.22) 0.69(0.56,0.83) 
      
Neurological complication      
Brown 1996 170/110 0.61(0.51,0.71) 0.88(0.82,0.88) 4.08(3.23,5.14) 0.46(0.36,0.58) 
      
Liver disease      
Brown 1996  170/110 0.58(0.47,0.69) 0.83(0.80,0.86) 3.48(2.72,4.44) 0.50(0.39,0.65) 
      
Adverse maternal outcome       
Menzies 2007  SBP>=160 0.67(0.55,0.77) 0.37(0.34,0.41) 1.06(0.89,1.26) 0.90(0.64,1.26) 
Menzies 2007  DBP>=110 0.38(0.26,0.50) 0.68(0.64,0.71) 1.16(0.85,1.60) 0.92(0.77,1.11) 
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Fig 13.1 Receiver Operating Characteristic plane of Blood Pressure as a predictor of adverse 
maternal outcome in pre eclampsia 
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Fig 13.2 Receiver Operating Characteristic plane of Blood Pressure as a predictor of adverse 
fetal outcome in pre eclampsia 
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13.4.3 Blood pressure and fetal outcome 
Six studies reported perinatal mortality, stillbirths and neonatal deaths for various threshold levels 
of BP.  The sensitivity and specificity were more than 70% in 4/6 (66%) and 5/6 (83%) of the 
studies respectively.  The LR+ ranged between 1.6 (95% CI 0.65, 3.9) and 3.8 (95% CI 2.5, 5.6) 
and the LR- between 0.19 (95% CI 0.03, 1.1) and 0.77 (95% CI 0.41, 1.4) respectively. 6 studies 
evaluated small for gestational age, fetal distress and preterm delivery. The specificity was more 
than 80% or more in all of them for threshold levels of BP 160/100 and 170/110. The sensitivity 
was less than 50% in the above studies (Table 13.2). Overall the specificity was more than 70% in 
11/15 (73.3%) studies and sensitivity was more than 70% in 6/15 (40%) studies (Fig 13.2). The 
AUC for adverse fetal outcomes was 0.74 (SE 0.07). 
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Table 13.2. Accuracy of blood pressure in the prediction of adverse fetal outcomes  
in women with pre eclampsia 
Study Year Cut off Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Small for gestational age 
Varma 1981 160/100 0.41(0.27,0.57) 0.80(0.73,0.86) 2.05(1.29,3.27) 0.74(0.57,0.95) 
Brown 1996 170/110 0.29(0.22,0.37) 0.81(0.78,0.84) 1.57(1.17,2.09) 0.87(0.78,0.97) 
Xiong 1999 160/110 0.25(0.15,0.38) 0.74(0.70,0.78) 0.99(0.63,1.58) 1.00(0.86,1.17) 
      
Fetal distress      
Varma 1981 160/100 0.44(0.28,0.62) 0.79(0.72,0.85) 2.14(1.34,3.43) 0.70(0.52,0.95) 
      
Neonatal death      
Varma 1981  160/100 0.80(0.28,1.00) 0.76(0.70,0.82) 3.40(2.05,5.62) 0.26(0.05,1.51) 
      
Still Birth      
Varma 1981  160/100 0.80(0.12,1.00) 0.76(0.69,0.82) 3.30(1.69,6.43) 0.26(0.02,3.15) 
      
Neonatal Intensive Care Unit admission 
Peek 1995  170/110 0.77(0.64,0.87) 0.68(0.56,0.78) 2.38(1.68,3.36) 0.34(0.20,0.56) 
      
Perinatal 
mortality      
Varma 1981 160/100 0.86(0.42,1.00) 0.77(0.71,0.83) 3.76(2.52,5.60) 0.19(0.03,1.14) 
Peek 1995 170/110 0.86(0.23,1.00) 0.50(0.41,0.59) 1.71(1.08,2.72) 0.29(0.02,3.74) 
Brown 1996 170/110 0.50(0.19,0.81) 0.80(0.77,0.82) 2.46(1.30,4.63) 0.63(0.34,1.17) 
Heilmann 1989 DBP>100 0.44(0.14,0.79) 0.72(0.55,0.86) 1.60(0.65,3.94) 0.77(0.41,1.43) 
      
Necrotising enterocolitis 
Peek 1995  170/110 1.0(0.03,1.0) 0.49(0.41,0.58) 1.48(0.65,3.35) 0.51(0.05,5.63) 
      
Intraventricular haemorrhage 
Peek 1995 170/110 0.67(0.09,1.00) 0.49(0.41,0.58) 1.31(0.58,2.98) 0.68(0.14,3.38) 
      
Preterm delivery      
Xiong 1999 160/110 0.39(0.20,0.62) 0.75(0.71,0.79) 1.57(0.92,2.67) 0.81(0.58,1.13) 
Dukler 2000 DBP>110 0.39(0.27,0.53) 0.87(0.82,0.90) 2.93(1.90,4.50) 0.70(0.57,0.88) 
 
13.5 Discussion 
Blood pressure was a better predictor of adverse fetal than maternal outcomes. Both sensitivity and 
specificity were lower for maternal complications than for fetal complications. A high BP reading 
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(160/100) is more likely to rule in adverse fetal outcomes, whereas a BP<160/100 is less likely to 
rule out a complication. The same phenomenon was observed for cut off levels of MAP>140 for 
eclampsia and abruption. 
 
The review was performed by identifying the relevant studies using a detailed search srtaegy 
without any language restriction with robust methodology. The composite adverse maternal and 
fetal outcomes have been identified by Delphic survey of experts. As with reviews of other tests in 
pre eclampsia, the included studies differ in the definition of pre eclampsia, the threshold values 
and the method of reporting of test (systolic or diastolic BP or both, MAP) and definition of the 
reference standard. Furthermore, there is limited data on the use of any interventions like anti 
hypertensives, steroids and magnesium sulphate that may have an effect on the outcomes. There is 
a lack of data on other potential predictor variables like gestational age and other clinical and 
biochemical parameters that may influence the predictice accuracy of BP. 
 
BP was prioritised as the most important test that can predict complications in women with pre 
eclampsia in the Delphi survey of experts.
17
 The findings from the review suggest that it may not be 
the case. One explanation could be that BP is the most amenable of all abnormal tests to 
intervention. Effective anti hypertensives exist that control high BP of any severity. The finding of 
BP is only a moderate predictor of complications does not mean that they should not be taken into 
account. Women with severe hypertension with systolic BP>160 mm Hg and diastolic BP >110 
mm Hg should be managed to reduce BP according to national or local guidelines.
327
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13.6 Conclusion 
BP is a moderate predictor of adverse maternal and fetal outcomes, with severe hypertension more 
predictive of fetal complications than maternal complications. Existing studies are small and of too 
varied quality to make any robust recommendations from the review. 
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CHAPTER 14: ACCURACY OF PULSE OXIMETRY AS A SCREENING 
TOOL IN THE DIAGNOSIS OF CONGENITAL HEART DISEASE IN 
NEWBORNS: A SYSTEMATIC REVIEW 
14.1 Abstract 
Background  
Congenital heart disease is the commonest group of congenital malformations with most deaths in 
the first year of life. Early detection of congenital heart disease in the asymptomatic period 
immediately after birth will reduce clinical deterioration by instigation of appropriate, timely 
management. This review aims to evaluate the accuracy of pulse oximetry as a screening tool for 
congenital heart disease in asymptomatic newborns.
  
 
Methods 
Systematic review of relevant
 
studies identified through Medline,
 
Embase, Cochrane Library, 
conference papers,
 
and bibliographies of retrieved primary and review articles.
 
Two reviewers 
independently extracted data on study characteristics,
 
quality, and results to construct 2x 2 tables 
with congenital heart disease as the reference standard.  We used a random-effects bivariate model 
to meta-analyse estimates of sensitivity and specificity. Logit pairs of sensitivity and specificity of 
each study were analysed in a single model, accounting for their correlation due to differences in 
threshold between studies.  
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Results  
We extracted 8 studies with a total of 35,960 newborns.  Pulse oximetry was performed on 
asymptomatic newborns in all studies, with three studies excluding newborns with an antenatal 
diagnosis of congenital heart disease.   The studies measured either functional or fractional oxygen 
saturation by pulse oximetry with oxygen saturation below 95% considered as the cut off level in 
most studies. Based on 8 studies, the summary estimates of sensitivity and specificity were 63% 
(95% CI, 39% to 83%) and 99.8% (95% CI, 99% to 100%) respectively, yielding a false positive 
rate of 0.2% (95% CI, 0% to 1%). 
 
Conclusion  
Pulse oximetry has been shown to be a highly specific screening tool with very low false positive 
rates.  Further large well conducted prospective studies are needed to assess its sensitivity with 
higher precision.  
 
Citation of paper from this work 
Thangaratinam S, Daniels J, Ewer AK, Zamora J, Khan KS. Accuracy of pulse oximetry in 
screening for congenital heart disease in asymptomatic newborns: a systematic review. Arch Dis 
Child Fetal Neonatal Ed. 2007; 92: F176-80 
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14.2 Background 
Congenital heart disease is the commonest group of congenital malformations and affects 7-8/1000 
newborns.
36;37
  It contributes to 3% of all infant mortality and 46% of deaths from congenital 
malformations, with most deaths occurring in the first year of life. 
36
 A significant proportion of 
these children require surgery in the first year.   
 
One of the major contributors to increased infant mortality and morbidity is clinical deterioration 
and collapse prior to diagnosis and treatment.
38-40
  Early detection of congenital heart disease in the 
asymptomatic period immediately after birth will reduce clinical deterioration by instigation of 
appropriate, timely management.  Currently infants are screened to detect congenital heart disease 
by physical examination within 24 hours of birth and a further examination after 6-8 weeks.
328
   
However, this method of screening fails to detect up to 50% of congenital heart defects at birth.
329
 
 
Pulse oximetry has been proposed as an alternative screening method for the detection of congenital 
heart defects.  It is a simple, non invasive investigation which measures the percentage of 
haemoglobin in blood that is saturated with oxygen.  It is proposed that the measurement of oxygen 
saturation identifies infants with mild cyanosis who do not have an audible murmur or other signs 
of cardiac abnormality and are not detected by routine clinical examination.
330
  Several studies have 
reported the use of pulse oximetry as a screening tool for the detection of congenital heart 
disease.
331-338
  Although very low false positive rates have been reported, individual studies have 
had only few cases with cardiac disease leading to imprecision in the estimation of true positive 
rates (sensitivity).   
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A recent Health Technology Assessment report reviewed the available evidence on the screening 
strategies for detection of congenital heart disease in newborns with the view to assist in policy 
making.
36
  The review identified 4 studies in which pulse oximetry was used as a screening test for 
congenital heart disease in asymptomatic newborns.  It did not pool the results statistically and 
suggested the need for further evaluation of pulse oximetry as a screening method.  Since the 
publication of this report, further large primary studies have become available which may 
potentially alter the report‟s conclusion.  We therefore conducted a systematic review to collate all 
results and to update information on accuracy of pulse oximetry to detect congenital heart disease 
in asymptomatic newborns. 
 
14.3 Methods 
The review was carried out with a prospective protocol using widely recommended 
methods.
55;230;236
 
 
We searched MEDLINE (1996-2006), EMBASE (1996-2006), Cochrane Library (2006) and 
MEDION (a database of diagnostic test reviews set up by Dutch and Belgian researchers) for 
relevant citations using the search terms „pulse NEAR oximetry‟, „infant-newborn‟, „neonate‟, 
„newborn‟, „infant‟, „congenital heart disease‟. The reference lists of all known primary and review 
articles were examined to identify cited articles not captured by electronic searches.  Language 
restrictions were not applied. A comprehensive database of potentially relevant citations was 
constructed.  
 
Studies which evaluated the accuracy of pulse oximetry in asymptomatic newborns for the 
detection of congenital heart disease were selected in a two-stage process. First, the electronic 
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searches were scrutinised and full manuscripts of all citations that were likely to meet the 
predefined selection criteria were obtained by two independent reviewers (ST and JD).  Secondly, 
final inclusion or exclusion decisions were made by the reviewers (ST and JD) after examination of 
these manuscripts.  Studies which met the predefined and explicit criteria regarding population, 
tests, outcomes and study design were selected for the review.  When disagreements occurred, they 
were resolved by consensus. In cases of duplicate publication, the most recent or complete versions 
were selected.  
 
Information was extracted from each selected article on the study population including age, test 
characteristics together with frequency and method of testing, and methodological quality including 
verification of diagnosis of congenital heart disease by echocardiography.  Accuracy data were used 
to construct 2 x 2 tables of pulse oximetry results (test positive if pulse oximetry values were below 
a threshold as defined in the primary study, and test negative if these were above the threshold) and 
presence or absence of congenital heart disease diagnosed by echocardiography (wherever 
employed).  Where accuracy data were not extractable, we contacted
 
the corresponding author by 
letter or email, to seek his or
 
her assistance in data extraction. 
 
All manuscripts meeting the selection criteria were assessed for their methodological quality.  
Quality was defined as the confidence that the study design, conduct and analysis minimised 
assessment bias in the estimation of test accuracy.  Based on existing checklists,
55;58;232;236;339
 
quality assessment involved scrutinising study design and relevant features of the population, test 
and outcomes of the study.  A study was considered to be of good quality if it used a prospective 
design, consecutive enrolment, full verification of the test result with reference standard, and had 
adequate test description.
58;232;236;339
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From individual studies, measures of accuracy like sensitivity and specificity were calculated with 
95% confidence intervals (CI).  The True Positive Rates (TPR) and False Positive Rates (FPR) for 
various test thresholds were plotted in the Receiver Operating Characteristics (ROC) space.  We 
used a random-effects bivariate model to meta-analyse estimates of sensitivity and specificity. 
Rather than using a single outcome measure per study, like the diagnostic odds ratio in the 
summary Receiver Operating Characteristic (sROC) approach, the bivariate model preserves the 
two-dimensional nature of diagnostic data by directly analysing the logit transformed sensitivity log 
(sensitivity/(1-sensitivity)) and specificity log (specificity/(1-specificity)) of each study in a single 
model. This model estimates and incorporates the correlation that might exist between logit 
sensitivity and specificity within studies due to possible differences in threshold between studies.
59
 
A standard correction of adding 0.5 to all four cells of the 2x2 table was applied when either 
sensitivity or specificity was 100%. The model produces the following results: a random effect 
estimate of the mean sensitivity and specificity with corresponding 95% CI, the amount of 
between-study variation for sensitivity and specificity separately, and the strength and shape of the 
correlation between sensitivity and specificity.  Using the parameters of the bivariate distribution 
we have calculated confidence ellipse around the summary estimates of sensitivity and specificity.  
All analyses were performed using MetaDisc statistical package
340
 except to fit the bivariate model 
for which the Proc Mixed procedure in SAS version 8.2 for Windows (SAS Institute Inc, Cary, NC, 
USA) was used.  
 
14.4 Results 
14.4.1 Literature identification and study quality 
Appendix 11 flow chart summarises the process of literature identification and selection.  A total of 
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558 citations were identified by electronic searches.  Detailed assessment of the papers led to 
inclusion of 8 primary articles that met the selection criteria including a total of 35960 
newborns.
331-338
 Salient features of each study according to the population subgroups, test 
characteristics and reference standards are provided in Appendix 26.  
 
Pulse oximetry was performed on asymptomatic newborns in all studies, with three studies 
excluding newborns who were antenatally diagnosed to have congenital heart disease.
335;336;338
 The 
studies measured either functional or fractional oxygen saturation by pulse oximetry with oxygen 
saturation below 95% considered as the cut off level in most studies.  Functional saturation is the 
ratio of oxygenated haemoglobin to all haemoglobin capable of carrying oxygen, fractional 
saturation is the ratio of oxygenated haemoglobin to all haemoglobin (including those which do not 
carry oxygen). Fractional saturation is approximately 2% lower than functional saturation.  There 
was variation in the age of first testing ranging from 2 hours to more than 24 hours.  Four studies 
measured levels of oxygen saturation after 24 hours of birth or just before discharge.
332;335;336;338
 
The outcomes assessed were congenital heart disease or critical cardiovascular malformation in all 
studies.  Six studies were prospective studies and two were case control studies.  There was lack of 
blinding for the reference standard assessment in all the studies.  There was differential verification 
of the pulse oximetry results for congenital heart disease by either echocardiography in neonates 
with low oxygen saturation or by clinical follow up in those with normal levels. The quality of the 
studies included in the review is provided in Appendix 15.  
 
14.4.2 Accuracy of pulse oximetry as a screening tool for Congenital Heart Disease 
The sensitivity (True Positive Rate) of pulse oximetry for detection of CHD varied between 25% 
(95% CI, 13% to 41%)
341
 and 98.5% (95% CI, 91.8% to 100%).
333
  The test had high specificity in 
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seven studies [98% (95% CI, 98% to 99%) to 100% (95% CI 99.8% to 100%)] resulting in false 
positive rates between 0% and 2% (95% CI, 1% to 2%).
331-333;335-338
  The case control study by 
Hoke et al
334
 had relatively low specificity [88% (95% CI, 87 to 89)] and high false positive rate 
compared to other studies [12% (95% CI, 11% to 13%)] for threshold level of functional saturation 
less than 95% in the foot. The actual number of patients with false positive results was not certain 
in this study as not all newborns with abnormal screening tests underwent echocardiography or 
clinical examination. The highest sensitivity [98.5% (95% CI, 91.8% to100%)] was obtained using 
threshold levels of functional saturation <95% in both limbs or at least 3% difference in saturation 
between foot and right hand.
333
 The highest specificity (100%) was obtained when the test was 
performed after 24 hours of birth or near discharge.
332;335;338
 Only one study explored the added 
value of pulse oximetry above the accuracy achieved through clinical examination. The 
combination of pulse oximetry and clinical examination had a sensitivity of 76.9% (95% CI, 46.2% 
to 95%) and specificity of 99.9% (95% CI, 99.8% to 100%).
332
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Fig 14.1.  True positive rates (TPR) and False positive rates (FPR) for various threshold levels 
of oxygen saturation (SaO2) measured by pulse oximetry for the detection of congenital heart 
disease in newborns 
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0 0.2 0.4 0.6 0.8 1
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(TPR) 
1-specificity
(FPR)
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
<95% both limbs or foot SaO2 >3% lower or higher than right hand
<95% both limbs or foot SaO2 s>3% lower than right hand
<95% in right hand
<95% both right hand and foot
<93% foot
<94% foot
<92% foot
<92% foot or 7% lower in foot
<91% foot
<90% foot
a. TPR and FPR of individual studies for the commonest 
threshold of SaO2 <95% with summary estimates of sensitivity 
and specificity and confidence ellipse around the estimates
b. TPR and FPR for different threshold 
levels of SaO2
 
The bivariate summary estimates of sensitivity and specificity were 63% (95% CI, 39% to 83%) 
and 99.8% (95% CI, 99% to 100%) respectively, yielding a false positive rate of 0.2% (95% CI, 0% 
to 1%). The summary estimates of the individual studies are represented as a confidence ellipse in 
Fig 15.1a.  The various other reported threshold levels of oxygen saturation and their accuracy 
measures are given in Fig 15.1b. 
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Table 14.1. The accuracy of pulse oximetry for diagnosing CHD in asymptomatic newborns 
 
14.5 Discussion 
Our review has identified pulse oximetry as a potentially useful screening test for congenital heart 
disease in asymptomatic newborns.  It is a non-invasive, readily available, relatively cheap, well 
validated test performed currently by either nurses or doctors.
36
  The high specificity reflecting the 
low false positive rate makes this test a suitable screening tool. The sensitivity of the test however 
is varied, with wide confidence intervals that may be attributed to the low prevalence of the 
condition.  Previous individual studies have lacked the necessary large number of patients to 
confidently estimate the sensitivity of the test.  Our review and the resulting meta-analysis have 
addressed this issue by providing a summary estimate of the accuracy measures by pooling the 
results of previously published studies. 
 
The validity of our review findings depends on the methodology of the systematic review and the 
Test  No. of  
patients 
Sensitivity 
(TPR) 
% (95% CI) 
Specificity 
 
% (95% CI) 
False Positive 
Rate(FPR) 
% (95% CI) 
Most commonly used threshold     
saturation
*
 ≤95% foot 11281 60 (14.7-94.7) 100 (100-100) 0 
saturation
*
 ≤95% foot or hand 2114 66.7(9.4-99.2) 99.9(99.7-100) 0.1(0-0.3) 
saturation
*
 ≤ 95% foot 3262 96.8(73.6-100) 99.7(99.5-99.9) 0.3(0.1-0.5) 
saturation
§
 <95% foot 5626 25(12.7-41.2) 99.6(99.4-99.7) 0.4(0.3-0.6) 
saturation
*
 ≤ 95% foot 5292 66.7(9.4-99.2) 100(99.9-100) 0(0-0.1) 
saturation
§
 <95% hand and foot 5211 30.8(9.1-61.4) 100(99.9-100) 0(0-0.1) 
saturation
*
 <95% foot 2733 75(57.8-87.9) 87.9(86.6-89.1) 12.1(10.9-
13.4) 
saturation
*
 <95% foot 266 89.4(79.4-95.6) 99(96.4-99.9) 1(0.1-3.6) 
 
Most accurate threshold 
saturation
*
 <95% in both limbs or a 
differential of >3% between foot 
and right hand 
 
Summary estimate 
 
 
266 
 
 
 
35785 
 
 
98.5(91.8-100) 
 
 
 
63.4(38.7-82.5) 
 
 
 
 
 
 
99.8(99-100) 
 
 
 
 
 
 
0.2(0-1) 
* functional oxygen saturation    § fractional oxygen saturation 
Summary using bivariate method of meta analysis 
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quality of the individual studies included. An extensive literature search was performed in relevant 
databases without any language restrictions to minimise the possibility of missing any studies.  The 
quality of most of the studies was compromised due to the differential verification by either 
echocardiography (in test positive cases) or clinical follow up (test negative) cases.  However, this 
is perhaps unavoidable.  Two were case control studies, a design that biases the results by 
overestimating the diagnostic odds ratio. Furthermore, the absence of blinding, absent or poor 
description of the test or reference standard could have affected the results of the review.  The 
significant heterogeneity observed in the results could be a reflection of the type of saturation 
chosen for the cut off level (functional Vs fractional), method of testing and the inclusion or 
exclusion of newborns diagnosed to have congenital heart disease antenatally, thereby leading to 
spectrum variation.  None of the studies evaluated acceptability of “babies” testing to parents and 
the psychosocial impact of false positive results or identification of non critical CHD.  
 
We used bivariate analysis model for meta-analysis using a random effects approach to obtain 
summary estimates of both sensitivity and specificity.  This model accounts for the heterogeneity 
between studies caused by different threshold settings. In addition, the model acknowledges the 
difference in precision by which sensitivity and specificity have been measured in each study. This 
means that studies with a larger number of patients with the target condition receive more weight in 
the calculation of the summary estimate of sensitivity, while studies with more patients without the 
target condition are more influential in the pooling of specificity.  Finally the model accounts also 
for the residual heterogeneity due to clinical or methodological differences between studies.  
Unfortunately, we could not perform an explicit analysis of these potential sources of heterogeneity 
due to the limited number of studies included in our review. 
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14.6 Conclusion 
Pulse oximetry has been shown to be a highly specific screening tool with very low false positive 
rates.  Large well conducted robust studies are essential to confirm the value of pulse oximetry as a 
screening test, in isolation or in combination with clinical examination to obtain precise estimates 
of its sensitivity.  Further evaluation is needed on the effect of screening on parents and its 
acceptability to parents and health care professionals, especially with the possibility of non 
significant lesions being detected during echocardiography and the costs and cost effectiveness of 
the screening program on healthcare services. 
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CHAPTER 15: CONCLUSION 
15.1  Summary of findings 
This chapter summarises the results of the individual chapters. The detailed results are provided 
separately within each of them. Below, is reproduced the table of structured questions from Chapter 
1 (Table 15.1), with a final column of findings from the various chapters of this thesis:  
Table 15.1: Structured questions of the chapters of this thesis with findings 
Chapter 
Number 
Population Intervention or 
Test 
Outcome(s) Research 
Design 
Results 
 
Objective A: Delphi Survey of practice where there is no robust evidence 
 
2, 3 Women with 
pre eclampsia 
Tests including 
clinical history, 
examination and 
investigation 
Maternal and fetal 
mortality and 
morbidity 
Delphi 
survey 
Blood pressure and proteinuria were 
considered as the most important 
predictors with mean scores of 4.7 
(± 0.47) and 4.6 (± 0.5) respectively 
followed by liver function tests (4.5, 
± 0.52) and pre-existing medical 
conditions (4.4, ± 0.81). Full blood 
count (4.3, ±0.9), renal function 
tests (4.1, ±0.94) and multiple 
pregnancy (3.7, ±0.79) were the 
other tests that were scored as 
significant predictors by all the 
experts. 
 
Objective B: To review the quality of systematic reviews in maternal and fetal medicine 
 
4 Maternal 
medicine 
reviews 
Cochrane Vs Non 
Cochrane 
Adherence to pre 
specified good 
quality items 
Systematic 
review 
Cochrane reviews had specified the 
question more than non Cochrane 
reviews (OR 20.3, 95% CI 1.1–
381.3, p = 0.04). They also framed 
narrowly focussed questions (OR 
30.9, 95% CI 3.7- 256.2, p = 0.001). 
Cochrane reviews attempted more 
often to include unpublished data in 
literature search (OR 5.6, 95% CI 
1.9–16.4, p =0.002). Meta analysis 
technique (OR 3.7, 95% CI 1.3–
10.8, p = 0.02) and assessment for 
heterogeneity (OR 38.1, 95%CI 2.1, 
688.2, p = 0.01) was found to be 
employed significantly more often 
by Cochrane reviews. 
5 Fetal 
medicine 
reviews 
Quality across 4 
areas: fetal 
aneuploidy, fetal 
therapy, fetal 
pathology and fetal 
growth 
Adherence to pre 
specified good 
quality items 
Systematic 
review 
Fetal growth reviews performed 
significantly better than reviews in 
other areas in question specification 
(p<0.03), search without language 
restriction (p<0.004), assessment of 
risk of missing studies (p<0.006) 
and study quality assessment 
(p<0.002). There was no difference 
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in other quality items. 
 
Objective C: To undertake systematic reviews and meta analyses of therapy studies 
 
6 Pregnant 
women at risk 
of pre term 
labour 
Progeterone Vs 
Placebo 
Delivery before 34 
weeks, 36 weeks, 
perinatal mortality 
and other clinically 
relevant outcomes 
Systematic 
review and 
meta analysis 
There were reductions in delivery 
rates before 37 weeks (OR 0.42, 
95% CI 0.31 to 0.57) and 34 weeks 
(OR 0.51, 95% CI 0.34 to 0.77) as 
well as in respiratory distress 
syndrome (OR 0.55, 95% CI 0.31 to 
0.96) with progestational agents. 
7 Pregnant 
women with 
epilepsy on 
lamotrigine 
Routine therapeutic 
monitoring Vs 
Management based 
on clinical features 
only 
Seizures, any other 
relevant maternal 
and fetal outcome 
Systematic 
review and 
meta analysis 
The combined rate of seizure 
deterioration was 0.40 (95% CI 0.26 
to 0.55) in women with lamotrigine  
dosage based on serum levels 
compared to 0.73 (95% CI 0.56 to 
0.86) in those managed by clinical 
features alone. 
 
 
Objective D: To undertake systematic reviews and meta analyses of test accuracy studies 
 
 
9 Women with 
pre eclampsia 
Proteinuria 
 
 
Adverse maternal 
and fetal outcomes 
Systematic 
review and 
meta analysis 
Sixteen primary articles with a total 
of 6749 women met the selection 
criteria. The area under the curve 
(AUC) for adverse maternal and 
fetal outcomes are 0.63 (95% CI 
0.22, 0.91) and 0.59 (95% CI 0.36, 
0.79) respectively. 
 
10 Women with 
pre eclampsia 
Uric acid 
 
Adverse maternal 
and fetal outcomes 
Systematic 
review and 
meta analysis 
There were 18 primary articles that 
met the selection criteria, including 
a total of 3675 women. The area 
under the curve for adverse maternal 
and fetal outcomes were 0.75 (95% 
CI 0.46, 0.92) and 0.69 (0.39, 0.86) 
respectively. 
 
11 Women with 
pre eclampsia 
Liver function tests 
 
Adverse maternal 
and fetal outcomes 
Systematic 
review and 
meta analysis 
There were 13 primary articles 
selected including a total of 2813 
women. For predicting adverse 
maternal outcome, AUC was 0.79 
(95% CI 0.51, 0.9). For predicting 
adverse fetal outcomes the AUC 
was 0.76 (95% CI 0.44, 0.93).  
12 Women with 
pre eclampsia 
Symptoms 
 
Adverse maternal 
and fetal outcomes 
Systematic 
review and 
meta analysis 
Six primary articles with 2573 
women were included.  The AUC 
for predicting complications with 
symptoms of headache, epigastric 
pain and visual disturbances were 
0.58 (95% CI 0.24, 0.86), 0.70 (95% 
CI 0.3, 0.93) and 0.74 (95% CI 0.33, 
0.94). The sensitivity and specificity 
of headache to predict adverse 
maternal outcomes were 0.54 (95% 
CI 0.27, 0.79) and 0.59 (95% CI 
0.38, 0.76) respectively.  The 
sensitivity of epigastric pain and 
visual disturbances are 0.34 (95% CI 
0.22, 0.5) and 0.27 (95% CI 0.07, 
0.65) with a specificity of 0.83 (95% 
CI 0.76, 0.89) and 0.81 (95% CI 
0.71, 0.88) respectively.  The 
sensitivity and specificity of nausea 
and vomiting to predict adverse 
outcomes were 0.24 (95% CI 0.21, 
0.27) and 0.87 (95% CI 0.85, 0.89) 
respectively. 
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13 Women with 
pre eclampsia 
Blood pressure Adverse maternal 
and fetal outcomes 
Systematic 
review and 
meta analysis 
Eight articles with 2304 women 
evaluated the accuracy of blood 
pressure in predicting adverse 
outcomes. The area under the curve 
(AUC) for any adverse maternal 
outcome was 0.68 (95% CI 0.29, 
0.92).  
14 Newborns  Pulse oximetry Congenital heart 
disease (CHD) 
Systematic 
review and 
meta analysis 
8 studies with 35,960 newborns 
were included. The summary 
estimates of sensitivity and 
specificity for detecting CHD were 
0.63 (95% CI 0.39, 83) and 0.998% 
(95% CI, 0.99, 100) respectively, 
yielding a false positive rate of 0.2% 
(95% CI, 0% to 1%). 
 
 
Accuracy of tests in pre-eclampsia 
Proteinuria has usually been associated with increase in maternal and fetal mortality and morbidity. 
Our review has shown that the magnitude of proteinuria in women with pre-eclampsia is a poor 
predictor of the major maternal and fetal complications.  The review on uric acid presents the best 
available evidence so far in addressing the question of significance of uric acid levels as a predictor 
of maternal and fetal complications in pre-eclampsia. Although uric acid as a marker may be of 
value in detecting pre-eclampsia, it has been identified as a poor predictor of any complications of 
pre-eclampsia. The provision of likelihood ratios stratified by the severity of pre-eclampsia and test 
thresholds will enable clinicians to understand the poor clinical value of this test in predicting 
complications in women with pre-eclampsia. In women with preeclampsia, LFTs had at best 
moderate prediction of maternal and fetal complications.  The test specificity, however, was better 
than sensitivity. This meant that with a positive test result one could be more confident about 
predicting poor outcome than one could about ruling out complications with a negative result.  
Among women with pre-eclampsia, symptoms of visual disturbance and epigastric pain were 
moderately good predictors of maternal complications.  Their predictive accuracy was better than 
headache as a test.  The symptoms overall had high specificity than sensitivity.  Thus, the presence 
of symptoms is clinically more useful for ruling in complications in comparison to their absence for 
ruling out complications.  Blood pressure was a better predictor of adverse fetal than maternal 
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outcomes. Both sensitivity and specificity were lower for maternal complications than for fetal 
complications. A high BP reading (160/100) is more likely to rule in adverse fetal outcomes, 
whereas a BP<160/100 is less likely to rule out a complication. The same phenomenon was 
observed for cut off levels of MAP>140 for eclampsia and abruption. 
15.2 Strengths and limitations 
The topic areas for the systematic reviews performed in the thesis were identified in a systematic, 
structured way through Delphi survey and review of existing reviews. The systematic reviews and 
the survey have been performed using robust methodology.
55;172
  An extensive literature search was 
performed in relevant databases without any language restrictions to minimise the possibility of 
missing any studies. Study quality was evaluated rigorously in the reviews and data extraction was 
done using pre determined data extraction forms in duplicate. In the review of effectiveness of 
progesterone in reducing pre term birth, both conventional and cumulative meta-analyses was 
carried out, to explore the size and significance of the effects as trials accumulated over time, and to 
evaluate the impact of quality of trials on effects. Furthermore, the applicability of the evidence to 
women at various baseline risks was assessed, and the evidence for safety of progestational agents 
was reviewed. Methodological deficiencies like verification bias and differential use of reference 
standards did not apply to the studies in the diagnostic reviews ensuring inclusion of acceptable 
quality studies. Meta analysis was performed where appropriate, allowing for heterogeneity and 
bivariate approach was used in the diagnostic reviews to confirm the robustness of the results.  
 
A significant limitation of the pre-eclampsia review was the heterogeneity noticed between 
individual studies with regards to population, definition of pre-eclampsia, test thresholds, frequency 
of testing, interval between the test and outcome, and reference standards. Furthermore there is 
inter and intra observer variation in the performance and interpretation of the test results. Lack of 
data on the results of other tests performed in these women meant that it was not possible to assess 
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the value of other tests on the performance of the test under review. They do not take into account 
the predictive role of more than one test result on the outcome. Furthermore, there was no separate 
quantification of risks especially in women with early onset pre eclampsia, given that gestational 
age was the most important determinant of perinatal outcome.
342
 Clinicians are hesitant to advocate 
expectant management due to uncertainties about the scale of maternal risk. Given the small 
number of the individual adverse outcomes, the studies did not have suffient sample size for precise 
results. Due to the rarity of the outcome of perinatal deaths, the results were imprecise for the 
effectiveness of progesterone in women at risk of pre term labour. The therapeutic review on the 
effectiveness of AEDs in pregnant women with epilepsy had very small studies with variable 
quality with ensuing imprecise results. 
 
15.3 Implications for clinical practice 
 
 Blood pressure is believed to be the most important predictor of adverse outcomes in 
women with pre eclampsia according to Delphi survey of the experts. This will need to be a 
target for clinical management in pre eclampsia.  
 Progesterone should be offered as a treatment option in women at risk of pre term labour 
given the very large treatment effects of progesterone in clinically important outcomes of 
delivery before 34 weeks (50% reduction in odds) and respiratory distress syndrome (45% 
reduction in odds) with evidence of safety.  
 Estimation of levels of proteinuria in women is not a clinically useful test to predict fetal or 
maternal complications in women with pre eclampsia.  
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 Uric acid is not a significant predictor of individual adverse maternal or fetal outcomes in 
women with pre eclampsia. 
 An abnormal liver function test in women with pre eclampsia has a moderate predictive 
value for identifying women at increased risk of maternal and fetal complications.  An 
abnormal test result is more likely to „rule in‟ a complication than a normal result „ruling 
out‟ disease.  
 In pre eclampsia, the presence of symptoms is more useful in their ability to predict 
complications compared to their absence in confidently excluding adverse events.   
 An abnormal pulse oximetry reading in the newborn is very likely to identify congenital 
heart disease due to high specificity and very low false positive rate.  
 The poor quality and small size of the studies evaluating the effective monitoring regimes 
(routine serum drug levels vs clinical features alone) in pregnant women with epilepsy on 
the anti epileptic drug lamotrigine means that there is very weak recommendation to follow 
either of the regimen. 
 
15.4 Implications for research 
 
 The quality of currently published systematic reviews in maternal and fetal medicine is 
variable. Future reviews should employ robust methods. 
 
  The systematic review of tests in pre eclampsia identified the: 
 paucity of quality primary studies to evaluate the predictive accuracy of tests 
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  poor quality, such that studies varied in design and conduct, with lack of details 
about the tests and reference standards, the duration between tests and outcome 
  the effect of other risk factors and interventions on prediction of complications 
  lack of information to evaluate the accuracy of combination of tests; inadequate 
sample size to precisely estimate accuracy measures.  
This has provided the evidence to justify a large prospective study in this area through a 
successful NIHR (National Institute for Health Research) grant to conduct a large 
multicentre prospective study, Prediction of Risks in Early onset Pre eclampsia (PREP) 
study. PREP will develop a prediction model in women admitted with early onset pre 
eclampsia for timely assessment of the risk of adverse maternal and fetal outcomes at 48 
hours and at discharge and externally validate the model. The data collated give face 
validity of the choice of tests chosen for use in the prediction model.   
 
 The pulse oximetry test had high specificity but varied sensitivity in detecting congenital 
heart disease in newborn. The findings led to the successful NIHR proposal for the 
multicentre Pulse Ox study that will assess the accuracy of pulse oximetry as a screening 
tool for congenital heart disease in newborn babies and evaluate its cost-effectiveness. 
 
 The evidence for the effective monitoring regimen in preventing seizures in pregnant 
women with epilepsy on the anti epileptic drug (AED) lamotrigine is of poor quality, 
indirect with imprecise results. The findings of this review had led to the start of a pilot 
study, SOAP (Study of Optimal Anti epileptic Drugs in Pregnancy) funded by the Research 
and Development (R & D) department of the Birmingham Women‟s Hospital.  More 
recently, it has contributed to the successful HTA grant for a multicentre randomised 
controlled trial in this area, AntiEpileptic drug (AED) Management in PREgnancy: An 
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evaluation of effectiveness, cost effectiveness and acceptability of dose adjustment 
strategies (EMPiRE trial).  
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APPENDICES  
Appendix 1. Flow chart of literature identification and study selection in the 
review of maternal medicine reviews 
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Appendix 2. Growth of primary research in fetal medicine and lack of 
corresponding development in their systematic reviews.  
(Numbers within figure represent cumulative number of citations) 
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Appendix 3. Flow chart of literature identification and study selection in the 
review of fetal medicine reviews 
Total citations retrieved from Medline, Embase, 
Cochrane library and DARE   n= 659
(2000-2005)
Citations retrieved for detailed evaluation 
n= 133
From reference list n=12
Review articles selected for evaluation n=84
Review articles excluded with 
reasons n= 49
Does not satisfy review criteria n=6
Not fetal subject matter n= 43
Citations excluded after screening 
abstracts n= 526
fetal 
growth 
13/84 (15%)
fetal 
aneuploidy 
11/84, (13%)
fetal 
therapy 
11/84, (13%)
fetal 
pathology 
49/84, (59%)
Aetiology 
14/84 (17%)
Prognosis 
19/84 (23%)
Diagnosis 
27/84 (31%)
Therapy 
24/84 (29%)
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Appendix 4. Flow chart of literature identification and study selection review of 
effectiveness of lamotrigine dosage based on serum levels vs clinical features in 
the management of pregnant women with epilepsy  
Total citations identified from electronic searches             n= 389
From electronic searches                            n= 30
From reference lists                                n= 3
Primary articles included in systematic review                  n=5
Citations excluded after screening titles and/or abstracts n=359
Articles excluded with reasons
Inappropriate population                                        n=19
Data not extractable                                            n=1
Reviews - n=5
n=3
Total excluded                                                  
Articles retrieved for detailed evaluation n=33
Case reports               
n=28
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Appendix 5. Flow chart of literature identification in Medline and study 
selection process for systematic review of tests predicting complications in pre 
eclampsia 
TEST OUTCOME
n=21218
POPULATION
OR
n=3789602
n=12527
n=11711
HISTORY EXAMINATION INVESTIGATION
n=1750218 n=410518 n=1627858
Animal only, letters excluded
n=3387126
AND
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Appendix 6. Flow chart of literature identification and study selection for role of 
proteinuria in predicting maternal and fetal complications in preeclampsia  
Potentially relevant citations identified from electronic searches to capture 
primary articles on proteinuria in preeclampsia (n=19500)
Potentially relevant citations (n=541)
References excluded after screening titles or abstracts 
(n=378)
Primary articles retrieved for detailed evaluation (n=173):
From electronic searches (n=163)
From reference lists (n=10)
Articles excluded (n=157):
Inappropriate population (n=47)
Data not extractable (n=48)
Inappropriate outcome (n=10)
Lack of original data i.e reviews or letters (n=9)
Inappropriate test (n=33)
Case control studies (n=10)
Primary articles included in systematic review (n=16)
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Appendix 7. Flow chart of literature identification and study selection process 
for role of uric acid in predicting maternal and fetal complications in 
preeclampsia  
 
 
 
 
 
Potentially relevant citations identified from electronic searches to capture 
primary articles on uric acid in preeclampsia (n=19.500)
Potentially relevant citations (n=436)
References excluded after screening titles or abstracts 
(n=322)
Primary articles retrieved for detailed evaluation (n=125):
From electronic searches (n=114)
From reference lists (n=11)
Articles excluded (n=107):
Inappropriate population (n=39)
Data not extractable (n=28)
Not a test accuracy study to predict complications of
preeclampsia (n=24)
Lack of original data i.e reviews or letters (n=9)
Articles that cannot be retrieved or translated (n=5)
Duplicate publication (n=2)
Primary articles included in systematic review (n=18)
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Appendix 8. Flow chart of literature identification and study selection process 
for role of liver function tests (LFT) in predicting maternal and fetal 
complications in preeclampsia  
 
 
Potentially relevant citations identified from electronic searches to capture 
primary articles on LFTs in preeclampsia (n=19500)
Potentially relevant citations (n=147)
References excluded after screening titles or abstracts (n=57)
Primary articles retrieved for detailed evaluation (n=104)
From electronic searches (n=90)
From reference lists (n=14)
Articles excluded (n=91):
Inappropriate population (n=26)
LFT not used as a test to predict complications of
preeclampsia (n=22)
Insufficient data to construct 2x2 table (n=34)
Articles unobtainable (n=9)
Primary articles included in systematic review (n=13)
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Appendix 9. Flow chart of literature identification and study selection process 
for role of symptoms in predicting maternal and fetal complications in 
preeclampsia 
 
 
 
Potentially relevant citations identified from electronic searches to capture 
primary articles on symptoms in preeclampsia (n=19500)
Potentially relevant citations  (n=215)
References excluded after screening titles or abstracts 
(n=115)
Primary articles retrieved for detailed evaluation (n=109):
From electronic searches (n=100)
From reference lists (n=9) 
Articles excluded (n=103): 
Inappropriate population (n=14)
Symptoms not considered (n=35) 
Data not extractable (n=19)
Lack of original data i.e reviews or letters         (n=6)
Articles that cannot be retrieved or translated (n=23) 
Duplicate (n=6) 
Primary articles included in systematic review (n=6)
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Appendix 10. Flow chart of literature identification and study selection process 
for role of blood pressure in predicting maternal and fetal complications in pre 
eclampsia 
 
Potentially relevant citations identified from electronic 
searches to capture primary articles on BP used in 
prediction of preeclampsia                                 (n=209)                                       
 
References excluded after screening titles 
or abstracts                                  (n=117) 
Primary articles retrieved for detailed evaluation       (n=96)  
 From electronic searches                               (n=92) 
 From reference lists                                       (n=4)  
Articles excluded                                (n=87)  
  Inappropriate population                   (n=79) 
  Data not extractable                          (n=5) 
  Articles that cannot be retrieved or 
translated                                             (n=3)  
  Duplicate                                           (n=1)  
Primary articles included in systematic review (n=8) 
  
202 
 
Appendix 11. Flow chart of literature identification and study selection process 
for systematic review of pulse oximetry as a screening test for congenital heart 
disease in newborn  
Total citations identified from electronic searches                         n= 558
Articles of accuracy of pulse oximetry in screening for congenital
heart disease of asymptomatic newborns for detailed evaluation  n=14                                              
Primary articles included in systematic review                         n=8
Citations excluded after screening titles and/or 
abstracts:                                                                                n= 544
Articles excluded with reasons
Lack of original data i.e reviews or letters                      n=3
Insufficient data for 2x2 table despite request to authors      n=2
Duplicate publication                                           n=1 
Total excluded                                                  n=6
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Appendix 12: Quality of trials included in the systematic review on the use of 
progestagens for the prevention of preterm birth  
 
Study 
(Year) 
Randomisation and 
Concealment 
Blinding Description 
of 
withdrawals 
Follow 
up 
(%) 
Quality 
score
343
 
da Foncesca 
et al 
2003 
Adequate randomisation 
using random number 
table; 
Concealment adequate 
with consecutive sealed 
envelopes 
 
Double 
blind 
Yes 91 5 
Meis et al 
2003 
 
Adequate randomisation by 
computer generated 
sequence; 
Adequate concealment 
 
Double 
blind 
Yes 99 5 
Noblot et al 
1991 
 
Adequate randomisation 
using random number 
table; 
Adequate concealment  
 
Double 
blind 
Yes 100 5 
Yemini et al 
1985 
 
Inadequate randomisation 
by last digit of registration 
number; 
Concealment inadequate 
 
Double 
blind 
Yes 99 2 
Sondergaard 
1985 
„Randomised‟: details not 
given; 
Concealment unreported 
 
Double 
blind 
Yes 100 2 
Johnson et al 
1975 
 
 
„Random double blind 
fashion‟: details not given; 
Concealment unreported    
 
Double 
blind 
Yes 86 2 
Papiernik-
Berkhauer 
1970 
 
„Randomised‟: details not 
given; 
Concealment unreported 
Not 
known 
Yes 100 1 
Le Vine et al 
1964 
 
Inadequate randomisation 
by alternate placement in 
two groups; 
Concealment inadequate 
 
Double 
blind 
Yes 54 2 
Swyer et al 
1953 
 
Inadequate randomisation 
by alternate assignment to 
each trial arms in one 
centre; “at random” in the 
other centre, but details not 
given; 
Concealment unreported 
 
None Yes 100 1 
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Appendix 13. Quality of studies included in the systematic review evaluating 
management of pregnant women on lamotrigine based on regular serum levels 
or clinical features alone  
 
5
5
5
5
2
5
5
3
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Follow up complete
Adequate description of
outcome
Adequate description of
intervention
Appropriate population
Blinding
Randomised
Prospective
yes
no
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Appendix 14. Quality of included studies in the reviews of tests that predict 
complications in women with pre eclampsia 
 
 
 
16
5
10
12
5
6
11
6
4
16
11
10
0% 20% 40% 60% 80% 100%
Adequate follow up 
Adequate reference standard 
description
Adequate test description 
Appropriate patient spectrum 
Blinding 
Prospective design 
Consecutive enrolment 
Feature present Feature absent, unclear or unreported  
18
9
12
13
8
3
9
6
5
18
10
15
0% 20% 40% 60% 80% 100%
6
6
5
2
3
4
1
4
6
3
2
0% 20% 40% 60% 80% 100%
6
6
5
2
3
4
1
4
6
3
2
0% 20% 40% 60% 80% 100%
Proteinuria Uric acid Liver function tests Symptoms
8
7
2
7
5
6
1
6
1
8
3
2
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Blood pressure
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Appendix 15. Quality of included studies in the review of pulse oximetry as a 
screening test in the detection of congenital heart disease in newborn 
 
 
8 
6 
8 
6 
6 
2 
8 
2 
2 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Adequate reference standard 
Adequate test description 
Appropriate patient spectrum 
Blinding 
Prospective design 
Consecutive enrolment 
Feature present Feature absent, unclear or unreported 
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Appendix 16. Details of included reviews in review of fetal medicine reviews 
Author Year Topic (classifications) No of  
Included 
studies 
No of  
Infants 
Summary of findings 
Kramer
344
 1987 Determinants of growth in 
utero 
(growth, etiology) 
895 Not 
reported 
Pathophysiological factors 
reviewed. From this 
smoking cessation, calorie 
supplementation and 
malaria prophylaxis thought 
to be beneficial 
Chang et al
345
 1992 Prediction of the SGA 
infant with ultrasound 
(growth, prognostic) 
60 Not 
reported 
In high risk subjects 
abdominal circumference 
below the tenth centile and 
estimated fetal weight 
below the tenth centile have 
the best association with 
SGA 
Ukwu et al
346
 1992 HIV in pregnancy and 
perinatal infection 
(pathology, prognostic) 
Not 
reported 
Not 
reported 
Majority of transmission 
occurs peripartum by a 
minor subset of HIV stains. 
Giles et al
347
 1993 Use of Doppler ultrasound 
in high risk pregnancy 
(pathology, 
diagnostic) 
6 4235 Significant reduction in 
perinatal mortality 
especially intrauterine 
deaths 
Alfirevic et al
348
 1995 Doppler ultrasonography in 
high risk pregnancies 
(pathology, 
diagnostic) 
12 7474 Associated with reduction in 
perinatal deaths 
Forouzan
349
  1995 Absent end diastolic flow in 
the umbilical artery 
(pathology, prognostic) 
Not 
reported 
Not 
reported 
Intense surveillance 
required and delivery at 
later gestations 
Gross et al
350
 1995 Isolated choroid plexus 
cysts and trisomy 18 
(aneuploidy, 
diagnostic) 
13 748 Poor positive predictive 
value for isolated CPC and 
trisomy 18 does not support 
invasive testing on isolated 
finding 
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Crowther  
et al
351
 
1996 Caesarean delivery for 
second twin not presenting 
cephalically (pathology, 
therapeutic) 
 
1 120 No improvement in neonatal 
outcome, increased maternal 
febrile morbidity 
Say et al
352
 1996 Calcium channel blockers 
for impaired fetal growth 
(growth, 
therapeutic) 
1 100 Insufficient evidence to 
evaluate 
Say et al
353
  
 
1996 TENS for suspected 
placental insufficiency 
0 0 Insufficient evidence to 
recommend practice 
Say et al 
354
 1996 Plasma volume expansion 
for suspected impaired fetal 
growth (growth, 
therapeutic) 
0 0 Inadequate evidence exists 
to support practice 
Schumacher et 
al
355
 
1996 Fetal transfusion for red 
blood cell alloimmunization 
(therapy, 
therapeutic) 
Not 
reported 
Not 
reported 
Transfusion is the best 
therapy remote from term, 
overall neonatal survival 
exceeds 80% 
Sherer et al
356
 1996 Prenatal ultrasound 
assessment of ductus 
arteriosus (pathology, 
diagnostic) 
Not 
reported 
Not 
reported 
Knowledge of 
pathophysiology and 
ultrasonography may aid 
management of complicated 
pregnancies 
Sherer et al
357
 1996 Prenatal ultrasound 
assessment of ductus 
venosus (pathology, 
diagnostic) 
Not 
reported 
Not 
reported 
Knowledge of 
pathophysiology and 
ultrasonography may aid 
management of complicated 
pregnancies 
Smith et al
358
 1996 Triple screen versus double 
screen for trisomy 21 
detection 
(aneuploidy, 
diagnostic) 
8 143094 Triple test improves the 
detection of trisomy 21 
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Giacoia
359
 1997 Fetomaternal haemorrhage 
(pathology, 
prognostic) 
Not 
stated 
134 Alternative early detection 
methods needed, the role of 
in utero transfusion needs to 
be defined and long term 
follow up is needed 
Goffinet et al
360 
1997 Use of Doppler ultrasound 
in high and low risk 
pregnancies 
(pathology, 
prognostic) 
13 9162 One third reduction in 
perinatal death in high risk 
pregnancies  
Gulmezoglu et 
al
361
 
1997 Effectiveness of 
interventions to prevent or 
treat impaired fetal growth 
(growth, 
therapeutic) 
126 Not 
reported 
Most interventions have no 
effect on perinatal outcome. 
Antimalarial prophylaxis in 
primigravidae, smoking 
cessation and balanced 
protein/energy 
supplementation may be 
beneficial 
Sherer et al
362 
1997 First trimester screening for 
fetal aneuploidy 
(aneuploidy, diagnostic) 
Not 
recorded 
Not 
recorded 
First trimester nuchal 
translucency and maternal 
biochemistry are feasible 
screening methods 
Sherer et al
363 
1997 Middle cerebral artery 
Doppler 
(pathology, 
diagnostic) 
Not 
recorded 
Not 
recorded 
May assist diagnosis and 
management of complicated 
pregnancies 
Conde-Agudelo 
et al
364
 
1998 Triple test as screen for 
Down syndrome 
(aneuploidy, 
diagnostic) 
20 194326 Effective screening method 
more effective in older than 
younger women 
Giles et al
365
 1998 Doppler ultrasound in 
multiple pregnancy 
(pathology, 
diagnostic) 
 
13  
(1 RCT) 
 
Not 
reported 
appears to be useful in 
management of twins and in 
delineating those 
complicated by FGR and 
TTTS  
Sherer et al 
366
 1998 
First trimester 
ultrasonography of multiple 
gestation  (pathology, 
diagnostic) 
 
Not 
reported 
Not 
reported 
Ultrasonography is useful in 
first trimester of multiple 
pregnancies. 
Sherer et al
367
 1998 Antepartum fetal 
intracranial haemorrhage- 
predisposing factors and 
sonography 
(pathology, 
etiology) 
Not 
reported 
Not 
reported 
Predisposing factors and 
sonographic findings 
reviewed 
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Sherer et al 
368
 1998 Prenatal ultrasonographic 
diagnosis of fetal 
intracranial tumours 
(pathology, 
diagnostic) 
Not 
reported 
Not 
reported 
Sonographic findings 
associated with different 
types of fetal tumours 
described 
Thummala et 
al
369
 
1998 Isolated single umbilical 
artery and risk of congenital 
malformations 
(pathology, 
prognostic) 
37 643338 Isolated single umbilical 
artery has a small 
association with minor renal 
abnormalities 
Yaegashi
370
 1998 Parvovirus B19 related 
hydrops fetalis following 
maternal infection 
(pathology, 
etiology) 
9 1194 Timing correlates with 
hepatic period of 
haemopoetic activity 
Brumback et 
al
371
 
1999 Adverse effects of CVS 
(pathology, 
etiology) 
31 1643655 CVS may be associated 
with an increased relative 
risk of limb defects between 
2.4 and 8.7 
Farrell et al
372
 1999 Intrapartum umbilical artery 
Doppler and adverse 
perinatal outcome 
(pathology, 
prognostic) 
8 2700 Poor predictor of adverse 
perinatal outcomes 
Pattinson et 
al
373
 
1999 Cardiotocograph for 
antepartum fetal assessment 
(pathology, diagnostic) 
4 1588 Not enough evidence exists 
to assess usefulness and 
limitations 
Sherer et al
374
 1999 First trimester nuchal 
translucency screening for 
aneuploidy 
(aneuploidy, 
diagnostic) 
Not 
reported 
Not 
reported 
Nuchal thickness >3mm 
between 10-4 weeks 
gestation may act as a 
screen for aneuploidy 
Sherer et al
375
 1999 Ultrasound to diagnose 
conditions associated with 
potential umbilical cord 
compression (pathology, 
diagnostic) 
Not 
reported 
Not 
reported 
Lack of prospective studies 
but suggests usefulness 
Wallon et al
376
 1999 Treatment of congenital 
toxoplasmosis in pregnancy 
(therapy, 
therapeutic) 
9 2077 Insufficient evidence that 
treatment reduces 
transmission 
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Yoder et al
377
 1999 Risk of trisomy 18 and 21 in 
second trimester fetus with 
isolated choroid plexus cyst 
(aneuploidy, diagnostic) 
13 246545 Likelihood of trisomy 21 
not increased. Trisomy 18 
risk 13.6 times greater- 
suggest offering karyotype 
to maternal age >36 or 
serum screen >1:3000 
Alfirevic et al
378
 1996 Biophysical profile for 
assessment in high risk 
pregnancies 
(pathology, 
diagnostic) 
4 Not 
reported 
Insufficient evidence to 
evaluate use 
Chein et al
379
 2000 Uterine artery Doppler and 
prediction of pre eclampsia 
and intrauterine growth 
restriction 
(pathology, 
diagnostic) 
27 Not 
reported 
Insufficient evidence to 
recommend as a screening 
test 
Hubinont et 
al
380
 
2000 Treatment of twin to twin 
transfusion syndrome 
(TTTS) by amniodrainage 
and septostomy 
(therapeutic) 
Not 
reported 
Not 
reported 
Severe TTTS 
amniodrainage and 
septostomy have similar 
survival to laser therapy 
Skari et al
381
 2000 Mortality factors for 
congenital diaphragmatic 
hernia 
(pathology, 
prognostic) 
51 2980 Prenatal diagnosis and 
associated abnormalities 
influence mortality rate 
Van Dyke et 
al
382
 
2000 Pharmacogenetics of 
congenital defects  
(pathology, etiology) 
Not 
reported 
Not 
reported 
Gene polymorphisms for 
specific enzymes may be 
related to susceptibility to 
fetal anomaly 
Von Dadelszen 
et al
383
 
2000 
Fall in mean arterial 
pressure and fetal growth 
restriction in pregnancy 
hypertension 
(growth, 
etiology) 
45 3773 Treatment induced falls in 
maternal blood pressure 
may affect fetal growth 
Vos et al
384
 2000 Accuracy of ultrasound 
detection of spina bifida in 
the second trimester 
(pathology, diagnostic) 
13 123872 Overall sensitivity was 
71%, specificity 100% 
Whitecar et 
al
385
 
2000 Songraphic methods to 
detect anaemia in red blood 
cell alloimmunisation 
(pathology, 
diagnostic) 
Not 
reported 
Not 
reported 
Sonographic techniques 
may reduce the number of 
invasive procedures used to 
detect anaemia 
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Woo et al
386
 2000 Single fetal death in twins 
outcome and management 
(pathology, 
prognostic) 
 
8 208 should be managed in 
tertiary centre and 
multidisciplinary approach 
required 
Allen et al
387
 2001 Management of 
monoamniotic twins 
(pathology, 
prognostic) 
49  113 Regular surveillance and 
appropriate steroids 
improves perinatal outcome 
Crowther  
et al
388
 
2001 Hospitalization and bed rest 
for multiple pregnancy 
(therapy, 
therapeutic) 
 
6 (RCT) 1400 No sound evidence to 
support the policy of routine 
hospitalization 
Divakaran et 
al
389
 
2001 Noninvasive techniques to 
detect fetal anaemia 
secondary to red blood cell 
alloimmunisation 
(pathology, 
diagnostic) 
8 362 Literature reporting non-
invasive techniques 
methodologically poor 
Murphy et al
390
 2001 Is abuse a risk factor for low 
birth weight (growth, 
etiology) 
8 6895 Abuse may be part of a 
number of factors associated 
with low birth weight 
Neal 
391
 2001 Management of RhD 
isoimmunization 
(therapy, 
therapeutic) 
Not 
reported 
Not 
reported 
All current strategies 
reviewed 
Roberts  
et al 
392
 
2001 Interventions to treat twin to 
twin transfusion syndrome 
(therapy, 
therapeutic) 
 
0 0 inadequate evidence to 
support any practice, needs 
RCT's 
 
Say et al
393
 2001 Betamimetics for suspected 
impaired fetal growth 
(growth, 
therapeutic) 
2 118 Insufficient evidence , 
larger well-designed studies 
needed 
Segal et al
394
 2001 Fetal abdominal wall 
defects and mode of 
delivery 
(pathology, 
prognostic) 
15 805 No benefit to caesarean 
delivery with abdominal 
wall defects 
Smith-Bindman 
et al
395
 
2001 Second trimester ultrasound 
to detect Down Syndrome 
(aneuploidy, 
diagnostic) 
56 132295 Isolated soft markers have 
poor sensitivity 
Spencer et al
396
 2001 Feto-maternal alloimmune 
thrombocytopenia 
(therapy, 
therapeutic) 
219 433 Intravenous 
immunoglobulin appears to 
reduce the risk of fetal 
intracranial haemorrhage 
Weissman et 
al
397
 
2001 Umbilical cord sonography 
and implications for the risk 
of fetal chromosomal 
abnormalities 
(pathology, 
diagnostic) 
Not 
recorded 
Not 
recorded 
Anatomical and Doppler 
abnormalities of the cord 
are associated with 
chromosomal aberrations 
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Westergaard et 
al
398
 
2001 Umbilical artery Doppler in 
high risk pregnancies 
(pathology, 
diagnostic) 
13 8465 Reduction in perinatal 
deaths and unnecessary 
interventions in pregnancies 
complicated by suspected 
intrauterine growth 
restriction and/or 
hypertensive disease of 
pregnancy 
Demasio et al
399
 2002 Isolated choroids plexus 
cysts in low risk women 
less than 35 years old 
(aneuploidy, 
diagnostic) 
8 106732 No evidence that isolated 
CPC increases trisomy 18 
risk in this group 
Gaytant et al
400
 2002 Congenital cytomegalovirus 
infection- Epidemiology 
and outcome 
(pathology, 
prognostic) 
Not 
reported 
Not 
reported 
Preexisting maternal 
immunity reduces but does 
not prevent transmission 
and severity in the fetus 
Patrick et al
401
 2002 Proinlammatory cytokines: 
link between 
chorioamnionitis and 
cerebral palsy 
(pathology, etiology) 
Not 
reported 
Not 
reported 
Relationship exists between 
chorioamnionitis, cytokines 
and cerebral palsy but 
duration and severity of 
exposure required is 
unknown 
Skupski et al
402
 2002 Intrapartum fetal 
stimulation tests 
(pathology, 
diagnostic) 
11 1297 May be useful to rule out 
fetal acidaemia but caution 
advised 
Skupski et al
403
 2002 Effect of treatment of Twin-
twin transfusion syndrome 
on the decision to delivery 
interval 
(therapy, 
prognostic) 
 
 
8 140 No difference in decision to 
delivery interval or survival 
for treatment versus 
expectant management. 
Small sample size 
Su et al
404
 2002 Diagnosis and management 
of monoamniotic twins 
(pathology, 
therapeutic) 
 
Not 
reported 
Not 
reported 
Optimal monitoring, timing 
and mode of delivery is 
controversial 
Wu 
405
 2002 Chorioamnionitis and 
cerebral palsy 
(pathology, etiology) 
19 Not 
reported 
Chorioamnionitis is a risk 
factor for cerebral palsy and 
cystic periventricular 
leucomalacia 
Alfirevic et al
406
 2003 Amniocentesis and CVS 
association with adverse 
outcome 
(pathology, 
etiology) 
14 Not 
stated 
Second trimester 
amniocentesis safer than 
CVS. Earlier CVS safer 
than early amniocentesis. 
 
Clark et al
407
 2003 Prenatal bladder drainage 
and fetal lower urinary tract 
obstruction 
(therapy,therapeutic) 
23 342 Limited available evidence 
suggests drainage improves 
outcome in poor prognosis 
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Dodd et al
408
 2003 Elective delivery for twins 
from 37 weeks gestation 
(pathology, 
therapeutic) 
 
1(RCT)  72 insufficient data to support 
the practice 
 
Dodd et al 
409
 2003 multifetal reduction for 
twins and higher order 
pregnancies  
( therapeutic) 
11 Not 
reported 
pregnancy reduction to 
twins improves outcome 
 
Gutierrez-
Alvarez
410
 
2003 Use of anticonvulsant drugs 
in pregnancy and 
malformations in the 
newborn 
(pathology, 
etiology) 
14 436399 Anticonvulsants increase 
risk of major malformations 
by 2-to3-fold 
Hogle et al
411
 2003 Caesarean delivery for 
twins 
(pathology, 
therapeutic) 
4 1932 no evidence to support 
planned CS, may reduce the 
risk of low apgar              
(particularly if 1
st
 twin is 
breech) 
Makrydimas et 
al
412
 
2003 First trimester nuchal 
translucency and subsequent 
cardiac defects 
(pathology, 
prognostic) 
8 58492 Nuchal translucency 
screening modestly efficient 
for detecting cardiac defects 
Merialdi et al
413
 2003 Nutritional interventions for 
prevention or treatment of 
impaired fetal growth 
(growth, 
therapy) 
65 Not 
reported 
Balanced protein energy 
supplementation reduced 
the risk of SGA as did 
calcium supplementation  
Neilson
414
 2003 Biochemical tests of 
placental function for 
assessment of high risk 
pregnancy 
(pathology, prognostic) 
1 622 Insufficient evidence to 
recommend practice 
Nordeng et al
415
 2003 Risk of anomalies with 
maternal antipsychotic 
medication 
(pathology, etiology) 
Not 
reported 
Not 
reported 
Third trimester usage 
increases extrapyramidal 
side effects in the newborn. 
First generation drugs do 
not appear to be teratogenic 
Ray et al
416
 2003 B12 deficiency and risk of 
neural tube defects 
(pathology, 
etiology) 
17 Not 
reported 
Moderate association 
between low maternal B12 
and neural tube defects but 
better studies needed 
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Rowe
417
 2003 Social and ethnic 
inequalities in offer and 
uptake of prenatal screening 
(growth, etiology) 
20 Not 
recorded 
Ethnic inequalities exist in 
offer and uptake of 
screening 
Say et al
418
 2003 Hormones for suspected 
impaired fetal growth 
(growth, therapeutic) 
0 0 Insufficient evidence to 
recommend oestrogen for 
suspected impaired fetal 
growth 
Say et al
419
 2003 Maternal nutrient 
supplementation for 
suspected impaired fetal 
growth (growth, 
therapeutic) 
3 121 Not enough evidence to 
evaluate 
Say et al
420
 2003 Maternal oxygen therapy 
for suspected impaired fetal 
growth 
(growth, therapeutic) 
3 94 Insufficient evidence exists 
to support practice 
Sotiriadis et 
al
421
 
2003 Intracardiac echogenic foci 
and Down syndrome risk 
(aneuploidy,diagnostic) 
11 51831 Intracardiac echogenic foci 
increase the down syndrome 
risk by 5 to 7-fold 
Tan et al
422
 
  
2003 minimally invasive 
treatment modalities for 
acardiac twins (therapy, 
therapeutic) 
32 74 no difference in outcome 
b/w cord occlusion vs 
intrafetal ablation, ablation - 
simpler , safer, more 
effective 
Helmerhorst et 
al
423
 
2004 perinatal outcome of 
singletons and twins in 
assisted conception 
(pathology, 
prognostic) 
 
25 10078 40% less PNM for twins, no 
difference in other outcome 
Maymon et al
424
 2004 Pregnancy outcome of 
euploid fetuses with 
increased nuchal 
translucency 
(pathology, 
prognostic) 
11 2128 70-90% of fetuses had 
normal outcomes 
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Olesen et al
425
 2004 Decreased fetal movements: 
assessment and 
management 
(pathology, 
prognostic) 
Not 
reported 
Not  
reported 
insufficient evidence to 
guide management 
Wilson et al
426
 2004 Congenital abdominal wall 
defects (pathology, 
prognosis) 
Not 
reported 
Not 
reported 
Gastroschisis and 
omphalocoele are common 
abdominal wall defects with 
significant morbidity and 
mortality 
Fox et al
427
 2005 Contemporary treatments 
for twin to twin transfusion 
syndrome. 
(therapy, 
therapeutic) 
4 
(1 RCT) 
448 Laser photocoagulation 
seems to be more effective 
with reduced perinatal 
morbidity and mortality. 
RCT=randomised controlled trial 
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Appendix 17. Examples of Numbers of women Needed to be Treated (NNTs) with 
progestational agents to prevent one case of various outcomes individualised 
according to baseline risks  
Outcome Historical risk factor Baseline 
risk of 
the 
outcome 
(%) 
 
Odds ratio (95% 
CI) 
Number needed 
to be treated 
(95% CI) 
 
Delivery 
before 37 
weeks 
 
Any previous preterm delivery 
 
 
Previous preterm delivery between 23 
and 27 weeks 
 
Previous preterm delivery between 28 
and 34 weeks 
 
Previous preterm delivery between 35 
and 36 weeks 
 
Previous 2 preterm deliveries 
 
Transvaginal scan cervical length*  
<=15mm 
<=25mm 
 
 
22
428
 
 
 
27
428
 
 
 
24
428
 
 
 
21
428
 
 
 
40 
 
 
 
64
429
 
50
429
 
 
 
0.42 (0.31 - 0.57) 
 
9 (7 - 12) 
 
 
7 (6 - 10) 
 
 
8 (7 – 11) 
 
 
9 (7 – 13) 
 
 
5 (4 -7 ) 
 
 
 
5 (4 – 7) 
5 (4 – 7) 
 
Delivery 
before 34 
weeks 
 
Any previous preterm delivery 
 
Previous preterm delivery between 23 
and 27 weeks 
 
Previous preterm delivery between 28 
and 34 weeks 
 
Previous preterm delivery between 35 
and 36 weeks 
 
Transvaginal scan cervical length*  
<=15mm 
<=25mm 
 
  
5
428
 
 
20
428
 
 
 
14
428
 
 
 
12
428
 
 
 
 
 
48
429
 
32
429
 
 
0.51 (0.34 – 0.77) 
 
42 (31-90) 
 
12 (8 – 26) 
 
 
16 (11 – 35) 
 
 
17 (12 – 37) 
 
 
 
 
6 (4 – 15) 
8 (5 – 19) 
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Appendix 18. Clinical characteristics of studies evaluating the lamotrigine dose 
management based on serum levels or clinical features only 
Author Year         Quality Population Intervention Outcome 
Number 
of women  
Inclusion 
Criteria 
Exclusion 
criteria 
Petrenaite 
2005 
Retrospective 
cohort  
No blinding  
Appropriate 
population 
Adequate 
description of 
the intervention  
Adequate 
follow up 
11  Pregnant 
women on 
LTG 
monotherapy   
Not known Management based 
on serum levels  
The percentage 
difference between 
LTG plasma 
concentration 
(mmol/l) /LTG dose 
(mg) ratio 
preconception and 
in each trimester 
and postpartum was 
calculated to 
increase the dose of 
LTG 
Seizure 
deterioration 
from seizure 
diaries  
Öhman 
2008 
Prospective  
Non randomised  
No blinding  
Appropriate 
population 
Adequate 
description of 
intervention  
Adequate follow 
up  
15  
 
Pregnant women  
with epilepsy on 
LTG monotherapy 
or polytherapy in 
combination with 
other AEDs 
(Levetiracetam, 
Clonazepam and 
topiramate).  
Not 
specified  
The LTG dose was 
not increased on LTG 
levels alone but 
increased if women 
had seizures. 
 
The baseline level 
was measured each 
trimester and one 
month after delivery.  
Reference group 
levels were taken 
from those on LTG 
monotherapy.  The 
dose plasma 
concentration ratios 
were then calculated.  
 
Dose/plasma 
concentrations 
for LTG and 
mean 2-N-
GLUC/LTG 
ratios during  
different stages 
of pregnancy 
 
Pennel  
2008 
Prospective cohort  
Non randomised 
No blinding 
Appropriate 
population 
Adequate 
description of 
intervention  
Adequate follow 
up 
 
53 
women 
on LTG 
monother
apy 
 
Women who 
Pregnant women 
with epilepsy on 
LTG therapy for 
either epilepsy 
(juvenile 
myoclonic 
epilepsy, primary 
generalised 
epilepsy, 
unspecified, 
localisation-
related epilepsy 
and epilepsy 
which was unclear 
whether focal or 
generalised) or 
psychiatric 
diagnoses.  
 
Subjects 
with 
Uncontrolle
d thyroid 
disease, 
severe 
anaemia, 
ethanol or 
recreational 
drug abuse, 
renal or 
hepatic 
dysfunction, 
poor 
compliance, 
age < 17 
year, active 
suicidal 
ideations, 
progressive 
cerebral 
Management based 
on serum levels  
The Ratio to target 
concentration RTC 
was calculated (total 
LTG / target LTG).   
 
 
LTG clearance, 
seizure 
frequency, 
maternal 
postpartum 
toxicity, fetal 
outcome 
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disease, 
inability to 
keep a 
seizure 
calendar 
personally  
or by a 
caregiver 
and co-
administrati
on of 
medications 
known to 
influence 
the 
metabolism 
of LTG.  
De Haan 
et al 2004 
Retrospective 
cohort (with 1 
prospective 
subject.) 
Non randomised 
No blinding 
Appropriate 
population 
Adequate 
description of 
intervention  
Adequate follow 
up 
 
9  Pregnant women 
on  LTG 
monotherapy 
including 2 
patients with  
juvenile absence 
epilepsy, 8 with 
symptomatic or 
cryptogenic 
localisation-
related epilepsy 
and one with 
unilateral nodular 
periventricular 
heterotopia as 
aetiology of her 
epilepsy.   
Not Known Management based 
on clinical features 
2 serum LTG levels 
were taken 1 hour 
apart.  The level to 
dose 
ratioµg/ml×100/presc
ribed LTG dose (mg) 
was calculated.    The 
mean level to dose 
ratio is given for each 
trimester 
(consecutive 10 week 
period).   
 
Seizure type, 
seizure 
frequency and 
side effects.  
Seizure 
aggravation was 
reported as an 
increase of 
100%  
Tran 2002 Observational 
cohort 
Non randomised  
No blinding  
Appropriate 
population 
Adequate 
description of 
intervention  
Adequate follow 
up   
12  Pregnant women 
on LTG and 
concomitant AED.  
 Management based 
on clinical features 
The apparent 
clearance AC was 
calculated and 
compared for pre 
conception, 1
st
, 2
nd
 
and 3
rd
 trimesters and 
postpartum.  AC is 
equal to the dose 
(mg/kg/d) / level 
(mg/l).   
Increase in 
seizures.  
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Appendix 19. Rates of major congenital malformations in women exposed to 
lamotrigine (LTG) in pregnancy 
 
 
 
 
 
Study/ Registry Year Rate of major congenital malformation % (95% CI) 
 LTG monotherapy LTG polytherapy with 
valproate 
LTG polytherapy 
without valproate 
Sabers A  2004 
 
Lamotrigine Pregnancy Registry  2009 
 
Tennis P. 2002 
 
Vajda FJ. 2003 
 
North American Antiepileptic Drug 
Registry (NAAED) 2008 
 
UK Epilepsy and Pregnancy Registry 2006 
 
Cunningham M. 2005 
 
Isojarvi JI. 2005 
 
Neurodevelopmental Effects of 
Antiepileptic Drug Study (NEAD). 2006 
 
Australian Pregnancy Register. 2007 
 
Reiff-Eldridge R. 2000 
 
Meador K. 2008 
 
Vajda. 2006 
 
Swedish Medical Birth Registry 2004
 
 
European and International Registry of 
Antiepileptic Drugs in Pregnancy (EURAP) 
2008 
2 (0.1-10.7)  
 
2.4 (1.7-3.4) 
 
1.8 (0.5-5.5) 
 
7.7  
 
1.5 (1.0-2.4) 
 
 
3.2 (2.1-4.9) 
 
 
 
 
2.8 (1.8-4.4) 
 
1.0  
 
 
 
8.6 (-6.4-14.6) 
 
6.5  
 
2.9 (2.0-3.8) 
 
0 
 
4.4 
 
6.0 
6.7 (0.8-22.1 ) 
 
10.9 (6.5-17.3) 
 
 
 
10 (3.7-22.6) 
 
 
 
 
9.5 (3.1-21.4) 
 
 
9.6 (5.7-15.7) 
 
11.7 (6.6-19.5) 
 
2.9 (1.1-8.2) 
 
2.2 (1.1-4.3) 
 
 
 
4.3 (1.6-10.3) 
 
 
 
 
2.5 (1.2-4.6)  
 
 
 
 
2.7 (1.0-6.6%)  
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Population Test Outcome Final 
History Examination Investigation Refinement 
1.  pre adj eclampsia 
2.  preeclampsia 
3.  hypertens$ 
4.  pregnan$ 
5.  pre-eclampsia#.DE. 
6.  hypertension#.DE. 
7.  pregnancy#.DE. 
8.  3 or 6(hypertension) 
9.  4 OR 7(pregnancy) 
10. 8 and 9(pregnancy 
and hypertension) 
 
 
 
 
 
12. history 
13. parity 
14. multiparity or nulliparity 
15. matern$ near age 
16. (previous or prior) near eclampsia 
17. (previous or prior) near 
preeclampsia 
18. (previous or prior) near pre adj 
eclampsia 
19. multiple near pregnan$* 
20. twin$ or triplet$ or quadruplet$ 
21. symptom$ 
22. headache 
23. epigastric near pain 
24. naus$ or vomit$ 
25. race 
26. diabet$ 
27. stress 
28. lupus 
29. thrombophilia 
30. medical-history-taking#.DE. 
31. maternal-age#.DE. 
32. pregnancy-multiple#.DE. 
33. headache#.DE. 
34. signs-and-symptoms-
digestive#.DE. 
35. vision-disorders#.DE. 
36. weight gain#.DE. 
37. population-groups#.DE. 
38. diabetes-mellitus#.DE. 
39. stress-psychological#.DE. 
40. autoimmune-diseases#.DE. 
41. thrombophilia#.DE. 
43. blood adj pressure 
44. oedema or edema 
45. tendon$ near 
reflex$ 
46. hyperreflexia 
47. clonus 
48. papilledema or 
papilloedema 
49. retina$ near 
change$ 
50. oliguria 
51. symphys$ near 
fundal 
52. symphys$ near 
height 
53. cardiotocogra$ 
54. oxygen near 
saturat$ 
55. blood-pressure-
determination#.DE. 
56. edema#.DE. 
57. reflex-
abnormal#.DE. 
58. retinal-
diseases#.DE. 
59.oliguria#.DE. 
60. 
cardiotocography#.DE
. 
61.oximetry#.DE. 
 
63. serum near uric adj acid 
64. urin near analys$ 
65. urin$ 
66. maternal near (feto adj 
protein$ or fetoprotein$ or 
alphafetoprotein$) 
67. urin$ near calcium 
68. hypoalbuminemia or 
hypoalbuminaemia 
69. microalbuminuria 
70. fibronectin$ 
71. proteinuria 
72. renal adj function near  test$ 
73. liver adj function near test$ 
74. liquor near volume 
75. biophysical near profile 
76. ultraso$ 
77. antithrombin$ 
78. platelet adj count 
79. anti adj thrombin$ 
80. fibrinogen 
81. antiphospholipid$ 
82. haemoglobin 
83. uric-acid-QN.DE 
84. alpha-fetoproteins#.DE 
85. calcium-ur.DE 
86. hypoalbuminemia#.DE. 
87. fibronectins.DE. 
88. proteinuria#.DE. 
89. kidney-function-tests#.DE. 
90. liver-function-tests#.DE. 
91. ultrasonography#.DE. 
92. haematologic-tests#.DE. 
93. antithrombin-III.DE. 
94. fibrinogen#.DE. 
95. antibodies-
antiphospholipid#.DE. 
96. diagnostic-imaging#.DE. 
99.  complicat$ 
100. (renal or kidney$) near (disease$ or complicat$) 
101. (hepatic or liver$) near (disease$ or complicat$) 
102. death or mortality 
103. morbidity 
104. eclampsia 
105. (pulmonary or lung) near (complicat$ or disease$) 
106. thromboembolism 
107. pulmonary near(oedema or edema) 
108. ventilat$ 
109. stroke 
110. uter$5 near haemorrhage 
111. abruption 
112. (heart or cardiac) near arrest$ 
113. (psychiatric or mental) near (illness$ or  complication$1 
or disorder) 
114. hospitali$ 
115. hypox$ near isch$ 
116. (development$ or learning) near (disorder$ or difficult$) 
117. pregnancy-complications#.DE. 
118. kidney-diseases#.DE. 
119. renal-dialysis# 
120. liver-diseases#.DE. 
121. death# 
122. eclampsia# 
123. pulmonary-embolism.DE. 
124. respiration-artificial# 
125. cerebrovascular-disorders#.DE. 
126. brain-edema.DE. 
127. intracranial-hypertension#.DE. 
128. uterine-haemorrhage.DE. 
129. abruption-placentae#.DE. 
130. heart-diseases# 
131. mood-disorders#.DE. 
132. hospitalization# 
133. infant-newborn-diseases# 
134. respiratory-distress-syndrome-newborn.DE. 
135. mental-disorders-diagnosed-in-childhood#.DE. 
137. 11 and 98 and 
136 
(Captures 
Population and Test 
and Outcome) 
138. animal=yes 
139. human=yes 
140. 138 not 139 
141. 137 not 140 
142. PT= comment 
or PT= letter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. 1 OR 2 OR 5 OR 
10 
(Captures Population) 
42. OR/12-41 
(Captures history) 
 
62. or/43-61 
(Captures 
examination) 
 
97. or/63-96 
(Captures investigation) 
136. or/99-135 
(Captures Outcome) 
143. 141 not 142 
Final citation set 
(animal only 
studies, comments 
and letters 
excluded) 
98. 42 or 62 or 97 
(Captures Test) 
Appendix 20: Search term combinations for identification of studies predicting complications of pre eclampsia 
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Appendix 21. Study characteristics of the trials included in the systematic review of accuracy of proteinuria in 
predicting complications in women with pre-eclampsia 
Study Population Test Outcome 
Study(Year) 
Language 
 
Quality  Number 
of 
patients 
Inclusion criteria Exclusion 
criteria 
Any 
intervention 
Gestation 
of testing 
Frequency of 
testing 
Cut off 
level 
 
Newman 
(2002) 
English 
Cross-
sectional 
Not blind 
Consecutive 
Retrospective 
Test not 
described 
 
 
209 Pre-eclampsia 
(ACOG definition) 
and chronic 
hypertension without 
proteinuria early in 
pregnancy 
Multiple 
pregnancy, 
renal disease 
Delivery if 
BP>=160/110, 
HELLP 
syndrome or 
fetal distress 
Not 
Known 
Within 48 
hours of 
admission 
Freq?? 
>=5g/24h 
>=10g/24h 
Eclampsia 
Severe hypertension 
5’Apgar<7 
HELLP syndrome 
Neonatal death 
NICU admission 
Delivery<32w 
RDS 
IVH 
NEC 
 
Buchbinder 
(2002) English 
Cross-
sectional 
Not Blind 
Prospective 
Test not 
described 
Arbitrary 
107 Singletons, previous 
H/O pre-eclampsia, 
BP≥140/90 on 2 
occasions 4 hours 
apart or 1 
DBP>=110 mm Hg, 
proteinuria>=300mg/
24h or 2 dipstick 
>=2+ (100mg/dl) 4h 
apart with no 
evidence of UTI  
Multiple 
pregnancy, DM, 
chronic HT, 
baseline 
proteinuria  
Low dose 
aspirin 
Not 
Known 
Frequency 
not known 
5g/24h Preterm delivery 
(delivery <37 weeks) 
Fetal death 
Neonatal death 
Abruptio placentae 
(Antepartum 
haemorrhage+uterine 
tenderness+placental 
examination) 
NICU admission 
IVH 
RDS 
Small for gestational age 
(Brenner table) 
RA Odegaard 
(2000) 
Cross-
sectional 
307 Increase in DBP of 
25mm Hg to at least 
Multiple 
pregnancy, 
Not available Not 
Known 
NA 2+ 
3+ (500 
Small for gestational age 
( 2 SD below EFW  or 
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English Not blind 
Retrospective 
Enrolment not 
described 
Test 
described 
90 mm Hg and 
proteinuria after 20w 
Unknown GA mg/24h) >24%lower than expected 
BWt or 840g reduction in 
B Wt for term infant) 
Schiff  
(1996) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Enrolment not 
described 
Test   not 
described 
66 Severe pre-eclampsia 
(BP>140/90 and 
proteinuria 
>=300mg/24h and 
hyperuricemia ua 
>5mg/dl and one of 
following- 
SBP>=160 or 
DBP>=110, 
proteinuria 
>=5g/24h, AST >72 
U/L) between 26 and 
32 w 
Chronic HT Delivery if 
thrombocytop
enia 
(<100,000/ 
ml), 
uncontrolled 
HT or 
persistent 
symptoms 
Between 
26 and 
32 
weeks 
Two tests 4 
or more 
days apart 
after 
admission 
Increase in 24h 
prot  by  >=2g 
HELLP 
CS for fetal distress 
Abruption 
Eclampsia 
Stillbirth 
5’ Apgar <=6 
 
Von Dadelzen 
(2004) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Consecutive 
enrolment 
Test 
described 
 
594 Women admitted 
with at least 2 of the 
following  
Hypertension 
(Systolic BP >=140 
and/or DBP>=90 
MM Hg 2 readings 4 
hours apart) after 20 
weeks 
Proteinuria 
(>=0.3g/day or >=2+ 
dipstick) after 20 
weeks 
HELLP syndrome 
Isolated eclamptic 
seizure without 
preceding 
hypertension or 
proteinuria 
  
Women in 
spontaneous 
labour 
Maternal 
outcome 
achieved before 
fulfilling 
eligibility 
criteria 
Not available Not 
available 
Last 
observation 
carried 
forward 
1+, 2+, 3+ ,4+ 
5+ 
Adverse maternal 
outcome 
(death or complication 
involving hepatic or 
central nervous system 
or renal or respiratory 
or hematological 
systems                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
) 
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Hall (2002) 
English 
Cross-
sectional 
Not blind 
Prospective 
Test 
described 
Not 
consecutive 
enrolment 
340 ISSHP definition of 
PE 
Singleton with early 
onset severe PE( 
>=24w, <34w) with 
heavy proteinuria 
(>=5g/24h) 
N/A Steroids 27-
33w 
MgSO4 
eclampsia or 
imminent sym 
IP 
Anti- HT to 
maintain BP at 
160/110 mm 
Hg 
Del at 34w if 
major mat or 
fetal 
complications 
24-34w Twice 
weekly 
Increase by 
2g/24h in two 
samples 
 
 
Eclampsia 
Abruption 
HELLP 
CS 
Pulmonary oedema 
ITU admission 
Ascites 
Fetal death 
Low apgar 
NNIC admission 
Taylor(1954) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Test not 
described 
Consecutive 
enrolment 
3258 Toxemia with 
previous normal BP 
observations 
Toxemia > 28w 
previous 
observations not 
known 
Vascular or 
renal disease 
Not available Not 
available 
Not 
available  
1+, 3+ Intra uterine death 
 Thurnau 
(1982) 
English 
Cross-
sectional 
Not blind 
Direction of 
data 
collection not 
available 
Not 
consecutive 
enrolment 
Test 
described 
83 Pre eclampsia 
ACOG definition 
Patients>24w 
Not available  Not available Not 
available 
Not 
available  
1+, 2+, 3+, 5g Severe pre eclampsia 
(ACOG definition) 
 
 
Martin (1999) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Not 
568 
Patients severe pre-
eclampsia (ACOG 
definition) 
 
Eclampsia Not available On 
admissio
n  
Not 
available 
2+, 3+ Significant maternal 
morbidity 
Renal, hepatic and/or 
gastrointestinal 
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consecutive 
enrolment 
Test 
described 
 
 
 
 
 
 
 
 
Paladini  1970 
Italian 
Cross-
sectional 
Not blind 
Retrospective 
Not 
consecutive 
enrolment 
Test not 
described 
 
379 Pre eclampsia 
defined as gestosis 
with systolic 
BP>140  and 
proteinuria>0.5g/l 
and oedema in 3
rd
 
trimester 
Only 1 or 2 
symptoms of 
gestosis 
Not available 3
rd
 
trimester 
Not 
available 
1g/l 
2g/l 
Perinatal death 
Fleigner 1975 Cross-
sectional 
Not blind 
Prospective 
Enrolment not 
described 
Test not 
described 
 
99 Patients with 
moderate or severe 
pre-eclampsia 
between 30 and 37 
weeks 
Multiple 
pregnancy 
Diabetes 
Stillbirth on 
admission 
Erythroblastosis 
Anti-
hypertensives 
Magnesium 
sulphate 
Anticonvulsan
ts 
Parenteral 
sedation 
Diuretics 
30-37 
weeks 
Not 
available 
1-5g/l Stillbirth 
Neonatal death 
Perinatal death 
Lao 1988 Cross-
sectional 
Not blind 
Prospective 
Consecutive 
enrolment  
Test 
described 
 
87 Nulliparous patients 
with pre-eclampsia 
(ACOG definition of 
patients with BP 
>=140/90mm Hg) 
Multiple 
pregnancy 
Diabetes 
Untreated 
urinary 
infection 
Renal disease 
Chronic 
hypertension 
Systemic Lupus 
Erythematosis 
(SLE) 
Anti-
hypertensives 
if DBP>=100 
mm Hg on 2 
or more 
occasions 
Not 
available 
4 times a 
day 
1+ Caesarean section 
Small for gestational age 
Neonatal Intensive Care 
Unit admission 
5’ Apgar<4 
Weenik 1983 Cross-
sectional 
57 Pre-eclamptics with 
DBP>=100 mm Hg 
Not available Not available Not 
available 
Not 
available 
0.5, 1,2,3,4,5 
g/24h 
Perinatal death or 
Neonatal Intensive Care 
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Not blind 
Direction of 
data 
collection not 
available 
Enrolment not 
described 
Test 
described 
 
or 20 mmHg above 
non pregnant levels 
Unit admission 
 
Chan 2005 Cross-
sectional 
Not blind 
Retrospective 
Consecutive 
enrolment  
Test 
described 
321 Pre-eclampsia 
(ISSHP definition) 
Hypertension 
(Systolic BP >=140 
and/or DBP>=90 
mm Hg) and 
Proteinuria 
(>=0.3g/24 hrs or a 
spot urine 
protein/creatinine 
ratio>=30 mg/mmol) 
after 20 weeks 
 
Pre-eclampsia 
superimposed 
on pre-existing 
hypertension, 
unavailable spot 
urine results, 
booking 
BP>=140/90 
mm Hg, 
postpartum 
diagnosis  
Not available Not 
Known 
Not Known Spot urine 
protein/ 
creatinine ratio 
500 mg/mmol 
900 mg/mmol 
Adverse maternal 
outcome 
Adverse fetal outcome 
Perinatal mortality 
 
Waugh 2005 Cross-
sectional 
Not blind 
Prospective 
Consecutive 
enrolment  
Test 
described 
195 Sustained diastolic 
BP>=90mmHg, or a 
systolic BP of >=140 
mmHg on 2 
occasions or a single 
diastolic BP of >110 
mmHg or systolic 
BP>160 mm Hg in 
women over 20 wks 
gestation 
Less than 20 
weeks gestation 
Not available Not 
Known 
Not Known 0.3g /24 h 
0.5 g/24 h 
(Benzethonium 
chloride assay) 
Small for gestational age 
Furukawa 2006 Cross-
sectional 
Not blind 
Retrospective 
Not 
Consecutive 
79 Pre-eclampsia as 
defined by National 
High Blood Pressure 
Program 
Multiple 
pregnancy, 
known renal 
disease, diabetes 
mellitus  
Pregnancy 
terminated in 
persistent 
severe 
hypertension 
(BP>=160/110 
At 
delivery 
Not Known 3+ Small for gestational age 
Non reassuring fetal heart 
rate 
Cord blood gas 
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enrolment  
Test 
described 
mm Hg), 
oliguria (<500 
ml/day), low 
platelets 
(<100,000/cu 
mm), HELLP 
syndrome, 
pulmonary 
oedema, 
eclampsia, non 
reassuring fetal 
heart rate 
patterns, 
persistent 
biophysical 
scoring<=4, 
growth arrest 
of head 
circumference 
of more than 2 
weeks in 
IUGR. 
IV 
hydrallazine in 
persistent 
severe 
hypertension. 
Magnesium 
sulphate for 
seizure 
prophylaxis 
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Appendix 22. Study characteristics of the trials included in the systematic review of accuracy of uric acid in predicting 
complications in women with pre-eclampsia 
Study Population Test Outcome 
Study 
(Year) 
Language 
 
Quality  Number 
of 
patients 
Inclusion criteria Exclusion 
criteria 
Any 
intervention 
Gestation 
of testing 
Frequency 
of testing 
Name of 
Test 
Cut off 
level 
Maternal  Fetal 
Yassaee  
(2003) 
 
Cohort 
Not blind 
Can‟t tell 
enrolment 
Can‟t tell 
direction of 
data collection 
Test not 
described 
 
 
103 Severe pre-eclampsia Not available Not available Not 
available 
Not 
available 
Uric acid 
6mg/dl 
Eclampsia 
Maternal 
death 
Caesarean 
section 
  
Intra uterine 
death 
Intra uterine 
growth 
restriction 
Williams 
(2002) 
English 
Cross-
sectional 
Not Blind 
Prospective 
Test described 
Can‟t tell 
enrolment  
 
194 BP≥140/90 after 
20weeks and 
proteinuria≥1+ or 
300mg/24hr  
Diabetes 
Chronic 
Hypertension 
Multiple 
pregnancy 
Not known Not 
Known 
On 
admission 
Frequency 
not known 
Uric acid 
450micmol/l 
(7.6 mg/dl) 
540micmol/l 
(9mg/dl) 
HELLP 
syndrome 
(SGOT>40IU/
L,LDH>600I
U/L,haemolysi
s on blood 
film, platelets 
≤150 x109/L) 
 
 
Severe 
Hypertension 
(Systolic 
BP≥160 
and/or 
diastolic 
Small for 
gestational age 
(Birth weight 
<10
th
 centile) 
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BP≥110 on 2 
occasions) 
D‟Anna 
(2000) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Can‟t tell 
enrolment 
Test described 
94 National Working 
Group on HT in 
pregnancy criteria for 
PE 
Chronic 
medical 
disease 
Not available Within 24 
hrs before 
delivery 
NA Uric acid  
339 
micmol/l 
(5.7mg/dl) 
 Intra uterine 
growth 
restriction 
Martin 
Jr(1998) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Not 
consecutive 
enrolment 
Test   not 
described 
 
568 Severe pre-eclampsia Eclampsia Not available On 
admission  
Single Uric acid 
6.5mg/dl 
7.8mg/dl 
Significant 
maternal 
morbidity 
Renal, hepatic 
and/or 
gastrointestina
l 
 
Brown 
(1996) 
English 
Cross-
sectional 
Not blind 
Prospective 
data collection 
Consecutive 
enrolment 
Test not 
described 
 
825 Australasian Society 
for the study of 
Hypertension in 
Pregnancy 
 Anti-
hypertensives 
Anti 
convulsants 
Delivery 
before 38 
weeks for fetal 
compromise, 
inability to 
control BP,  
persistent 
neurological 
disturbances, 
increasing 
liver enzymes 
or decreasing 
platelets 
Not 
available 
Twice 
weekly 
Uric acid 
350micmol/l 
(6mg/dl) 
Severe 
Hypertension 
Systolic 
BP>=170 mm 
Hg or 
Diastolic 
BP>=110 
mmHg 
 
 
 
  
Small for 
gestational age 
Birth weight 
<=10
th
 centile 
corrected for sex 
 
Perinatal 
mortality 
Stillbirths and 
neonatal deaths 
per 1000 
hypertensive 
pregnancies 
Odendaal 
(1996) 
English 
Cross-
sectional 
Not blind 
229 Severe pre eclampsia 
 
Not available Magnesium 
sulphate after 
admission 
On 
admission  
until 
Twice 
weekly 
Peak value 
Uric acid 
5.2mmol/l 
(8.7mg/dl) 
Caesarean 
section 
 
Small for 
gestational age 
(Tygerberg 
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Prospective 
Can‟t tell 
enrolment 
Test described 
 
 
 
 
Anti-
hypertensives 
Delivery at 34 
weeks or 
earlier  if 
maternal or 
fetal distress 
 
delivery for analysis Preterm 
delivery 
hospital growth 
curves) 
Intra uterine 
death 
Neonatal death 
Perinatal 
mortality 
(within 7days) 
Shah 
(1996) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Consecutive 
enrolment 
Test 
description not 
adequate 
 
271 Pre eclampsia (de 
novo development of 
hypertensive disorder 
in 2
nd
 half of 
pregnancy). It 
includes proteinuric 
pre eclampsia 
>300mg/dl in 24h 
or≥1+  6 hours apart 
AND non proteinuric 
pre eclampsia with 
increased BP in 2
nd
 
half of pregnancy and 
elevated uric acid or 
other systemic 
involvement markers.  
Not available No surfactant 
used in this 
period, 
Anti 
hypertensive if 
severe pre 
eclampsia  
Not 
available  
Not 
available  
Uric acid 
6mg/dl 
Caesarean 
section 
Adverse 
perinatal 
outcome that 
includes  
1.perinatal death 
2.perinatal 
morbidity of 
prematurity due 
to hypertensive 
disease, 
moderate or 
severe hyaline 
membrane 
disease, Patent 
ductus 
arteriosus, Intra 
ventricular 
haemorrhage 
3. perinatal 
morbidity due to 
uteroplacental 
vasculopathy, 
Intra uterine 
growth 
restriction, 
abruption, fetal 
distress  
Peralta 
Pedero 
(2004) 
Spanish 
Cross-
sectional 
Not blind to 
outcome 
216 BP≥140/90 after 20 
weeks and ≥1+ 
proteinuria 
 
Liver and 
renal 
insufficiency, 
Diabetes 
Not available From 
admission 
to 
delivery 
Multiple Uric acid 
3mg/dl 
Severe 
hypertension 
BP≥160/110 
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Can‟t tell 
enrolment 
Test not 
described 
mellitus 
Voto 
(1988) 
English 
Cross-
sectional 
Not blind 
Can‟t tell 
enrolment 
Test not 
described 
125 BP≥140/90 in 3rd 
trimester 
Mild pre-eclampsia 
BP          140-159/90-
99 
Severe pre-eclampsia 
BP ≥160/100 
Not available Not available  Not 
available  
Maximum 
concentrati
on of 
uricemia 
Uric acid 
6mg/dl 
Severe 
Hypertension 
 BP≥160/100 
 
Intra uterine 
growth 
restriction 
Sagen 
(1984) 
English 
Cross-
sectional 
Not blind 
Prospective 
Test described 
Not 
consecutive 
enrolment 
72(actual 
recruitm
ent) 
52 
(analysa
ble data) 
Severe pre-eclampsia 
BP≥160/110 and 
proteinuria≥5g/24hr 
Uncertain 
dates, diuretic 
treatment, 
twins, 
congenital 
anomalies, 
bloods taken 
after fetal 
death 
All patients 
had protein 
rich food, bed 
rest, 
hydralazine 
derivatives 
From 
admission 
to 
delivery 
Twice 
weekly 
Interval 
between 
last test 
and 
delivery 
was 1-3 
days 
Uric acid 
Urate 
increment 
≥50 
micmol/l in 
last 3days 
prior to 
delivery, 
≥350mmol/l 
(6mg/dl) 
 Perinatal 
distress 
(perinatal death, 
apgar,7 at 1‟ or 
5‟, later 
development of 
neonatal 
asphyxia, 
Respiratory 
distress 
syndrome, 
hypoglycemia or 
fits) 
 
Small for 
gestational age 
(<10
th
centile) 
Liedholm 
(1984) 
English 
Cross-
sectional 
Not blind 
Retrospective 
Test described 
Consecutive 
enrolment 
26 BP≥140/90 after 
20weeks, 
proteinuria≥=1+ on 
two or more 
occasions 
Urate values 
not available, 
patients on 
treatment 
other than 
Beta blockers 
or 
hydralazine, 
Diabetes 
Use of beta 
blockers or 
hydralazine 
Not 
available 
Not 
available  
Uric acid 
350micmol/l 
(6mg/dl) 
Caesarean 
section 
 
Use of any 1 
anti-
hypertensive, 
use of 2 anti-
hpertensives 
(hydralazine 
added on to 
Beta blocker) 
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Varma 
(1982) 
English 
Cross-
sectional 
Not blind 
Prospective 
Not 
consecutive 
enrolment 
Test described 
200 BP≥140/90 after 
24weeks on two or 
more occasions 24 
hours apart. 
Mild Pre eclampsia 
BP<160/100without 
albuminuria 
Severe Pre-eclampsia 
BP≥160/100,with 
albuminuria 
Not available  Early delivery 
if serious 
maternal risk 
or impending 
fetal death. 
All patients 
delivered 
between 38 
and 40weeks 
 
On 
diagnosis 
of pre-
eclampsia 
Last test 
performed 
24-48 
hours 
before 
delivery 
Weekly Uric acid 
≥60micmol/
l on ≥2 
consecutive 
samples or 
max ≥330 
micmol/l 
(5.5mg/dl) 
 Intra uterine 
growth 
restriction 
(Birth Weight 
<10
th
 centile) 
 
 Fetal distress in 
labour  
 
Neonatal death 
 
Stillbirth 
Mathews 
(1980) 
English 
Cross-
sectional 
Not blind 
Prospective 
Not 
consecutive 
enrolment 
Test described 
 
 
40 Diastolic BP≥90, 
>trace protein 
Infection in 
High vaginal 
swab/Midstrea
m urine,  
< two 
consecutive  
tests before 
delivery, 
protocol 
amendment 
All patients 
had 
chlormethiazol
e qds orally 
20patients 
were rested 
20 patients 
were 
ambulatory 
 On 
admission 
Daily for 4 
days , at 
least 
maximum 
7 days 
Uric acid 
0.24mmol/l 
(4mg/dl) 
before 
34weeks 
0.36 mmol/l  
(6mg/dl) 
after 
34weeks 
 Perinatal death 
Dequiedt 
(1979) 
French 
Cross-
sectional 
Not blind 
Prospective 
data collection 
Can‟t tell 
enrolment 
Test described 
 
43 BP>=140/80 with 
proteinuria in 3
rd
 
trimester and blood 
pressure returned to 
normal post natally 
Not available Not available Not 
available 
Not 
available 
Uric acid 
300micmol/l  
(5 mg/dl) 
Caesarean 
section 
Intra uterine 
growth 
restriction  
Still birth 
 
Fadel 
(1969) 
English 
Cross-
sectional 
Not blind 
Prospective 
Test described 
Can‟t tell 
enrolment 
62 „Pre-eclamptic‟ 
patients 
BP>140/90 and/or 
proteinuria in latter 
half of pregnancy 
Not available  Not available  Within 24 
hours of 
admission 
Not 
available  
Uric acid 
4mg/dl 
6mg/dl 
Eclampsia  
Connon  Cross- 124 BP≥140/90 with Not available Not available Not Not Uric acid Severe pre-  
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(1968) 
English 
sectional 
Not blind 
Retrospective 
data collection 
Not 
consecutive 
enrolment 
Test described 
 
proteinuria available available 6mg/dl eclampsia 
Lancet 
(1956) 
English 
Cross-
sectional 
Not blind 
Can‟t tell 
enrolment 
Can‟t tell data 
collection 
Test   not 
described 
 
469 Not available Not available Not available Not 
available 
Daily in 
eclampsia 
Uric acid 
6mg/dl 
 
Severe pre-
eclampsia 
 
Eclampsia 
 
Seitchik 
(1953) 
English 
Cross-
sectional 
Not blind 
Retrospective 
data collection 
Method of 
enrolment not 
known 
Test described 
14 BP≥140/90 mm Hg Not available Not available Third 
trimester 
Not 
available 
Uric acid 
6mg/dl 
Severe pre-
eclampsia 
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Appendix 23. Study characteristics of the trials included in the systematic review of accuracy of liver function tests in 
predicting complications in women with pre-eclampsia 
Study Population Test Outcome 
Study 
(Year) 
Language 
 
Quality  Number 
of 
patients 
Inclusion criteria Exclusion 
criteria 
Any 
intervention 
Gestati
on of 
testing 
Frequen
cy of 
testing 
Name of 
Test 
Cut off 
level 
Maternal  Fetal 
Odendall 
(2000) 
English  
Casecontrol 
Retrospective 
Not 
consecutive 
patient 
enrolment 
Blinded 
Follow up 
complete 
 
 
340 Early severe pre-
eclampsia 
 Nil >28/40 Multiple Liver 
function 
LDH 350  
Abruption 
Diagnosis of 
abruption 
placenta: ≥ 
15% of the 
maternal 
surface of the 
placenta is 
covered with 
blood clots 
 
 
Audibert 
(1996) 
English 
Cohort study 
Retrospective 
Consecutive 
enrolment 
Blinding not 
known 
Follow up 
complete 
 
327 Severe pre-
eclampsia or 
HELLP syndrome 
as defined by 
ACOG 
 
Laboratory 
abnormalities 
from other 
disorders 
Magnesium 
sulphate to all 
women with 
severe pre-
eclampsia, 
glucocorticoid
s  <34/40 
Not 
specifie
d 
Not 
known 
Liver 
function 
LDH 600 
AST 70 
ALT 70 
Eclampsia 
Caesarean 
section 
Blood 
transfusion 
Disseminated 
intravascular 
coagulation 
Pleural 
effusion 
Wound 
Haematoma 
Acute renal 
failure 
Abruption 
Pulmonary 
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oedema 
Intracerebral 
haemorrhage 
Death 
 Abramovici, 
(1999) 
English 
Cross sectional 
Retrospective 
Consecutive 
Blinding not 
known 
Follow up 
complete 
 
269 Severe pre 
eclampsia as 
defined by ACOG 
 
History of 
renal, liver or 
haematologic
al 
abnormalities
, multiple 
pregnancies 
Nil 24/40-
36/40 
Not 
known 
Liver 
function 
LDH 600 
AST 70 
Caesarean 
section 
 
Intrauterine 
growth 
retardation 
Neonatal death 
Respiratory 
distress 
syndrome 
Necrotising 
enterocolitis 
grade 2-3 
Bronchopulmon
ary dysplasia 
Mechanical 
ventilation 
Intraventricular 
haemorrhage 
grade 3-4 
 
 
Haddad, 
(2000) 
English 
Case control 
Retrospective 
Can‟t tell 
enrolment 
Not blinded 
Follow up 
complete 
 
64 Severe pre 
eclampsia 
 
History of 
haematologic
al or liver 
diseases. 
Gestation 
>28 weeks at 
admission 
Intravenous 
magnesium 
sulphate 
routinely to all 
severe pre-
eclamptics 
< 28/40 Not 
known 
Liver 
function 
LDH 600 
AST 70 
Eclampsia 
Abruptio 
placentae 
Disseminated 
intravascular 
coagulation 
Ascites 
Pulmonary 
oedema 
Pleural 
effusion 
Acute renal 
failure 
Transfusion 
of blood 
products 
Neonatal death 
Respiratory 
Distress 
Syndrome 
Intraventricular 
Haemorrhage 
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Caesarean 
section 
 
Martin Jr 
(1999) 
English 
Retrospective 
Cohort 
Consecutive 
enrolment 
No blinding 
Follow up 
complete 
 
568 Severe Pre-
eclampsia with or 
without  HELLP 
syndrome 
 
Eclampsia Not specified Not 
specifie
d 
Admissi
on data 
Liver 
function 
LDH 
1000-
1400 
AST 50-
150 
ALT 30-
100 
Combined 
maternal 
adverse 
outcome 
Renal, hepatic 
and/or 
gastrointestinal 
  
 
 
 
 
 
 
 
Aali 
(2004) 
English 
 
 
 
Cross sectional 
Prospective 
Consecutive 
No blinding 
Follow up 
complete 
 
200 Pre eclampsia 
according to 
ACOG 
 Magnesium 
sulphate to all 
patients to 
prevent or 
control 
convulsions,i.v
. hydralazine 
given when 
diastolic 
BP>110 
mmHg, 
Betamethasone 
given from 24-
34 weeks 
gestation to 
accelerate lung 
maturity 
No Multiple Liver 
function 
AST 500 
ALT 300 
Eclampsia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crisp Cohort 64 Not specified   Nil No Multiple Liver Eclampsia  
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(1959) 
English 
Prospective 
Consecutive 
Follow up 
complete 
 
 function 
AST 70 
 
 
 
 
 
Borglin 
(1958) 
English 
 
 
 
 
Cohort 
Prospective 
Not blinded 
Follow up 
complete 
 
53 Symptoms of 
toxaemia or liver 
damage 
 
Evidence of 
chronic 
nephropathy 
Nil Last 
trimeste
r 
Multiple, 
weekly 
Liver 
function 
Raised 
AST and 
ALT 
Eclampsia 
 
 
 
 
 
 
 
Romero 
(1988) 
English 
Cohort 
Retrospective 
Consecutive 
enrolment 
Not blinded 
Follow up 
complete 
 
355 Pregnancy 
induced 
hypertension 
 
Mean 
Arterial 
Pressure<10
5 in 3
rd
 
trimester, 
chronic 
hypertension 
without 
superimpose
d PIH, 
multiple 
gestation, 
cholelithiasis 
and liver 
diseases 
causing 
raised SGOT 
Nil >26/40 Multiple Liver 
function 
AST 2SD 
Pulmonary 
oedema 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preterm 
delivery 
Respiratory 
distress 
syndrome 
Intrauterine 
growth 
retardation 
Fetal distress 
Neonatal death 
Apgar<7 @1 min 
Apgar<7 @5min 
 
Yucesoy 
(2005) 
English 
Cross sectional 
Retrospective 
Consecutive 
enrolment 
Not blinded 
Follow up 
complete 
 
255 Hypertensive 
disorder in 
pregnancy 
 Magnesium 
sulphate 
infusion in 
severe pre-
eclampsia to 
prevent 
convulsions,  
Nifedipine to 
control high 
blood pressure, 
>20/40 Multiple Liver 
function 
Increase 
in AST / 
ALT 
/LDH 
 
Placental 
abruption 
Acute renal 
failure 
Disseminated 
intravascular 
coagulation 
Pulmonary 
edema 
Adult 
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2 doses of 
betamethasone 
for foetal lung 
maturity in 28-
34 weeks 
gestation. 
respiratory 
distress 
syndrome 
Retinal 
detatchment 
Intracranial 
bleeding 
Maternal 
death 
 
Woldeselassi
e 
(2005) 
English 
Retrospective,
Cross 
sectional, 
Consecutive 
enrolment, 
Not blinded 
Follow up 
complete 
 
230 Pre-eclampsia  
 
 
Only 
symptomatic 
with no 
confirmed 
diagnosis 
Anti-
hypertensives 
and 
magnesium 
sulphate 
Not 
specifie
d 
Multiple Liver 
function 
ALT 60 
AST 43 
LDH 181 
Eclampsia 
Severe pre-
eclampsia 
(HELLP) 
 
 
 
 
 
 
Girling 
(1997) 
English 
Prospective 
Cross sectional 
Consecutive 
enrolment 
Not blinded 
Follow up 
complete 
 
 
 Pre eclampsia 
2 consecutive 
measurements of 
diastolic BP >=90 
mm Hg 4 or more 
hours apart or a 
single reading 
>=110 mmHg, 
with proteinuria 
>0.3g/24h or 
>=2+ on dipstick 
testing 
Liver 
pathology, 
hypertensio, 
multiple 
pregnancy 
Not specified Not 
specifie
d 
Multiple Liver 
function 
Gestation 
specific 
95% 
reference 
range 
ALT 32 
AST 30 
Bilirubin 
14 
GGT 41 
Maternal 
complication
s (medical 
complication 
due to pre 
eclampsia) 
Caesarean 
section 
Induction of 
labour 
 
 
 
Neonatal death 
Pre term 
delivery 
 
Menzies 
(2007) 
English 
Cohort 
Prospective 
Consecutive 
enrolment 
No blinding 
Adequate 
population, 
737 Pre eclampsia of 
any severity 
Inclusion criteria: 
BP 
≥140/90mmHg 
(twice  ≥ 4 hours 
apart, after 20 
Women who 
have already 
achieved any 
component 
of the 
adverse 
maternal 
Anti 
hypertensives, 
magnesium 
sulphate 
After 
20 
weeks 
Multiple LDH 600 
ALT/AST 
40/55 
Adverse 
maternal 
outcome 
(death or 
complication 
involving 
hepatic or 
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test and 
outcome 
description 
Follow up 
complete 
weeks ) and either 
proteinuria ( 
≥2+by dipstick,  ≥ 
0.3g/24h or  ≥ 30 
mg/mmol by spot 
protein:creatinine 
ratio) or 
hyperuricemia  
HELLP syndrome 
Superimposed pre 
eclampsia, defined 
as pre existing 
hypertension with 
accelerated 
hypertension, new 
proteinuria or new 
hyperuricemia. 
Exclusion criteria: 
Women who have 
already achieved 
any component of 
the adverse 
maternal outcome 
outcome central nervous 
system or renal 
or respiratory 
or 
haematological 
systems )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
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Appendix 24. Study characteristics of the trials included in the systematic review of accuracy of symptoms in 
predicting complications in women with pre-eclampsia 
Study Population Test Outcome 
Study 
(Year) 
Language 
 
Quality  Number 
of 
patients 
Inclusion criteria Exclusion 
criteria 
Any 
intervention 
Gestation 
of testing 
Frequency 
of testing 
Name of Test 
Cut off level 
Maternal   
Harms et al 
(1991)
 
Cohort 
Retrospective 
Enrolment not 
described 
Not blind 
Test method 
not described 
Follow up 
complete 
201 Preeclampsia defined as 
2 BP (≥140/90mmHg) 
readings within 6 hours 
of each other 
No paper  Not known Not known Not known Symptoms 
Headaches, 
Visual 
Disturbances, 
Epigastric 
pain Nausea 
and vomiting 
HELLP  
Witlin 
(1999) 
Cohort 
Prospective 
Consecutive 
enrolment 
No blinding 
Follow up 
complete 
Adequate 
population, test 
and outcome 
description 
445 Severe preeclampsia and 
eclampsia according to 
ACOG 
 
Women with 
indication for 
immediate 
delivery 
(nonreassuring 
fetal status, 
vaginal 
bleeding, 
eclampsia, 
uncontrolled 
severe 
hypertension, 
pulmonary 
edema, 
compromised 
renal function, 
persistent 
Antihypertensive 
therapy if BP is 
>160/100 
Magnesium 
sulphate and 
Corticosteroid to 
those who are for 
conservative 
management 
(<34 weeks) 
Delivery for 
HELLP 
syndrome or 
gestation >34 
weeks 
Not known Not known Symptoms 
nausea and 
vomiting, 
epigastric 
pain, 
headache, 
visual 
symptoms  
Abruption 
placentae 
eclampsia 
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severe 
headache or 
visual changes, 
platelet count 
<100,000/mm, 
or aspartate 
aminotransferas
e or alanine 
aminotransferas
e value more 
than twice the 
upper limit of 
normal, with 
epigastric pain 
or right upper-
quadrant 
tenderness) 
Martin 
(1999) 
Case-control 
Retrospective 
Consecutive 
No blinding 
Follow up not 
known 
Adequate 
population, test 
and outcome 
description 
777 Severe preeclampsia and 
eclampsia with or 
without HELLP 
syndrome 
 Not known Not known Not known  cardiopulmonary 
hematologic and 
coagulation central 
nervous system 
and visual renal 
hepatic and 
gastrointestinal 
infection 
preeclampsia fluid-
related 
 
Ben Salem 
(2003) 
Case-control 
Retrospective 
Matched 
No blinding 
Follow up not 
known 
Adequate 
population, test 
and outcome 
description 
120 Preeclampsia and 
eclampsia according to 
WHO criteria 
 
Women with 
other causes of 
convulsions, 
epilepsy, 
meningitis, 
cerebral 
haemorrhage 
and cerebral 
tumours 
Not known Not known Not known Symptoms 
headache, 
visual 
symptoms  
Eclamptic 
convulsions 
 
 
 
 
 
 
 
 
 
 
Black Case-control 100 Mild and severe  Not known Not known Not known Symptoms Severity of  
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(2005) Prospective 
Consecutive 
No blinding 
Follow up not 
known 
Adequate 
population, test 
and outcome 
description 
preeclampsia Vertigo, 
epigastric 
pain, 
headache, 
blurred vision, 
scotoma, 
inability to 
concentrate 
preeclampsia 
Menzies 
(2007) 
Cohort 
Prospective 
Consecutive 
enrolment 
No blinding 
Adequate 
population, test 
and outcome 
description 
Follow up 
complete 
737 Pre eclampsia of any 
severity 
Inclusion criteria: BP 
≥140/90mmHg (twice  ≥ 
4 hours apart, after 20 
weeks ) and either 
proteinuria ( ≥2+by 
dipstick,  ≥ 0.3g/24h or  
≥ 30 mg/mmol by spot 
protein:creatinine ratio) 
or hyperuricemia  
HELLP syndrome 
Superimposed pre 
eclampsia, defined as 
pre existing 
hypertension with 
accelerated 
hypertension, new 
proteinuria or new 
hyperuricemia. 
 
Women who 
have already 
achieved any 
component of 
the adverse 
maternal 
outcome 
Anti 
hypertensives, 
magnesium 
sulphate 
After 20 
weeks 
Multiple Symptoms 
Frontal 
headache 
Visual 
disturbances 
Persistent 
right upper 
quadrant pain 
Severe nausea 
and vomiting 
Adverse maternal 
outcome (death or 
complication 
involving hepatic 
or central nervous 
system or renal or 
respiratory or 
hematological 
systems                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
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Appendix 25. Study characteristics of the trials included in the systematic review of accuracy of blood pressure in 
predicting complications in women with pre-eclampsia  
Study Population Test Outcome 
Study 
(Year) 
Language 
 
Quality  Number 
of 
patients 
Inclusion criteria Exclusion criteria Any 
intervention 
Gestation 
of testing 
Frequency 
of testing 
Name of Test 
Cut off level 
Maternal  Fetal 
Dukler D 
(2001) 
English 
Retrospective 
Cohort 
Not blinded  
Consecutive 
enrolment 
Prospective data 
collection 
Patient sample 
defined 
Test described 
 
 
380 Pre-eclampsia 
[Systolic BP >140 & 
Diastolic BP >90 mm Hg 
and at least + of 
proteinuria on 2 
occasions in the second 
trimester] 
Lack of prenatal 
care 
 
Missing data 
Induction of 
labour 
Caesarean 
section 
Second 
trimester  
Multiple BP 
Mild 
hypertension= 
Diastolic BP 
between 90-
110 
Severe 
hypertension= 
Diastolic BP 
>110 
 
  
Spontaneous 
preterm labour 
and delivery 
 
Xiong Xu 
(1999) 
English 
Retrospective 
Cohort 
Not Blind 
Consecutive 
enrolment 
Retrospective 
Patient sample 
defined 
Test described 
 
428 Pre-eclampsia 
[Systolic BP >130 & 
Diastolic BP >90 mm Hg 
and proteinuria (at least 
1+ and +2 in 2 dipstick 
samples or > 0.3g/ 24 
hours urine collection of 
on 2 occasions 6 hours 
apart] 
Chronic cardio-
vascular disease, 
Chronic 
hypertension or 
history of 
hypertension, 
Chronic/ history of 
renal disease, 
Diabetes, 
Multiple gestation 
Not stated 
 
Third 
trimester  
Mutiple  BP 
Mild 
preeclampsia
= 
>130/90 and 
<160/110 mm 
Hg with 
Proteinuria +1 
and +2 
Severe 
hypertension= 
Diastolic BP 
≥160/110 mm 
Hg and or 
Proteinuria of 
>2+ on 
dipstick or 5g 
Caesarean 
section 
Instrumental 
delivery 
 
 
Preterm 
delivery 
Low birth-
weight baby 
Intrauterine 
growth 
restriction 
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in 24-hours 
urine. 
Witlin  
(1999) 
English 
 
Prospective 
Cohort 
Consecutive 
enrollment 
Not blind 
Patient sample 
described  
445 Severe Preeclampsia and 
eclampsia, as per ACOG 
definition: 
Not stated Antihypertensiv
e therapy if BP 
is >160/100 
Magnesium 
sulphate and 
Corticosteroid to 
those who are 
for conservative 
management 
(<34 weeks) 
Delivery for 
HELLP 
syndrome or 
gestation >34 
weeks 
  BP 
Mean arterial 
pressure: 
≤105 mm Hg 
>120 mm Hg 
>140 mm Hg 
>160 mm Hg 
Placental 
abruption 
Eclampsia 
 
 
 
Brown  
(1996) 
English 
Cohort 
Not blind 
Prospective data 
collection 
Arbitrary 
enrolment 
Test not 
described 
 
825 Pre-eclampsia: 
Australian Society 
classification of 
Hypertension in 
Pregnancy 
[BP >140/90 mm Hg on 
repeated occasion and 
proteinuria ≥300 mg/24 
hours] 
Not stated Laboratory tests. 
Treated if BP 
≥160/90 mm Hg 
Before 
delivery  
Multiple  BP 
Mild 
hypertension= 
Diastolic BP 
between 90-
110 
Severe 
hypertension= 
Diastolic BP 
>110 
 
  
Renal 
impairment 
Liver 
dysfunction 
Thrombocytope
nia 
Neurological 
abnormalities 
 
Perinatal 
mortality 
Low birth-
weight baby 
Intrauterine 
growth 
restriction 
 
Peek MJ 
(1995) 
English 
Cohort 
Not blinded  
Consecutive 
enrolment 
Prospective data 
collection 
Patient sample 
defined 
Test described 
137 Pre-eclampsia (mild and 
severe): BP ≥140/90 or 
rise of systolic BP ≥ 25 
and /or diastolic BP ≥ 15 
mm Hg on 2 occasions, 6 
hours apart; plus  
proteinuria >300mg/day 
or ≥ 2+ with dipstick 
Chronic 
hypertension, 
Diabetes, 
Multiple gestation 
Antihypertensiv
es for both mild 
and severe 
hypertension.  
Third 
trimester  
Multiple  BP 
Mild 
preeclamp
sia= 
>130/90 
and 
<160/110 
mm Hg 
with 
Proteinuri
a +1 and 
+2 
Severe 
hypertensi
on= 
Spontaneous 
labour 
Spontaneous 
vaginal 
delivery 
In-patient 
admission 
Forceps 
delivery 
Caesarean 
section 
 
 
Perinatal 
mortality  
Admission to 
NICU 
Intraventric
ular 
haemorrhag
e 
Necrotising 
enterocolitis 
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Diastolic 
BP 
≥160/110 
mm Hg 
and or 
Proteinuri
a of >2+ 
on 
dipstick or 
5g in 24-
hours 
urine. 
Heilmann 
L (1989) 
English 
Case-control 
Not blind 
Retrospective 
Enrolment: not 
stated 
Test not 
described 
 
52 Pregnancy-induced 
Proteinuric (>1% in 24 
hours) hypertension (BP 
>140/85)  
Not stated Biochemical and 
cardio-
pulmonary 
monitoring 
After 24th 
week  
Not stated BP 
Mean arterial 
pressure: 
≤105 mm Hg 
>120 mm Hg 
>140 mm Hg 
>160 mm Hg 
 Perinatal 
mortality 
Birth 
weight 
Varma 
(1981) 
English 
Cohort 
Not blind 
Prospective data 
collection 
Arbitrary 
enrolment 
Prospective 
Test described 
 
 
 
 
200 Pre-eclampsia 
 
Not available  
 
Third 
trimester 
Multiple  BP 
Mild 
hypertension= 
Diastolic BP 
between 90-
110 
Severe 
hypertension= 
Diastolic BP 
>110 
 
  
 Fetal 
distress 
Stillbirth 
Perinatal 
death 
Neonatal 
death 
 
 
Menzies 
(2007) 
Cohort 
Prospective 
Consecutive 
enrolment 
No blinding 
Adequate 
population, test 
and outcome 
description 
Follow up 
complete 
737 Pre eclampsia of any 
severity 
Inclusion criteria: BP 
≥140/90mmHg (twice  ≥ 
4 hours apart, after 20 
weeks ) and either 
proteinuria ( ≥2+by 
dipstick,  ≥ 0.3g/24h or  
≥ 30 mg/mmol by spot 
protein:creatinine ratio) 
or hyperuricemia  
HELLP syndrome 
Women who have 
already achieved 
any component of 
the adverse 
maternal outcome 
   Systolic BP 
≥160 mmHg 
Diastolic BP 
≥110 mm Hg 
Adverse 
maternal 
outcome (death 
or complication 
involving 
hepatic or 
central nervous 
system or renal 
or respiratory 
or 
hematological 
systems)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
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Superimposed pre 
eclampsia, defined as pre 
existing hypertension 
with accelerated 
hypertension, new 
proteinuria or new 
hyperuricemia. 
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Appendix 26. Study characteristics of the trials included in the systematic review of accuracy of pulse oximetry  in 
detecting congenital heart disease in asymptomatic newborns  
 
 
 
Study Population Test Outcome 
Study 
(Year) 
 
Quality  No. of 
newborns 
No. of  
newborns 
with CHD 
Inclusion 
criteria 
Exclusion 
criteria 
Age at 
testing 
Method of 
testing 
Frequency of 
testing 
Cut off level 
De-Wahl 
Granelli 
(2005) 
 
Case control 
Retrospective 
Non 
consecutive 
enrolment 
Test described 
Not blind 
266 66 Cases – 
Normal 
full term 
infants 
 12 hours 
(controls) 
Prior to 
surgery 
(cases) 
Right hand 
and either 
foot 
Multiple Functional 
saturation <95% in 
right upper and 
lower limbs and 
readings in lower 
limb 3% higher or 
lower than right 
hand 
Critical Congenital 
Heart Disease 
(CCHD) – duct 
dependant or cyanotic 
heart disease 
Bakr  
(2005) 
 
Cross 
sectional 
Prospective 
Consecutive 
Test described 
Not blind 
5211 13 Asympto
matic 
newborns 
Symptom
atic 
newborns 
NICU 
admission 
 
Before 
discharge 
Right hand 
and foot 
Multiple Fractional 
saturation <95% in 
right hand or foot  
Congenital Heart 
disease 
Arlettaz 
(2005) 
 
Cross 
sectional 
Prospective 
Consecutive 
Test described 
Not blind 
3262 15 Healthy 
newborns 
≥35w 
GA<35w 
Symptom
atic 
Respirator
y disorder 
in 
newborns 
6-12 hours Foot Multiple Functional 
saturation in foot 
<95% 
Congenital Heart 
disease of functional 
consequence 
Rosati  
(2005) 
Cross 
sectional 
5292 3 Asympto
matic 
Symptom
atic prior 
>24 hours N/A Single Saturation ≤ 95% 
in foot  
Critical Cardio 
Vascular 
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 Prospective 
Consecutive 
Test described 
Not blind 
newborns to 
screening 
Prenatal 
diagnosis 
of CHD 
Malformation 
(CCVM) 
Koppel (2003) 
 
Cross 
sectional 
Prospective 
Consecutive 
Test not 
described 
Not blind 
11281 5 Asympto
matic 
newborns 
Symptom
atic 
newborns 
Prenatal 
diagnosis 
of CHD 
>24 hours 
or at 
discharge 
Foot Single Functional 
Saturation ≤ 95% 
in foot 
Critical Cardio 
Vascular 
Malformation 
(CCVM) 
Richmond 
(2002) 
 
Cross 
sectional 
Prospective 
Consecutive 
Test not 
described 
Not blind 
5626 40 Asympto
matic 
newborns 
Symptom
atic 
newborns 
 
 
≥2 hours 
to before 
discharge 
Foot Multiple Fractional 
saturation <95% in 
foot 
Congenital Heart 
disease 
Reich 
(2002) 
Cross 
sectional 
Prospective 
Consecutive 
Test described 
Not blind 
2114 3 Asympto
matic 
newborns 
Fetal 
echocardi
ogram, 
Symptom
atic 
newborns 
NICU 
admission 
Birth 
weight 
<1500g, 
assisted 
ventilation
, transfer 
to a 
tertiary 
neonatal 
unit 
Consent 
not 
As close 
to 
discharge 
as possible 
Foot or 
hand 
Multiple Functional 
saturation ≤ 95% 
in foot or hand  
Cyanotic Congenital 
Heart disease 
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provided 
Hoke 
(2002) 
Case control 
Ambispective 
Arbitrary 
recruitment 
Test described 
Not blind 
2908 36 Cases-
Newborns 
with 
congenital 
heart 
disease 
Controls-
Healthy 
newborns 
at least 34 
weeks 
gestationa
l age at 
birth 
Less than 
34 weeks 
Less than 
6 hours of 
life, at 24 
hours of 
life and/or 
at 
discharge 
Right arm 
and either 
leg 
Multiple -functional 
saturation <95% in 
foot 
-functional 
saturation <92% 
lower limb or 7% 
lower in foot than 
hand 
-functional 
saturation<94% 
foot 
-functional 
saturation<93% 
foot 
-functional 
saturation<92% 
foot 
-functional 
saturation<91% 
foot 
-functional 
saturation<90% 
foot 
 
 
Critical Congenital 
Heart Disease 
(CCHD) – duct 
dependant or left 
heart obstructive 
disease 
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Appendix 27. Data extraction form for review of progesterone for women at risk 
of pre term labour 
 
           Name of Reviewer:                                    ID:             Author:              Year 
 
1) Population: 
- Women at risk of preterm labour                   yes  no 
 
2) Intervention: 
-  Progesterone                            yes  no 
 
 
3) Comparison with: 
- Placebo                                                           yes  no 
 
4) Outcome 
 
- Maternal outcomes:     yes  no 
    
 
- Fetal outcomes:     yes  no 
  
 
5) Include paper:      yes              no 
(Only include study if answered yes to all of the above criteria)    
 
 
 
6) Design: 
RCT Cohort study    
Quasirandomisation 
 
7) Type: 
prospective    retrospective 
 
8) Blinding 
yes     no 
 
          a) If yes: 
    single blind   double blind 
 
9) Concealment: 
yes     no 
 
10) Intention to Treat (ITT) analysis? 
yes     no 
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11) Follow up: 
> 90%   80-90%  <80% 
 
 
 
 
Inclusion criteria: 
 
Exclusion criteria: 
 
Use of other tocolytics        Yes                No 
 
Type of progesterone          Parenteral                   vaginal              Other 
 
Progesterone commenced           1
st
 tri          2
nd
 tri            
 
Dose stopped at   ...........................weeks 
 
Dose of progesterone  
 
Use of steroids                 Yes          No 
 
Mode of delivery 
 
GA at delivery 
 
     Birth weight     Normal / SGA / LGA 
Congenital abnormalities                 Yes                  No 
 
Maternal side effects ................................................. 
 
 
 
     
 
 
 
 
 
 
 
 
 
Delivery before 37 weeks yes no 
Progesterone   
Placebo   
Delivery before 34 weeks yes no 
Progesterone   
Placebo   
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Neonatal death yes no 
Progesterone   
Placebo   
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Appendix 28. Data extraction form for review of optimal dosage regimen of 
lamotrigine in pregnant women with epilepsy 
 
Name of Reviewer:                                   ID:                      Author                          Year 
 
1) Population: 
- Pregnant females with epilepsy:                   yes  no 
 
2) Intervention: 
-  Increasing lamotrigine dose:   yes  no 
 
 
3) Comparison with: 
- Maintaining pre pregnancy lamotrigine dose: yes  no 
 
4) Outcome 
- Pharmacokinetics of lamotrigine:    yes  no 
 
- Maternal outcomes:     yes  no 
- if yes what are they looking at: 
- Fetal outcomes:     yes  no 
 - if yes what are they looking at:    
 
5) Include paper:      yes              no 
(Only include study if answered yes to all of the above criteria)    
 
 
 
6) Design: 
RCT Cohort study   Case controlled study 
Quasirandomisation 
 
7) Type: 
prospective    retrospective 
 
8) Blinding 
yes     no 
 
          a) If yes: 
    single blind   double blind 
 
9) Concealment: 
yes     no 
 
10) Intention to Treat (ITT) analysis? 
yes     no 
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11) Follow up: 
> 90%   80-90%  <80% 
 
Use of other AED        Yes                No 
 
Total no. of AED            1                2                     3              4 
 
Other AED drugs          Sodium valproate                   Carbamazepine              Other 
 
LTG commenced           Pre-preg            1
st
 tri          2
nd
 tri           3
rd
 tri 
 
LTG dose escalation         No            1
st
 tri          2
nd
 tri           3
rd
 tri 
 
Total dose of LTG / day        ….mg/day 
 
      Mode of delivery                      Normal vaginal/Caesarean section/instrumental 
Postpartum haemorrhage             Yes                      No 
Birth  Weight 
Congenital abnormalities                 Yes                  No 
 
Population.................................................Outcome………………………………………. 
 
     
 
 
 
 
 
Population.................................................Outcome………………………………………. 
 
 
 
 yes no 
LTG dose escalation   
LTG dose maintenance   
 yes no 
LTG dose escalation   
LTG dose maintenance   
  
255 
 
Appendix 29. Data extraction form for the review of tests in pre eclampsia 
 
Reviewer:  Paper No.:                  Language:  1
st
 Author: 
 
 
1. population – women with pre eclampsia           yes / no 
 
                                                                                  
 
2. Test proteinuria/uric acid/liver function test/symptom/blood pressure                                                    
yes / no 
           
3. Reference standard         
Maternal :  1)severe pre eclampsia  2)eclampsia                                                                                                                       
3)abruption     4)death     5) other…………. 
 
 Fetal:       1)death    2)IUGR   3)Low pH    4)Low  Apgar                    
                  5)prematurity    6)other 
 
  
         2x2 table construction possible                              yes / no 
 
         Select this diagnostic test study (1-3 inclusive) yes / no       if no reject & specify 
reason below 
 
………………………………………………………………………………………………………………………
……….. 
 
………………………………………………………………………………………………………………………
……….. 
 
 
 
 
 
 
 
 
 
 
Population: 
 
Study Design    Cohort / Cross-sectional / Case control / Other…………… 
 
Data Collection   Prospective / Retrospective / Cannot tell / Other…………. 
 
Patient Enrolment   Consecutive / Arbitrary / cannot tell / Other…………….. 
Data Retrieval: 
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Additional Description of Study Design 
 
 Blind comparison with reference standard Yes No Can‟t tell 
 
Defined sample of patients   Yes No Can‟t tell 
 
 Narrow population spectrum    Yes No Can‟t tell 
 
 Differential use of reference standard   Yes No Can‟t tell 
 
 
 
Baseline prevalence of the disease: .......................... (State figure if provided, otherwise circle 
below) 
 
High  Low  Not mentioned 
 
Please circle characteristic of sample population(s): [Assuming this is not a risk factor study] 
 
Mild     Moderate     Severe Associated medical problem Can‟t tell 
 
If sample classified, state the definition: 
 
...................................................................................................................................................... 
 
 
Inclusion criteria stated  Yes 
 No  
  Description: 
 
...................................................................................................................................................... 
 
 
No. patients recruited   
A original population   n=…… 
 
B Pre-enrolment exclusions n=……   
           (reasons eg pop characteristics)…………………………………… 
 
C actually recruited (A-B)   n=……    
      
D post-enrolment exclusions n=…… 
(reasons eg missing data etc)………………………………………… 
 
E analysable data (C-D)  n=…… 
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Setting              Community / hospital 
 
Parity stated:                                     Yes  No/not sure   
 
Previous H/O pre eclampsia/eclampsia          Yes  No/not sure 
 
Symptoms   (Headache, Nausea, vomiting, visual, epigastric pain)     Yes  No/ not sure 
If symptomatic, what symptom:………………………………………………..  
Intervention: 
 
More than one test performed on the patient:  Yes 
 No 
 
Type of intervention („the test‟): ………………………………… 
 
How many measurement(s):        Single           Multiple 
 
Gestation at which „the test‟ was applied: ............weeks or
 ............ trimester 
 
Method described: Yes No     Other interventions 
 
If there‟s cut off level, this must be stated for the test to be considered adequate:   Yes       No 
 
Cut off level of the test: …… 
 
Test positive cases    n=……  
 
Test negative cases    n=……  
 
 
 
Reference standard (maternal or fetal outcome): 
 
State maternal outcome:                           
………………………………………………………………..  
 
State fetal outcome:                                  ……………………………………………………………..
  
 
Blinding of test result  
 yes / no 
 
Completeness of Follow up (%)  >90 / 81-90 / <81  (FU% = E/C x 100% =…… %) 
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Completeness of Follow up (%)  Positive cases  % Negative cases % 
Regarding the outcome(s): 
 
How was the result reported [ie the summary outcome measure(s)]: {please circle} 
 
Receiver Operator Curve (summary) ROC  Likelihood Ratio (LR) 
 
Sensitivity SpecificityNegative predictive value
 Positive predictive value 
 
Others (please state): ........................................................................................ 
 
 
Space for free comment by reviewer: 
 
 
 
Outcome (maternal or fetal complications): (2x2 table) 
 
If deriving 2x2 by severity of pre eclampsia, then use separate table for category(mild,mod,severe) 
 
State the type of outcome for these tables (eg Low Apgar,Eclampsia) 
Population.................................................Outcome………………………………………. 
 
 Outcome present Outcome absent Total 
Positive    
Negative    
Total    
 
 
Population.................................................Outcome………………………………………. 
 
 
 Outcome present Outcome absent Total 
Positive    
Negative    
Total    
 
  
259 
 
  
260 
 
Appendix 30. Data extraction form for the review of Pulse Oximetry in detecting 
Congenital Heart Disease in asymptomatic newborns 
 
 
Reviewer:  Paper No.:                  Language:  1
st
 Author: 
 
 
 
 
1. population – asymptomatic newborns          yes / no 
 
                                                                                  
 
        2.  Intervention      pulse oximetry                               Yes / no 
 
                                        clinical examination                 Yes / no 
           
       3.   Reference standard                                              Echocardiograph 
  
         2x2 table construction possible                              yes / no 
 
         Select this diagnostic test study (1-3 inclusive) yes / no       if no reject & specify 
reason below 
 
………………………………………………………………………………………………………………………
……….. 
 
………………………………………………………………………………………………………………………
……….. 
 
 
 
 
 
 
 
 
 
Population: 
Study Design    Cohort / Cross-sectional / Case control / Other…………… 
 
Data Collection   Prospective / Retrospective / Can‟t tell / Other…………. 
 
Patient Enrolment   Consecutive / Arbitrary / can‟t tell / Other…………….. 
 
Additional Description of Study Design 
Selection criteria (diagnostic test 
study): 
Data Retrieval: 
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 Blind comparison with reference standard Yes No Can‟t tell 
 
Defined sample of patients   Yes No Can‟t tell 
 
 Narrow population spectrum    Yes No Can‟t tell 
 
 Differential use of reference standard   Yes No Can‟t tell 
 
 
 
Baseline prevalence of the disease: .......................... (State figure if provided, otherwise circle 
below) 
 
High  Low  Not mentioned 
 
 
Please circle characteristic of sample population(s): [Assuming this is not a risk factor study] 
 
Low risk     Moderate risk      severe risk        Associated medical problem   Can‟t tell 
 
If sample classified, state the definition: 
................................................................................................. 
 
 
Inclusion criteria stated     Yes      No   
Description: 
 
................................................................................................................................................................ 
 
 
No. patients recruited  A original population   n=…… 
 
B Pre-enrolment exclusions n=……   
           (reasons eg pop 
characteristics)…………………………………… 
 
C actually recruited (A-B)   n=…… 
   
      
D post-enrolment exclusions n=…… 
(reasons eg missing data 
etc)………………………………………… 
 
E analysable data (C-D)  n=…… 
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Setting              Community / hospital 
 
Age stated:                                     Yes  No  Can‟t tell
 …………. 
 
Previous antenatal diagnosis                 Yes  No  Can‟t tell            
…………..   
 
GA at birth                                                          Yes                       No                     Can‟t tell            
……….. 
 
Birth weight                                                         Yes  No  Can‟t tell              
………. 
 
Clinical examination                                             Yes                     No                      Can‟t tell            
………….. 
 
Intervention: 
More than one test performed on the patient:  Yes 
 No 
 
Type of intervention („the test‟): ………………………………… 
How many measurement(s):        Single           Multiple 
Age after birth at which „the test‟ was applied:............hrs   or
 ............ days  or    ……………….. 
 
Method described: Yes No   
 
Limb:                               Upper                Lower           Other           ………… 
 
Saturation:                       Functional          Fractional                                     
If there‟s cut off level, this must be stated for the test to be considered adequate:   Yes       No 
 
Cut off level of the test: …… 
 
Test positive cases    n=……  
 
Test negative cases    n=……  
 
Clinical examination  
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Age after birth at which clinical examination was done ............
 hrs   or ............
 days  or    ……………….. 
 
Method described: Yes No 
If there‟s cut off level, this must be stated for the test to be considered adequate:   Yes       No 
 
Cut off level of the test: …… 
 
Test positive cases    n=……  
 
Test negative cases    n=……  
 
Combined Pulse oximetry and clinical examination 
Test positive cases    n=……  
 
Test negative cases    n=……  
 
 
Reference standard (Echocardiography):    
 
Blinding of test result  
 yes / no 
 
Completeness of Follow up (%)  >90 / 81-90 / <81  (FU% = E/C x 100% =…… %) 
 
Completeness of Follow up (%)  Positive cases  % Negative cases % 
 
 
Outcome 
CHD:                                                       Any CHD                  cyanotic CHD 
 
 
Regarding the outcome(s): 
How was the result reported [ie the summary outcome measure(s)]: {please circle} 
Receiver Operator Curve (summary) ROC  Likelihood Ratio (LR) 
 
Sensitivity       Specificity      Negative predictive value          Positive predictive value 
 
Others (please state): ........................................................................................ 
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Space for free comment by reviewer: 
 
Outcome (CHD): (2x2 table) 
 
Population...............................Outcome………………………………………. 
 Outcome present Outcome absent Total 
Positive    
Negative    
Total    
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Appendix 31. Data extraction form for review of maternal and fetal medicine 
reviews 
Reviewer                                                          Paper ID                                          Author 
Area – Maternal medicine / fetal medicine 
Specify topic ................................................ 
Cochrane / Non Cochrane      
Framing of question: Yes/Adequate 
No/Inadquate/Not 
reported 
Not 
applicable 
Question specified 
   Narrow focus of question 
   Explicit testable hypothesis 
   Literature search 
   Adequate search description 
   Use of reference list 
   Search without language restriction 
   Assessment for risk of missing studies 
   Inclusion of unpublished data 
   Methods of review: 
   Quality assessment of included 
studies: 
   Potential sources of bias (ie. 
randomisation) 
   Data collection 
(prospective/retrospective) 
   Follow-up 
   Blinding of assessors 
   Description of intervention 
   Tabulation of results (incl. study 
characteristics) 
   Meta-analysis 
   Assessment for heterogeneity 
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Appendix 32. Questionnaire of the list of tests to predict maternal and fetal 
complications of pre-eclampsia – First iteration of Delphi survey 
Please score using the following scale 
0-unnecessary; 1-not important; 2-slightly important; 3-moderately important; 4-very important; 5-essential 
Mark „X‟ in the appropriate boxes 
 
Tests to predict complications of pre-eclampsia 0 1 2 3 4 5 
             
History       
Parity       
Race       
Maternal age       
Previous history of severe pre eclampsia/Eclampsia       
Family history of pre eclampsia       
Obesity       
Weight gain       
Pre existing hypertension, renal disease, diabetes       
History of lupus, thrombophilia, other auto immune diseases       
Multiple pregnancy       
Symptoms-headache, epigastric pain, nausea, visual disturbance        
Examination       
Blood pressure       
Peripheral oedema       
Exaggerated tendon reflexes        
Clonus       
Papilloedema, Retinal changes       
Oliguria       
Symphysio fundal height       
Investigations       
Serum uric acid       
Proteinuria ( 24 hr collection, dipstick)       
Renal function tests       
Liver function tests       
Urinary calcium excretion       
Hypoalbuminaemia       
Microalbuminuria       
Fibronectin       
Maternal serum Alpha feto protein(MSAFP)       
Serum Human Chorionic Gonadotrophin (HCG)       
Coagulation screen       
Full blood count       
Thrombophilia screen       
Ultrasound including doppler       
CT/ MRI of brain       
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Appendix 33. Tests in the order of priority for prediction of pre eclampsia 
complications – Second iteration of Delphi survey 
 
Please score using the following scale 
0-unnecessary; 1-not important; 2-slightly important; 3-moderately important; 4-very important; 5-
essential 
 
Tests to predict 
complications of 
pre eclampsia 
Mean scores 
Your previous 
rating Your new rating 
Blood pressure 
 
4.8   
Papilloedema, 
Retinal changes 
 
4.3   
Liver function tests 
 
4.3   
Proteinuria ( 24 hr 
collection, dipstick) 
 
4.3   
Symptoms-
headache, epigastric 
pain , nausea, visual 
disturbance  
 
4.1   
Full blood count 
 
4.1 
  
Pre existing 
hypertension, renal 
disease, diabetes 
 
4.1   
Renal function tests 
 
4.1   
Oliguria 
 
3.9   
Ultrasound 
including Doppler 
 
3.7   
History of lupus, 
thrombophilia, other 
auto immune 
diseases 
 
3.9   
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Appendix 34. Search strategy for optimal dosage regimen of lamotrigine in 
pregnant women with epilepsy  
1. MEDLINE; lamotrigine.af;  
2. MEDLINE; lamictal.af;  
3. MEDLINE; 1 OR 2;  
4. MEDLINE; exp PREGNANCY/;  
5. MEDLINE; pregnancy.ti,ab;  
6. MEDLINE; 4 OR 5;  
7. MEDLINE; exp EPILEPSY/;  
8. MEDLINE; epilepsy.ti,ab;  
9. MEDLINE; 7 OR 8;  
10. MEDLINE; 3 AND 6 AND 9;  
11. MEDLINE; exp DOSE-RESPONSE RELATIONSHIP, DRUG/;  
12. MEDLINE; "dose increase".ti,ab;  
13. MEDLINE; "increased dose".ti,ab;  
14. MEDLINE; "decreased dose".ti,ab;  
15. MEDLINE; "dose decrease ".ti,ab;  
16. MEDLINE; 11 OR 12 OR 13 OR 14 OR 15;  
17. MEDLINE; 10 AND 16;  
18. MEDLINE; exp "QUALITY OF LIFE"/;  
19. MEDLINE; (quality AND of AND life).ti,ab;  
20. MEDLINE; 18 OR 19;  
21. MEDLINE; 10 AND 20;  
  
269 
 
Appendix 35. Search for pulse oximetry as a test to diagnose congenital heart 
disease in newborns 
 
1 MEDLINE − 1996 to date oximetry    
2 MEDLINE − 1996 to date pulse   
3 MEDLINE −1996 to date 1 AND 2  
4 MEDLINE −1996 to date pulse NEAR oximetry  
5 MEDLINE −1996 to date 3 OR 4  
6 MEDLINE −1996 to date infant−newborn#  
7 MEDLINE −1996 to date neonat$2  
8 MEDLINE −1996 to date newborn  
9 MEDLINE −1996 to date 6 OR 7 OR 8  
10 MEDLINE −1996 to date 5 AND 9  
11 MEDLINE −1996 to date 
YEAR=2006 OR YEAR=2005 OR 
YEAR=2004 OR YEAR=2003 OR 
YEAR=2002 unrestricted  
12 MEDLINE −1996 to date 10 AND 11 unrestricted  
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Appendix 36. Contributions to the chapters of the thesis 
Chapter 1. Introduction 
Shakila Thangaratinam 
Chapter 2. The Delphi Technique 
Shakila Thangaratinam: Drafting revision of the manuscript, literature serach 
Charles Redman: Critical revision of the manuscript 
Khalid S Khan: Supervision of the project; and constructive feedback into the manuscript 
Chapter 3. Prioritisation of tests for the prediction of complications in pre eclampsia: A 
Delphi survey 
Shakila Thangaratinam: Development of the protocol and questionnaire, conduct of survey, 
analysis, drafting and revision of manuscript 
Arri Coomarasamy: Development of the protocol and questionnaire, critical revision of manuscript 
Steve Sharp: Literature search 
Khaled MK Ismail: Critical revision of manuscript 
Shaughn O’Brien: Critical revision of manuscript 
Fidelma O’Mahony: Critical revision of manuscript 
Khalid S Khan: Development of the protocol and questionnaire; supervision of the project; and 
critical revision of manuscript 
Chapter 4. A review of systematic reviews in maternal medicine 
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Shakila Thangaratinam: Contribution mainly to the analysis; drafting and revision of manuscript. 
Protocol revision input provided. 
Lumaan Sheikh: Literature search; data extraction; and drafting of manuscript 
Shelley Johnston: Data extraction 
Khalid S Khan: Development of protocol; and critical revision of manuscript 
Mark D Kilby: Critical revision of manuscript 
Chapter 5. A review of systematic reviews in fetal medicine 
Shakila Thangaratinam: Contribution mainly to the analysis; drafting and revision of manuscript. 
Protocol revision input provided. 
Ellen Knox: Development of protocol; literature search; data extraction; and drafting of manuscript 
Khalid S Khan: Development of protocol; supervision of the project; and critical revision of 
manuscript 
Mark D Kilby: Development of protocol; critical revision of manuscript 
Chapter 6. Progesterone for the prevention of preterm birth: A systematic review of 
effectiveness 
Shakila Thangaratinam: Development of protocol; data extraction; and drafting and revision of 
manuscript 
Arri Coomarasamy: Development of protocol; literature search; data extraction; analysis and 
critical revision of manuscript 
Khalid S Khan: Supervision of the project; and critical revision of manuscript 
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Harry Gee: Critical revision of manuscript 
Chapter 7. A systematic review of effectiveness of lamotrigine dosage based on serum levels 
compared to clinical features 
Shakila Thangaratinam: Development of protocol; literature search; data extraction; analysis and 
drafting and revision of manuscript 
Dulcie Pirie: Data extraction 
Victoria Houston, Ayesha Siddiqua: Literature search; and data extraction 
Manjo Doug: Revision of manuscript 
Khalid S Khan: Supervision of the project; and critical revision of manuscript 
Doug McCorry, Alex Pirie, Manny Bagary, Kelly HardLyn Greenhill: Critical revision of 
manuscript 
 Chapter 8. Tests for predicting complications of pre eclampsia: A protocol for systematic 
reviews 
Shakila Thangaratinam: Development of protocol; literature search; and drafting and revision of 
manuscript 
Arri Coomarasamy: Development of the protocol; and critical revision of manuscript 
Steve Sharp: Literature search 
Khaled MK Ismail: Development of the protocol; and critical revision of manuscript 
Shaughn O’Brien: Critical revision of manuscript 
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Fidelma O’Mahony: Critical revision of manuscript 
Khalid S Khan: Development of protocol; supervision of the project; and critical revision of 
manuscript 
Chapter 9. Proteinuria as a predictor of complications in pre eclampsia 
Shakila Thangaratinam: Development of protocol; literature search; data extraction; analysis; 
drafting and revision of manuscript 
Arri Coomarasamy: Development of the protocol; and critical revision of manuscript 
Steve Sharp: Literature search 
Javier Zamora: Analysis 
Fidelma O’Mahony, Khaled MK Ismail: Data extraction; and critical revision of manuscript 
Shaughn O’Brien: Critical revision of manuscript 
Khalid S Khan: Development of protocol; supervision of the project; and critical revision of 
manuscript 
Chapter 10. Serum uric acid as a predictor of complications in pre eclampsia 
Shakila Thangaratinam: Development of protocol; literature search; data extraction; analysis; 
drafting and revision of manuscript 
Arri Coomarasamy: Development of the protocol; analysis and critical revision of manuscript 
Steve Sharp: Literature search 
Khaled MK Ismail: Data extraction; and critical revision of manuscript 
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Khalid S Khan: Development of protocol; supervision of the project; and critical revision of 
manuscript 
Chapter 11. Liver function tests as a predictor of complications in pre eclampsia 
Shakila Thangaratinam: Development of protocol; literature search; data extraction; analysis; 
drafting and revision of manuscript 
Corinne Koopmans: Data extraction 
Shalini Iyengar: Data extraction 
Javier Zamora: Statistical input 
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Ben WJ Mol: Critical revision of manuscript 
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Chapter 12. Symptoms as a predictor of complications in pre eclampsia 
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Neki Meah: Study selection 
Sa’ada Usman: Study selection 
Khaled MK Ismail: Critical revision of manuscript 
Khalid S Khan: Supervision of the project; and critical revision of manuscript 
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Chapter 13. Blood pressure as a predictor of complications in pre eclampsia 
Shakila Thangaratinam: Development of protocol; literature search; data extraction; analysis; 
drafting and revision of manuscript 
Adrija Datta: Data extraction 
Khaled MK Ismail: Critical revision of manuscript 
Khalid S Khan: Supervision of the project; and critical revision of manuscript 
Chapter 14. Accuracy of pulse oximetry as a screening tool in the diagnosis of congenital 
heart disease in newborns: a systematic review 
Shakila Thangaratinam: Development of protocol; literature search; data extraction; analysis; 
drafting and revision of manuscript 
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